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Summary 
Molluscum contagiosum virus (MOCV) and human cytomegalovirus (HCMV) each 
encode two MHC-I homologues: mc080 and mc033 in MOCV, UL18 and UL142 
in HCMV. Codon optimised versions of the mc080 and mc033 genes were cloned 
in to a second-generation lentivirus system, vaccinia virus and a replication-
deficient adenovirus (Ad) vector. MOCV mc033 and mc080 were expressed from 
the Ad vector as endoglycosidase H (EndoH) sensitive glycoproteins with apparent 
molecular weights of 64kDa and 44kDa respectively, both localised predominantly 
to the ER.  MC033 had no effect on either MHC-I or HLAE expression, nor did it 
impact NK cells or T cell function. MC080 downregulated cell surface expression 
of classical HLA-I and HLA-E in a TAP independent, although not MICA/B. This 
downregulation of HLA-1 correlated with protection against CD8+ T cell 
activation, thus MC080 is here identified as a novel viral T cell evasion function. 
MC080 was capable of supressing or activating NK cell, depending on context and 
consistent with MC080’s control of HLA-I and HLA-E.  
UL142 expression was enhanced by optimising codon usage and through provision 
of an alternative leader sequence. Using an Ad vector, UL142 was expressed as a 
heavily glycosylated 105kDa protein that localised to the ER, cell surface and was 
released into the supernatant in an EndoH-resistant form. When over-expressed from 
the Ad vector UL142 suppressed full length MICA, but not in the context of a 
productive HCMV infection where that function was performed by the US12 gene 
family. Preliminary allogenic functional NK cell assays showed UL142 to suppress 
NK cell function in one of four donors. However, cell-associated and secreted UL142 
both activated NK cell degranulation when the assay was moved to an autologous 
setting. The results suggest that UL142 can modulate NK cell function independently 
of MICA.   
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 2 
1.1DNA viruses: Taxonomy and Classification of MOCV 
and HCMV 
Viruses have relatively small genomes and their genes tend to be mainly involved 
in functions essential for efficient replication, including receptor recognition to 
promote entry into cells, enzymes involved in the transcription and replication of 
the viral genome and structural proteins required for the formation of new virus 
particles. Some viruses, like papilloma virus, have very small genomes with less 
than 10 open reading frames, whilst relatively large mammalian viruses can encode 
well over a hundred gene products; most notably poxviruses and members of the 
Herpesviridae. The Poxviridae is a family of enveloped double stranded DNA 
viruses that have been isolated from a large number of vertebrate or invertebrate 
hosts (Fields et al. 2013). Poxviruses replicate in the cytoplasm and encode many 
proteins needed for macromolecular precursor pool regulation, biosynthetic 
processes. Also, these viruses have a complex morphogenesis, which involves the 
de novo synthesis of virus-specific membranes and inclusion bodies. Interestingly, 
these viruses encode many immune evasion proteins which interact with host 
processes at both the cellular and systemic levels. The most notorious member of 
the Poxviridae is the causative agent of smallpox, variola virus (VARV), which 
although now eradicated from human populations worldwide is still retained in two 
high containment facilities; one in the United States and the other Russian 
Federation. Poxviruses infections are generally acute, molluscum contagiosum 
virus (MOCV) is an exception, and commonly infect the epidermis directly (e.g. 
VARV, MOCV) but can also. be transmitted by the oral route, e.g. ectromelia in 
mice (Buller and Palumbo 1991; Fields et al. 2013). Like Poxviruses, members of 
the Herpesviridae are also large enveloped double-stranded DNA viruses that are 
distributed across a wide range of vertebrates and invertebrates. However, 
herpesviruses genomic replication and encapsidation takes place in the nucleus. In 
contrast to poxviruses that are associated primarily with short term acute infections, 
herpesviruses invariably establish lifelong persistent or latent infections which the 
host immune response is unable to clear; the site of latency/persistence in the host 
does vary. MOCV is unusual in being a poxvirus that causes a benign skin tumour 
capable of persisting for months or years, although the infection is ultimately 
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eliminated. Some herpesviruses are also associated with malignancy (e.g. EBV, 
KSHV), yet even if the herpesvirus malignancy is controlled the virus infection will 
persist.  (Buller and Palumbo 1991; Elliott and O'Hare 2000; Sinzger et al. 2000; 
Alba et al. 2001).  
Herpesviruses (HV) have been classified into three subfamilies: the 
Alphaherpesvirinae, Betaherpesvirinae, and Gammaherpesvirinae, this 
classification based in differences in the cellular tropism, genome organization, and 
gene content. All herpesviruses families are thought to have a common ancestral 
HV species, as judged by extensive equivalences in their gene complements. The 
herpesvirus genome encodes between ∼70 to 173 proteins. Although numbers vary 
depending on the analysis, the best estimate currently is that human 
cytomegalovirus (HCMV, HHV-5) contains about 173 canonical protein coding 
genes (Alba et al. 2001; Davison et al. 2003b; Murphy et al. 2003; Dolan et al. 2004; 
Gatherer et al. 2011) Phylogenetic analysis helps in the classification of viruses and 
assessing the relationships between different viruses and their genes. Phylogenetic 
trees can be constructed based upon numbers of shared genes between completely 
sequenced virus genomes, the functionally related proteins usually have shared 
conserved sequence motifs (Fitz-Gibbon and House 1999; Snel et al. 1999).  
The family Herpesviridae consists of viruses belong to the Alpha-, Beta- and 
Gammaherpesvirinae subfamilies that can be classified on the basis of their sequence 
similarity and gene content; these comprise all characterized HVs identified in 
mammalian, avian and reptilian hosts (figure 1.1). A new family, the 
Alloherpesviridae will be assigned for a group of piscine and amphibian HVs, while 
the invertebrate HVs will be assigned to Malacoherpesviridae. A new higher-level 
taxon, the order Herpesvirales includes Alpha-, Beta- and Gammaherpesvirinae 
subfamilies. The wide sequence comparison between the genome of  HV subfamilies 
reveals at least 26 conserved open reading frames (ORFs) (McGeoch et al. 2006) that 
encode a diverse range of functions required for packaging of the viral genome, 
replication, or transcription, also, the ORFs that involved in the formation of virus 
structure, like nucleocapsid and glycoprotein spikes.  A third of known ORF of viral 
protein of Alpha and Gamma-herpes viruses are conserved, yet a lower proportion of 
the Betaherpesvirinaes because of their larger genomes (Alba et al. 2001). The 
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Betaherpesvirinaes is divided further to four genera: Cytomegalovirus, 
Muromegalovirus, Roseolovirus and Proboscivirus. The genus Cytomegalovirus 
includes human cytomegalovirus (HCMV; species, Human herpesvirus 5), rhesus 
cytomegalovirus (RhCMV; species, Macacine herpesvirus 3), and chimpanzee 
cytomegalovirus (CCMV; species, Panine herpesvirus 2). The 
genus Muromegalovirus comprises murine cytomegalovirus (MCMV; 
species, Murid herpesvirus 1) and rat cytomegalovirus (RCMV; species, Murid 
herpesvirus 2) (Davison et al. 2009). While the herpesviruses all establish life-long 
persistent infections, they have undergone divergent speciation during co-evolution 
with their respective hosts that can readily be tracked by a comparison of their 
genomes (McGeoch et al. 1995; McGeoch et al. 2000). HCMV naturally infects only 
humans, and its success in host species is closely associated with the acquisition of 
mechanisms to evade or subvert the human host immune response (Wilkinson et al. 
2015)  
Over fifty complete genome sequences of poxviruses are available in online 
databases. The Poxviridae are classified into two subfamilies according to host range. 
Viruses classified under the Chordopoxvirinae infect vertebrates and members of the 
Entomopoxvirinae infect insects. (Lefkowitz et al. 2006). The Chordopoxvirinae are 
divided into eight genera (Orthopoxvirus, Parapoxvirus, Avipoxvirus, 
Capripoxvirus, Leporipoxvirus, Suipoxvirus, Molluscipoxvirus, and Yatapoxvirus), 
while the Entomopoxvirinae are devided into three genera (Entomopoxvirus A, 
Entomopoxvirus B and Entomopoxvirus C) (figure 1.2).  The members of the same 
genus are geneticlly and antigenically related, besides they have similar morphology. 
The genus Orthopoxvirus has been the subject of intense investigation  as it includes 
both VARV and Vaccinia virus (VACV). Ectromelia virus and Rabbitpox virus 
(closely related to VACV) are been studied as animal models for smallpox; they are 
highly virulent for mice and rabbits respectively (Smee and Sidwell 2003; Schriewer 
et al. 2004).  
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Figure 1.1: Species phylogenetic tree for the Herpesviridae. Based on alignment of  amino acid 
sequences of six genes from 40 HV species, the phylogenetc tree was constructed. In 
the Betaherpesvirinae, HCMV is most closely related to Chimpanzee cytomegalovirus (CCMV) and 
the Simian CMVs (SCMV). 0.1 divergence means 10 % differences in amino acid sequences between 
two species . (McGeoch et al. 2006) 
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Figure 1.2: Gene sequence phylogeny of the family Poxviridae  The phylogenetic analysis is 
based on the alignments of the complete genomic sequences of a range of poxvirus including 
MOCV type-1 and MOCV type-2. MOCV type-1 and MOCV type-2 are most closly related to each 
yet realtively close to  squirrel poxvirus (Sarker et al. 2018) 
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1.2 Vaccinia virus from vaccination vector to immune 
evasion 
 
In 1796 Edward Jenner first deliberately used the cowpox virus to vaccinate 
successfully against smallpox. Over the next two centuries, vaccination was used to 
prevent smallpox disease and control VARV spread worldwide. Smallpox was the 
first disease that was prevented using vaccination, ultimately its eradicated being 
declared by the WHO in 1977 after worldwide vaccination. The virus used in the 
eradication program was known as vaccinia virus (VACV) but was of  uncertain 
origin as it was  grown in skin of calves or another large animal prior to the systematic 
WHO campaign; when its genomic sequence was defined VACV was shown to be 
an orthopoxivirus but not cowpox (LeDuc and Becher 1999; Smith 2011). Modified 
vaccinia virus Ankara (MVA) is a vaccinia strain that has been used as a vaccine. 
MVA vaccine was produced by the Bavarian State Vaccine Institute between 1968 
and 1985, it was administered to around 120,000 people in large field trials in 
Germany. While MVA has a good safety record, its efficacy against smallpox itself 
could not be evaluated as VARV was already under control. MVA has been studied 
extensively as a viral vector as VACV does occasionally cause disease and the 
occasional fatality. MVA was attenuated by propagation in chicken embryo 
fibroblast, a process  that lead to a loss of around 10% of the VACV genome and its 
ability to replicate in many mammalian cells; since it is  replication deficient in 
human cells it can safely be used even in immunosuppressed individuals (Mayr et al. 
1978; Gomez et al. 2011; Volz and Sutter 2013). 
VACV is the prototypic and the most studied virus species of orthopoxvirus, a third 
of its genome and a half of its coding genes are dedicated to modulate immune system 
and establish infection.  VACV virus has a linear double strand DNA genome which 
could be divided into around 100 kb encodes viral replication protein locate in the 
central region while the terminal part of genome encodes immune evasion proteins 
mainly affect innate immune system (Kotwal and Moss 1988; Smith et al. 2013a). 
The complement system, part of the innate immune response, consists of complex of 
well-regulated proteins that work in harmony to destroy viruses, virus-infected cells 
and other pathogens. Complement promotes opsonization of virions resulting in their 
elimination by phagocytosis. VACV complement protein (VCP) is able block 
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activation of classical and alternative complement pathways by binding to 
components C3b and C4b and enhances their cleavage. VCP also binds to the VACV 
A56 protein; A56 is expressed on the surface of extracellular enveloped vaccinia 
virus (EEV) and VACV-infected cells to shield both from the complement system 
(Kotwal and Moss 1988; McKenzie et al. 1992). EEV acquires host complement 
control protein CD46, CD55 and CD 59 in its envelope to help protect the virus 
particles from elimination by complement system (Vanderplasschen et al. 1998). 
Interferons (INF) are generally considered to constitute the most potent innate 
immune defence against virus infections. The elimination of virus infections in the 
hosts usually relies on interferon type I response. IFN- α and IFN- β are families of 
type I IFN which are secreted as an alarm signal from cells infected with viruses 
whereas NF-gamma  (type II IFN) is secreted by activated immune cells, notably 
cytotoxic T cells and NK cells, it is important in macrophage activation and it has 
antiviral activity mediated either by induction of effector molecules like IL-1, IL-6 
or by enhancing antigen presentation by increasing expression of MHC I and MHCII.  
(van den Broek et al. 1995; Bartlett et al. 2005; Smith et al. 2013a).  IFN-I (α and β) 
expression is activated during the early stages of virus infection often as a result of 
direct recognition of viral genetic material, transcripts or antigens by pattern 
recognition receptors (PRRs) triggering the IFN response. One of IFN-I functions is 
transmission of its signals to healthy cells surrounding the infected tissue.  Binding 
to the type I IFN receptor (IFNAR) stimulates the Jak/STAT signalling pathway 
followed by further transcription of several interferon stimulated genes (ISGs), they 
are together acting as antiviral to control virus replication and spreading (Sen and 
Sarkar 2007; Schneider et al. 2014). Type I IFNS with ability to amplify antigen 
presentation and this promote recognition by antigen-specific T cells.   
 
IFNs are corner stone in protection against orthopoxvirus infections, many 
poxviruses exploit multiple genes, to neutralise the antiviral action of IFN (Hernaez 
et al. 2018).In VACV, E3L protein binds double strand RNA to prevents it 
recognition by the dsRNA-activated protein kinase R (PKR). VACV K3L is similar 
to eukaryotic initiation factor 2a (elF2a), a host protein needed for initiation of 
translation. K3L inhibits elF2a phosphorylation by PKR by acting as competitive 
substrate for PKR (Beattie et al. 1991; Chang et al. 1992). VACV VH1 also inhibits 
all INF receptors signalling by STAT 1 (signal transducer and activator of 
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transcription) and STAT2 whereas B18 is able to bind type I INFs to block its 
antiviral action in uninfected cells (Alcami et al. 2000; Mann et al. 2008; Montanuy 
et al. 2011; Smith et al. 2013a). VACV encodes C4, A49, A46, A52, E3, K7, K1, N1 
and M2 proteins during early phase of infection, they are able to inhibit NF-kB 
activation (Smith et al. 2013a) 
Cytokines are small protein which important in cell signalling and regulation of 
innate and acquired immune response, they are classified into families according to 
their structures. VACV encodes multiple proteins to block cytokine function, e.g., 
F1, B15 and B13 all targets IL while B13 protein inhibits mature IL18, C12 protein 
binds soluble IL18 and suppress NF-kB or IRF activation. VACV is able to sequester 
extracellular TNF and prevent its binding to cellular receptors. Moreover, VACV 
secretes chemokine binding protein able to bind CC chemokines. While HLAE 
downregulation does render VACV-infected cells more susceptible to NK cells 
attack, the existence of VACV NK evasion genes is predicted but they have yet to be 
discovered (Smith et al. 2013a) 
1.3 MOCV Genome Overview  
The poxviruses have large DNA genomes ranging in size from 130 to 380 kbp (Fields 
et al. 2013). However, the VARV and molluscum contagiosum virus (MOCV) are 
the only poxviruses to known infect humans only. VARV is responsible for smallpox, 
two types are known: variola major viruses caused case fatalities ranging to 30%, 
and variola minor viruses (known as Alastrim variola minor virus), which caused less 
than 2% case fatalities (Shchelkunov et al. 2000). VARV is eradicated through 
immunization by using live vaccinia virus. MOCV is the sole member of the genus 
molluscipoxvirus. MOCV has  a large double strand DNA genome with a high GC 
content (63%), especially when compared with only  34%  in VARV and VACV 
(Senkevich et al. 1996), and four distinct genotypes (Dohil et al. 2006). The genome 
of MOCV type I (figure 1.3) has been sequenced and  comprises of 190289bp with 
GenBank Accession No. U60315 (Senkevich et al. 1997).  
MOCV is predicted to contain 182 open reading frames (ORF) that are likely to 
encode for functional proteins. When the MOCV genome is compared with that of 
the orthopoxviruses (OPV), 105 genes are homologous to proteins of OPV and 55 
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genes of these are more widely conserved poxvirus genes. The conserved gene set 
are responsible for replication or expression of the viral genome or are structural 
component of virion. All the VACV genes that are essential for virus growth in cell 
culture are conserved in MOCV; this correlation implies that the processes involved 
in productive MOCV replication is similar to that of the OPV. However, the MOCV 
genes known to modulates the host immune response lack homologues in the OPV, 
examples of those genes are:  mc066L, mc080R, mc148R and mc033L (Senkevich 
et al. 1996; Senkevich et al. 1997). 
The ORFs in the MOCV genome occurs in series of blocks transcribed in the same 
direction, rightward-oriented ORFs are located mainly in the middle and on the right 
side of the genome, whereas the leftward-oriented ORFs tend to be on the left side 
(figure 1.3). The first annotated gene on the left-hand end, mc001R, consists of 488 
codons and begins proximal to the tandem repeats within the left ITR and the final 
gene, mc164L, sits adjacent to the right ITR and encodes 680 amino acids protein. 
36 MOCV proteins were identified as having cellular homologues with conserved 
functional motifs. MC066L is a glutathione peroxidase homologue, MC148R is CC 
chemokine homologue and MC080R is an MHC I homologue; MC080R has 20 to 
30% sequence identity with MHC-I molecules, while MC066L is 74% identical to 
selenocysteinyl glutathione peroxidase (Senkevich et al. 1997). 
MOCV is predicted to encode a number of proteins that may help evade the immune 
system or be targets for antiviral agents. MC007L does not have homology to other 
poxvirus genes yet encodes a mitochondrial outer membrane (MOM) protein, the 
protein uses its N-terminal mitochondrial targeting sequence to attach to the MOM. 
MC007L inactivates retinoblastoma protein pRb by mis-localising and sequestrating 
it at mitochondrial membranes, MC007L co-immunoprecipitates with the 
endogenous pRb/E2F-1 complex. Interestingly, MC007L has ability to transform 
primary rat kidney cells thus it likely plays a crucial role in MOCV-mediated cell 
transformation (Mohr et al. 2008). MC039L has homology to vaccinia virus DNA 
polymerase E9L gene and is a potential target the cidofovir and other polymerase 
inhibitors (Magee et al. 2005). MC054L is a homologue of human interleukin 18 
binding protein (IL-18BP); IL-18 is a potent activator of macrophage through its  
 
 11 
 
 
 
 
Figure 1.3: The complete genome of MOCV type I. MOCV type 1 genome encodes 182 
hypothetical open reading frames. 95 MOCV ORFs have early promoters indicating they are involved 
in setting up the host cell for viral replication and extend the survival of the virus infection by 
suppressing elements of the immune system active in the human epidermis. These include two MHC 
homologs MC033 and MC080. The black represents the genes conserved between poxviruses, the 
genes depicted in green are unique to MOCV. Adapted from (Senkevich et al. 1997).    
to NK cell lysis 
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capacity to induce production of cytokines, including IFNγ.  By acting as decoy 
receptor for IL18, MC054L acts to supress the IL-18-mediated synthesis of gamma 
interferon, activation of NK cells and T helper cell response (Dinarello 1999). 
Interestingly, MC054 has two forms the full length MC054 which neutralise locally 
produced IL18 and the soluble N-terminal fragment which responsible for 
neutralising of IL18 systemically (Xiang and Moss 2001,2003). MC051L and 
MC053L are hypothetical proteins that also exhibit homology to human IL-18-
binding protein and may act with MC054 to neutralise IL18. (Xiang and Moss 2001).  
MC148R a secreted protein that shares amino acid sequence homology with the 
chemokine receptor CCR8 (Bugert et al. 1998). Two forms of mc148R have been 
studied, the mc148R1 from MOCV type-1 and mc148R2 from MOCV type-2. 
MC148R1 inhibited the migration of monocytes, lymphocytes and neutrophils by its 
action on multiple CC and CXC chemokine (Krathwohl et al. 1997; Damon et al. 
1998). MC148R1 has the ability to block CXCL12a and CCL3 whilst MC148R2 
inhibits CCL3 only. The interaction of MC148R1 with CXCL12α prevents the host 
chemokine from binding CXCR4 (Jin et al. 2011). Also, MC148R1 binds to CCR8 
and blocks its function. (Luttichau et al. 2000). MC148R is expressed early in the 
MOCV lifecycle, and the CCR8 (the receptor blocked by MC148) is found on 
monocytes, natural killer (NK) cells and thymocytes. This suggests that MC148R has 
anti-inflammatory activity and may act to suppress the recruitment of an 
inflammatory cells to MOCV lesions in co-operation with other MOCV 
immunomodulating protein (Bugert et al. 1998; Luttichau et al. 2001). Also, 
MC148R1 shows homology to locus chemokine (ILC) that is strongly and selectively 
expressed in epidermis (Ishikawa-Mochizuki et al. 1999). mc066L exhibits 
homology to the eukaryotic gene encoding glutathione peroxidase, an enzyme that 
protects cells from oxidative damage. Consequently, MC066L is thought to help 
protect infected cells against UV-light and peroxide-induced cellular apoptosis. By 
inhibiting apoptosis, MC066L may allow the MOCV infected cells to survive longer 
in UV exposed skin (Shisler et al. 1998).  
Apoptosis can act as a highly effective host defence mechanism when it triggers the 
destruction of virus-infected cells. Many DNA viruses, including MOCV, encode 
proteins that block apoptosis allowing virus-infected cells to survive long enough to 
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produce new virions. TNF and Fas ligand bind receptors TNFR and Fas respectively 
to initiate death receptor signalling, mediated through the recruitment of the adapter 
molecule Fas-associated death domain (FADD) to the death receptor and formation 
of the death-inducing signalling complex (DISC). DISC causes caspase-8 to be 
cleaved to its active form, the activated caspase 8 in turn activates effector caspases, 
such as caspase 3 and caspase 7, resulting in apoptosis. The cellular FLICE (FADD-
like IL-1β–converting enzyme)	-inhibitory proteins (c-FLIP), has ability to compete 
with caspase-8 for FADD binding and they contain death effector domains as well. 
The results of recruitment of c-FLIP are inhibition of apoptosis and alteration in 
death-inducing signalling complex composition (Scaffidi et al. 1999; Lavrik and 
Krammer 2012). TNFa activates the transcription factor NF-kB (nuclear 
factor kappa-light-chain-enhancer of activated B cells) which promotes the 
expression of proteins involved in malignant transformation, cell adhesion, 
controlling cell growth, controlling apoptosis, in immune functions and even 
embryonic development. Moreover, NF-kB has important antivirus responses as 
activation of NF-kB leads to induction of expression of ß IFN, HLA class I, and many 
inflammatory cytokines (Thanos and Maniatis 1995; Barkett and Gilmore 1999; Pahl 
1999).  
MC159 is a viral FLIPs, similar to other known cellular and viral FLIPs, MC159 has 
two tandem protein–protein interaction domains which called death effector domains 
(DEDs; DEDA, DEDB). MC159 bocks NF-kB activation by inhibiting TNF. Also, 
MC159 protein inhibits PMA-induced NF-kB activation or MyD88 over-expression 
that activates NF-kB, MC159 may inhibit TNFR1 signalosome. The MC159 N-
terminal DED inhibits NF-kB and mediates MC159–TRAF2 interactions (Murao and 
Shisler 2005). Randall et al also found that MC159 enhance the expression of 
Mitochondrial antiviral-signalling protein (MAVS), TANK-binding kinase 1 
(TBK1) or IκB kinase e (IKKe)  which leads to inhibition of Interferon regulatory 
factor 3 (IRF3) but by a constitutively active (Randall et al. 2014).  
The MOCV ORF mc002L, mc161R and mc162L were grouped into a family of 
MOCV genes because of they have positional amino acid homology between the N 
terminal portions of the predicted proteins, and they are expressed at the early stage 
during infection. All of this family share predicted signal peptides, a carboxyterminal 
transmembrane domain and  a marginal amino acid homology to the human SLAM 
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(Signalling lymphocytic activation molecule) proteins, a cellular membrane protein 
that has a truncated form lacking the transmembrane domain that can act as a self-
ligand that has ability to induce the activation of T lymphocytes (Bugert et al. 2000). 
MC002 and MC162 both have consensus PY motifs in their cytoplasmic domains, 
the PY motif (PY motifs are proline-rich sequence, which the site of binding by 
proteins having a WW domain) normally interact with the Hrs endosomal switching 
protein and with cellular ubiquitin ligases AIP4 and NEDD4. The SLAM proteins 
have a dual role in both viral lifecycle and immune evasion role, and there is 
suggestion that SLAM gene family involves in T lymphocyte inhibition and surface 
receptors recycling. (Chen et al. 2013). 
Senkevich et al identified two MHC homologues during the original analysis of the 
MOCV genomic sequence: mc080R has 24.5% amino acid homology to the human 
major histocompatibility class I antigen and mc033L has 28% homology to Xenopus 
class I histocompatibility antigen (Senkevich et al. 1997) (Table 1.1). MC080 protein 
was found to be glycosylated, localised to the ER and Golgi apparatus compartments, 
and formed a stable complex with ß2m but could not be detected on the cell surface. 
To function as an MHC-I mimic, MC080 would need to be expressed on the cell 
surface (Senkevich and Moss 1998). The role of MC033L has yet to be studied. 
 
 
Table 1.1: MOCV genes 033 and 080 
 
MOCV 
gene 
Location bp 
(codon length; 
calculated MW) 
Identification 
criteria 
Promotor 
type  
Homology 
(%identity)  
Prediction 
structure and 
feature  
MC033L Located between 
38362-40098 
with 579aa 
which has 
62kDa 
Sequence 
conserved 
 
GeneMark 
Prediction 
Early  
Xenopus 
classI 
histocompati
bility antigen 
gi630859 
28% 
Signal Peptide, with 
transmembrane 
helix, C-terminal 
immunoglobulin 
domain 
MC080 Located between 
96986-98170 
with 395 aa 
42kDa, 
46kDa(with 
signal peptide)  
Sequence 
conserved 
 
GeneMark 
Early  
Rat MHCI 
protein 
gi11521,  
24.5% 
3-transmembrane 
helix, N-terminal, 1 
transmembrane 
helix, N-terminal, 
MHCI heavy chain 
homolog 
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1.4 HCMV Genome Overview 
The herpesviruses have linear, double-stranded DNA genomes whose  architecture 
is divided into six classes, A to F, as exemplified by HHV-6B, herpesvirus saimiri, 
EBV, VZV, HCMV, and tupaia herpesvirus, respectively (Fields et al. 2013). 
Accordingly, HCMV has a typical of class E herpesvirus genome consisting of two 
main regions of unique sequences the unique long [UL] and unique short [US] 
flanked by two sets of inverted repeats, ab (TRL/IRL) and ac (IRS/TRS) (figure 1.4). 
At approximately 230 kb, the HCMV genome is the largest reported for any 
herpesviruses and any human virus. In 1990, the first complete HCMV genomic 
sequence was reported for strain AD169 at 229,354 bp with the preliminary 
annotation describing 208 ORFs (Chee et al. 1990).  Mutations in HCMV are known 
to accumulate in passage. The relatively low passage strain Toledo already exhibits 
evidence of adaptation to in vitro tissue culture, the most dramatic being a large 
sequence inversion (UL133-UL148) that is reflected in the reverse numerical order 
of the standard gene annotation in this region. The most commonly used laboratory 
strains AD169 and Towne have been serially passaged numerous times and this has 
resulted in substantial genetic alterations. The most notable genetic change observed 
being 15 kb and 13 kb deletion in the UL/b’ region of strains AD169 (encompassing 
UL132-UL150A) and Towne respectively relative to the low passage strain Toledo 
or Merlin (Cha et al. 1996; Davison et al. 2003b). A diagrammatic representation of 
the genetically intact Merlin HCMV strain genome with an up-to-date definition of 
the canonical gene set is given in figure 1.4.  
HCMV is most commonly passaged in human foreskin fibroblast cells and, according 
to the extent of culture following isolation from clinical samples the HCMV, can be 
designated either high or low passage viruses. Typically, clinical virus replicates 
extremely inefficiently in vitro until tissue culture-adapted mutants have been 
selected. The epithelial cells tropism of high- and low-passaged HCMV strains are 
different. When clinical viruses are cultured in fibroblasts, they undergo genetic 
changes that substantially affect their growth characteristics and lose the capacity to 
infect myeloid, epithelial and endothelial cells. By 8 to16 passages of HCMV clinical  
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Figure 1.4: Genome annotation of the low-passage HCMV strain Merlin (GenBank accession 
NC_006273). The single line represents the dsDNA genome. HCMV has two terminal repeats (TRL, 
TRS) and two internal repeat regions (IRL, IRS) which represented in white boxes in the genome. The 
HCMV has 12 genes family which represent in the arrows which have different colour codes, below 
the genome is the gene family names. Figure reproduced from (Sijmons et al. 2014).  
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isolates in fibroblasts, mutations disabling the RL13 genes have been selected that 
permit more efficient plaque formation, and this change is followed by a further 
mutation in one of three genes contained in the UL128 locus (UL128L: UL128, 
UL130 or UL131A) by passage from 15 to 20.  On further in vitro passage, additional 
defects can arise elsewhere on the genome. There is a tendency for a mutation in the 
in UL/b′ region to occur focusing on the gene UL140–UL145 region to emerge by 
passage 32 to 63. The UL128L mutation was mainly associated with growing the 
virus using fibroblast cell lines (Dargan et al. 2010; Murrell et al. 2013). The UL128L 
encodes three proteins that, along with gH and gL, form the pentameric complex 
packaged into virion envelopes. The presence of pentameric complex in appropriate 
concentrations in virions appears to be required not only for efficient infection of 
cells other than fibroblasts but also for driving direct cell-to-cell infection, rather than 
spread by release of free virus in to the supernatant.  These genetic changes all occur 
naturally. However, the researchers need also to be aware that during the cloning of 
HCMV genomes in to BACs, a deletion is often deliberately introduced into the virus 
genome to make space for the prokaryotic genome. To construct Towne, Toledo and 
AD169 BAC incorporated the prokaryotic vector cassette in a stably integrated 
element with in US region, where it replaced genes US2, US3, US6 and (in some 
cases) US11. As a result of that, the effect of MHC-I and MHC-II of the viruses 
derived from these BACs is different from clinical virus, consequently, this has 
profound effects on NK and T cell assays (Murphy et al. 2003; Murrell et al. 2013). 
HCMV research has historically been based on the high passage AD169 and Towne 
laboratory strains. However, when the growth comparison between Toledo, Towne, 
and AD169 in the SCID-hu (thymus plus liver) mouse, it has been noticed that Toledo 
replicated at higher levels (at least 3 orders) than the other two strains. These 
differences could be related to the loss of genetic information by Towne and AD169 
during propagation in cell culture (Cha et al. 1996). 
The Merlin HCMV strain (ATCC VR-1590) is the main virus used in our laboratory, 
it was isolated from the urine sample of a congenitally infected neonate in Cardiff. 
To provide sufficient DNA initially to sequence the whole strain Merlin genome, the 
virus was expanded through three passages in fibroblast cell culture, after which 
HCMV genomic DNA was cloned into an M13 vector and analyse by Sanger 
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sequencing. Strain Merlin (clinical sample 742) was selected as the main virus used 
in our laboratory because its genome appeared to be relatively intact and the virus 
could be readily recovered from frozen (−70 °C) stocks (Davison et al. 2003b; Dolan 
et al. 2004). At passage three the complete 235 646 bp genome of Merlin was 
sequenced and originally 170 protein-coding canonical genes identified during 
annotation (Dolan et al. 2004). The original clinical sample was retained for 
comparison, and with the advent of Next Generation sequencing the complete virus 
genome was subsequently determined direct from the urine and found to match the 
published sequence. Strain Merlin was designated the reference HCMV genome 
sequence by the National Centre for Biotechnology Information (GenBank 
AY446894; RefSeq NC_006273). It was the first World Health Organization (WHO) 
International Standard for HCMV (Davison et al. 2003b; Dolan et al. 2004; Fryer et 
al. 2016). The sequencing of the Merlin BAC clone revealed a nucleotide substitution 
in UL128 which is necessary for growth the virus in vitro. Additional defects in RL13 
were revealed when sequencing of multiple clones; all Merlin BAC clones had a 
mutation in RL13 but that not all mutations were the same (Stanton et al. 2010). 
Nine multigene families were identified in the original annotation of strain AD169, 
and three more families added subsequently  (Chee et al. 1990; Davison et al. 2003a). 
The RL11 family is one of the largest consists of at least 12 genes (RL11, RL12, 
RL13, UL1, UL4, UL5, UL6, UL7, UL8, UL9, UL10 and UL11). As illustrated in 
figure 1.4, the 12 RL11 family genes are located close to each other near left terminus 
of the genome, and each contains a RL11D (CR1) domain which encodes a variable 
length key motif formed around three conserved amino acid residues. All but two 
members are predicted to contain N-linked glycosylation sites, the structure of 
individual RL11 genes vary between the RL11D regions and a similar domain has 
been identified in proteins encoded by some human adenovirus serotypes (Chee et 
al. 1990; Davison et al. 2003a; Davison et al. 2003b; Dolan et al. 2004). The entire 
RL11 gene family is dispensable for virus growth in cell culture.  
An unusual feature US22 gene family is that is ancient, as evidence by it having 
homologues in rodent CMVs: the family consists of 12 members in both HCMV and 
MCMV and 11 in rat CMV. The US22 family is relatively dispersed through the 
HCMV genome, as indicated by the gene allocations UL23, UL24, UL28, UL29, 
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UL36, UL43, TRS1, IRS1, US22, US23, US24 and US26 (figure 1.4). Certain genes 
of US22 gene family have up to four conserved sequence motifs and many have 
stretches of hydrophobic and charged residues (Nicholas 1996). A number of US22 
family encode proteins have regulatory functions. However, not all US22 gene 
family members have been studied. For example, the US22 gene itself is expressed 
with early kinetics and specifies a nuclear and cytoplasmic protein that is secreted 
into the extracellular medium but its function still unknown, (Mocarski et al. 1988). 
UL36 suppresses Fas-mediated apoptosis activation by interfering with caspase 8 
activation (Skaletskaya et al. 2001).   
US27, US28, UL33, and UL78 are members of the GPCR family and all chemokine 
receptor homologues. It has been suggested the family has been pirated from a 
mammalian-genome during virus evolution (Chee et al. 1990; Gompels and 
Macaulay 1995).  US28 and US27 homologues have been identified only in primate 
CMVs, whereas UL33 and UL78 homologues are conserved throughout the β-
herpesvirus family (Penfold et al. 1999). There have been many studies published 
about US28, it has ability to bind to different members of the CC family of 
chemokines, including CCL5, CCL2, and CX3CL1. US28 is internalized rapidly 
after chemokine binding, thus raising the possibility UL28 works as a chemokine 
sink in the viral life cycle (Randolph-Habecker et al. 2002).   
The US2 family consists of two homologous genes, US2 and US3; it was found that 
the genes of the US2 and US6 gene families maybe evolved from a common 
precursor. According to genes alignments, and the functions of both gene family. The 
US2 and US6 family genes may arise by gene duplication, that is why sometimes 
they represent in a single family of proteins referred to US6 family (Ahn et al. 1996; 
Benz and Hengel 2000; Gewurz et al. 2001). The HLA class I antigen presentation 
pathway is inhibited by genes US2, US3, US6 and US11 by different mechanisms 
(Table 1.3), and accordingly these functions act in concert to protect HCMV infected 
cells against cytotoxic CD8+ T lymphocytes (Benz and Hengel 2000).  
While the HCMV US12 gene family is also not essential for viral replication in 
cultured cells, it is highly conserved among clinical isolates. US12 family encodes a 
series of 7-transmembrane spanning proteins that share only limited homology with 
the cellular transmembrane bax-inhibitor one motif-containing proteins (TMBIM) 
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(Murphy et al. 2003; Das and Pellett 2007; Fielding et al. 2014). The US12 gene 
family composed of ten contiguous, tandemly arranged genes (US12 through US21). 
At least four members of US12 gene family have a role in suppressing NK cells 
killing of HCMV infected cells. Fielding et al showed that the expression of full-
length MICA was inhibited US18 and US20; MICA is a stress ligand that binds the 
NK cell activating receptor NKG2D. Expression of B7-H6 is also induced by cellular 
stress (including virus infection) and also activate natural killer cells, B7-H6 is a 
ligand for the NK cell activating receptor NKp30.  While B7-H6 is activated in 
productive HCMV infections, it fails to reach the cell surface due to the action of 
US18 and US20 (Fielding et al. 2014; Charpak-Amikam et al. 2017; Fielding et al. 
2017). 
1.5 HCMV and MOCV Immune Evasion Mechanisms 
There are four MOCV genotypes, the genome of MOCV type I has been sequenced 
and comprises of 190289bp with 164 predicted genes, thirty-six MOCV proteins 
have recognizable cellular homologues (Senkevich et al. 1996; Senkevich et al. 1997; 
Dohil et al. 2006). MOCV encodes a number of proteins that help it evade the 
immune system (Table 1.2). MOCV infection is characterized by prolonged absence 
of inflammatory cells at the site of replication. MOCV has yet to be propagated in 
cell culture or in animals, though limited replication in human foreskin keratinocyte 
grafted mice has been reported (Buller et al. 1995; Fife et al. 1996). The inability to 
grow MOCV in cell culture have restricted investigation of virus-host interaction. 
Interestingly, infected keratinocytes in MOCV lesions were observed not to display 
β2m on the cells surface (Viac and Chardonnet 1990), this observation implies the 
MOCV is capable of suppressing cells surface expression of MHC-1.  
Table 1.2: MOCV immune evasion genes 
 
Gene Target Mechanism 
mc066L  
 
Glutathione 
peroxidase 
homologues  
Inhibit apoptosis in infected cells by inhibiting 
peroxide radicals  
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mc002L  
 
homologues to 
human SLAM 
protein CD150  
Inhibit T lymphocyte activation   
mc161R  
 
Has homology 
to human SLAM 
protein CD150  
Inhibit activation of T lymphocyte  
mc162R  
 
homologues to 
human SLAM 
protein CD150 
Inhibit T lymphocyte activation  
 
MC54L  
 
Has similarity to 
human 
interleukin 18 
binding protein  
 
Antagonist of the proinflammatory cytokine 
IL18 (it inhibits the activates macrophages and 
several cytokines include INFg, that is leads to 
inactivation of NK cells and Th1 responses) 
MC148R  
 
Chemokine 
receptor 
antagonist 
Possess anti-inflammatory properties, it 
prevents chemotaxis in epidermis before the 
engagement of other mechanisms  
mc007L  
 
 Mislocalization and inactivation of 
mitochondrial membrane protein by cytosolic 
sequestering of retinoblastoma protein (pRb)  
 
An exceptionally wide variety of functions have been selected through evolution to 
allow cytomegaloviruses (CMVs) to both evade and modulate host immune 
responses and thereby permit the establishment of infection, persistence and onward 
transmission. Inflammatory cytokines, NK cells, adaptive CD4+ and CD8+ T cell 
responses and high avidity neutralizing antibodies released by B cells combine to 
combat HCMV infection. While many poxviruses immune evasion function are often 
clear homologues of host genes, this is much less common with the herpesviruses. 
Nevertheless, HCMV encodes a number of chemokines and chemokine receptor 
homologues, a number of which have been demonstrated to be functional, including 
UL146 (IL-8 like), the IL-10 homologue UL111a (vIL-10) (Kotenko et al. 2000) and 
the chemokine receptor homologues UL33, UL78, US27 and US28 (Randolph-
Habecker et al. 2002)  
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NK cells play an important role in the early control of HCMV infections. NK cells 
are composed of many different subsets that express a distinct repertoire of inhibitory 
and activating receptors, which affect their mode of activation and their functional 
properties (Vivier et al. 2011). The capacity of HCMV to promote evasion of NK 
cells has been studied extensively and has provided a better understanding of how 
NK cells regulate HCMV pathogenesis  (Wilkinson et al. 2008). HCMV evades NK 
cells by three main strategies: enhancement of expression of ligands for inhibitory 
NK cell receptors, suppressing cell surface expression of activating ligands and 
suppressing formation of the immune synapse. Some of the better characterised 
HCMV immune evasion genes are detailed in table 1.3. 
Table 1.3: HCMV immune evasion genes     
Gene 
 
Target 
 
Mechanism 
 
UL18 MHC I 
homologue  
UL18 forms a trimeric complex with β2- 
macroglobulin that binds the inhibitor receptor 
LIR-1. UL18 inhibits LIR-1+ NK cells but 
stimulates LIR- NK cells.  
UL33 CCR1 homologue UL33 is homologous to chemokine receptor, 
located in HCMV envelope.  
UL78 CCR1 homologue UL78 forms heteromers with CCR5 and 
CXCR4 chemokine receptors, it is similar to 
the fMLP receptor. Has a role in inflammatory 
response and leukocyte migration 
UL111A IL-10 homologue UL111A encodes a secreted viral cytokine 
CMV IL10 which binds to IL10 binding 
receptor. 
UL146  CXCL8 (IL-8) 
homologues 
UL146 is a chemokine homologue that mimics 
CXCL8. Stimulates chemotaxis 
US27 
 
CCR1 homologue US27 is a chemokine receptor-like protein, 
inhibits chemotaxis. 
US28 CCR1 
homologues 
 US28 is a constitutively active CCR5-like 
chemokine receptor homologue that binds to 
CCL5, CCL2, and CX3CL1 – possibly as a 
chemokine ‘sink’  
US3 HLA-I and HLA-
II 
US3 retains HLA-I in ER. Also binds to class 
II α/β heterodimers to interferes with the 
maturation of HLA class II   
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US2 HLA-I and HLA-
II 
US2 prevents HLA-I cell surface expression 
by promoting their retrograde transport to the 
cytosol where they are rapidly degraded by 
proteasomes. US2 is also responsible for 
downregulation of MHC II by degradation of 
HLA-DR-alpha and DM-alpha molecules.  
US11 HLA-I US11 prevents HLA-I cell surface expression 
by promoting their retrograde transport from 
ER to the cytosol where they are rapidly 
degraded by proteasomes  
US6 HLA-I US6 downregulates HLA-I and HLA-E by 
inhibition of TAP-dependent peptide 
translocation 
SPUL40 HLA-E, UL18 The peptide derived from UL40 signal 
sequence (SPUL40) binds to and stabilises both 
HLA-E and gpUL18 to enable surface 
expression in a TAP-independent manner. 
HLA-E binds CD94/NKG2A (inhibitory 
receptor) and CD94/NKG2C (paired activating 
receptor) on NK cells 
 
UL16  MICB, ULBP1-4 
and RAET1G 
UL16 inhibits NK cell killing by downregulate 
multiple NKG2D ligands 
miR-
UL112 
MICB, TLR2 and 
Modulates 
TLR2/IRAK1/NF
-κB Signalling 
Pathway 
miR-UL112 inhibits NK cell killing by 
downregulating MICB 
UL135 Remodels actin 
cytoskeleton 
UL135 suppresses formation of the 
immunological synapse 
UL141 CD112, CD155 
and TRAIL-R2 
UL141 elicit robust protection against NK cell 
activation 
UL142 MICA alleles 
except 
MICA*008 
UL142 inhibits NK cell killing by 
downregulate NKG2D  
UL148 Downregulates 
CD58 (LFA3) 
UL148 causes suppression of co-stimulation 
impairs T and NK cell responses 
US12 
family 
Regulate array of 
cell surface 
immune ligands 
The family acts in concert to regulate cell 
surface proteome. E.g US18 and US20 and 
both involved in suppressing cell surface 
expression of MICA (NKG2D ligand) and 
B7H6 (NKp30 ligand) in productive infection. 
UL36-38    UL36-38 suppresses apoptosis 
IRS1 and 
TRS1 
 IRS1 and TRS1 suppress interferon  
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1.6 MOCV biology 
MOCV is an interesting human skin pathogen that has been the only endogenous 
human poxvirus after eradication of smallpox. The sole member of Molluscipoxvirus 
genus has four distinct genotypes, a double-stranded DNA genome of some 190289 
bp (GenBank accession U60315: MOCV type 1/80) and is predicted to possess 164 
genes (Senkevich et al. 1997; Dohil et al. 2006). MOCV is an enveloped, 
pleomorphic (mainly ovoid to brick shaped) virus which, like the orthopoxviruses, 
has a dumbbell-shaped central core with lateral bodies similar and replicates in the 
cytoplasm of human epidermal cells (Birthistle and Carrington 1997). MOCV causes 
self-limited benign tumours of the skin, it mainly infects children and can be a sign 
of immunodeficiency. The lesions are limited to the epidermis (figure 1.5) and can 
persist for months, sometimes years, even when they show signs of inflammation. 
Attempts to treat MOCV infections are usually associated with spread of the infection 
and may cause greater distress.  
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Figure 1.5: Clinical picture of molluscum contagiosum. MOCV causes superficial skin infection 
which occurs most commonly on exposed skin, the lesion begins as a small papule and, when 
mature, is a discrete, waxy, smooth, dome-shaped pearly or flesh-colored nodule, often umbilicated. 
The number of individual lesions is usually fewer than 20, MOCV infects the skin with around 3 to 
5mm in diameter (A to G, L and M); MC infects the eyelid causing follicular conjunctivitis (H, I).  
MCV lesions from an immunocompromised patient with Dedicator of cytokinesis 8 (DOCK8) 
deficiency, showing varying degrees of acute inflammation (J, K). NIH Clinical Center: Bugert and 
Turner, 1993. (Chen et al. 2013).   
 
 26 
 
 
Figure 1.6: Lifecycle of molluscum contagiosum and local immune responses in infected skin. 
The maturation MOCV in human skin. (A) The virus infects the basal layer of epidermis, the mature 
virus released from differentiated keratinocytes. (B)  MOCV supresses immune response at the 
lesions, the immune effector cells are unrecognized at site of infection. C) The lesions are surrounded 
by inflammatory cells which an early sign of cure. The figure is reproduced from Chen et al., 2013.  
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1.6.1 Epidemiology 
 
While molluscum contagiosum has a worldwide distribution, it is more common in 
areas with tropical and humid climates.  The MOCV species contains of four 
clinically indistinguishable genotypes, types 1 and 2 being the commonest. Usually, 
the diagnoses are based on the appearance of the characteristic lesions with only a 
minority of cases being confirmed by analysing biopsies (Senkevich et al. 1996; 
Husar and Skerlev 2002; Leung et al. 2017). Humans are the only known host for 
MOCV.  Epidemiologic data on the incidence of molluscum contagiosum is limited 
so the true prevalence of MC has probably been underestimated (Tyring 2003).  
The MOCV genotype 1 is the most common and is responsible for 98% of cases 
reported in the United States. Other genotypes are significantly more common in 
immunocompromised patients, including HIV-infected persons, as well as in 
countries outside the United States (Dohil et al. 2006). All genotypes are clinically 
indistinguishable. The typical presentation of MC is multiple skin lesions, MC is 
mainly transmitted by direct skin contact which leads to typical cutaneous lesions. 
However, mucosal lesions are rarely recognized. Also, MC transmitted by fomites 
on bath sponges and bath towels with beauty parlours, school swimming pools, and 
Turkish baths all having been responsible for transmission of infection (Dohil et al. 
2006). 
MC is common in sexually active adults with sexual transmission and skin contact in 
sports being well documented modes of transmission. The incidence of MC infection 
in the United States has been increasing since the 1960s where the condition is 
recognized as a sexually transmitted disease. According to the results of surveys 
performed in two clinics for sexually transmitted disease over period 1966-1983, MC 
mainly infected persons in an age group between 15 and 29 years of age (Niizeki et 
al. 1984; Becker et al. 1986). 
Agromayor et al examined 147 HIV-negative Spanish patients clinically and 
analysed their blood for the presence of MOCV and typed isolates. 66% were 
children and 49% had atopic dermatitis, the lesions were indistinguishable between 
different age groups. However, patients with atopic dermatitis had larger lesions in 
comparison with non-atopic patients. In adults, the lesions were mainly in genital 
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area, MOCV type I was predominant with the ratio of MOCVI to MOCVII was 146:1 
(Agromayor et al. 2002). 
A study on 93 patients in a London hospital based on endonuclease digest pattern of 
MOCV DNA found that MOCVI: MOCVII was 3.23:1(Porter et al. 1989) whilst as 
analysis of 222 MOCV isolates from the Grampian region in Scotland found that 
MOCV type I was about 40 times more common than type II; MOCV genotypes did 
not change over time in the same patient, or when passed on in a contact group 
(Scholz et al. 1989). 
1.6.2 Host range and tissue and cell tropism   
Vertebrate poxviruses commonly cross species, MOCV is exceptional in being 
restricted to a single species. Moreover, MOCV replicates only in keratinocytes of 
the epidermis (Buller et al. 1995). The virus promotes cell mitosis to generate a slow 
benign skin tumour. The histopathology of the lesion characterised by acanthotic 
squamous epithelium (acanthoma) forming central crater filled with keratin and 
large eosinophilic intracytoplasmic known as Henderson Peterson bodies (figure 
1.6). The basal layer of epidermis stays intact (Chen et al. 2013). 
1.6.3 Cell culture and animal system 
Many attempts to grow MOCV in primary cells and cell lines have been 
unsuccessful, the virus does not produce infectious progeny in standard cell culture 
systems (Bugert et al. 2001). Placa prepared virus suspensions from MC patient skin 
lesions, and inoculated extracts in to human amnion cell cultures. While such 
infection produced typical cytopathic changes, there was no evidence of virus 
multiplication (Placa 1966). MOCV suspensions alter amnion cells by a cytotoxic 
reaction rather than by replication of intracellular virus  (Burnett 1968). Buller and 
co-workers were more successful using human foreskin grafts in to athymic mice, 
where MOCV infection induced morphological changes that were indistinguishable 
from patient biopsies and included the development and migration of molluscum 
bodies (Buller et al. 1995). Using a similar approach, pieces of foreskin were 
exposed to extracts from MC patients lesions then implanted under the renal capsule 
of athymic mice. The infected implants showed the presence of cytoplasmic 
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inclusions containing typical poxvirus particles within 2 – 3 weeks of implantation. 
However, attempts to pass the virus from one infected implant to another were 
unsuccessful (Fife et al. 1996; Paslin et al. 1997). MOCV infection of human 
fibroblasts and keratinocytes culture results in transcription only of MOCV early 
mRNAs and an abortive infection (Bugert et al. 1999; Melquiot and Bugert 2004). 
1.7 HCMV biology 
 
HCMV has a worldwide distribution with an estimated seroprevalence of 45–90% in 
adult populations depending on socioeconomic status. HCMV is an important 
pathogen in immunocompromised patients (e.g. AIDS or tumour patients) and 
individuals with immature (e.g. neonates) or compromised (e.g. pregnancy, patients 
with organ transplantation) immune responses. However, HCMV appears to be 
relatively harmless in most immunocompetent individuals. Following an acute 
infection, HCMV establishes lifelong persistence in its host. Exposure to HCMV 
results in the induction of a comprehensive humoral and cellular immune response 
that is not capable of completely suppressing reactivations or superinfection with a 
different strain (Gandhi and Khanna 2004; Cannon et al. 2010; Boeckh and Geballe 
2011). HCMV has broad host-cell tropism during acute infection that include 
epithelial cells, fibroblasts, smooth muscle cells, endothelial cells and macrophages 
(Sinzger et al. 2000). 
The development of efficient cell culture methods in the middle of the last century 
enabled the isolation and propagation of HCMV to be reported by three groups 
independently in 1956 and 1957 (Wilkinson et al. 2015).  The detection of HCMV in 
clinical specimens initially required weeks of cultivation to isolate the virus. In the 
1980s, rapid diagnosis was enabled by adopting immunofluorescence assays capable 
detecting HCMV antigens, in particular the major immediate early protein.  Rapid 
diagnosis proved invaluable with the advent of antiviral therapies in the 1990s. 
Antiviral therapy and enhanced patient management has improved the outcome for 
solid organ and bone marrow transplant patients with HCMV disease. Further 
advances in diagnosis (notably PCR) has aided patient management over the past two 
decades. Nevertheless, HCMV still accounts for substantial morbidity, mortality, and 
cost (Boeckh and Geballe 2011).   
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1.7.1 HCMV Epidemiology 
 
HCMV infection was originally detected in the 19th century when they studied organs 
in people who had died from unknown causes. Histologically the lesion contained 
cytomegalic cells with intranuclear inclusion bodies in epithelial and salivary glands 
that reflect the name ultimately given to the virus (Just-Nubling et al. 2003). Infection 
were widely reported in newborns during the early 20th century that were detected 
as large cells in the urine of children and associated with cytomegalic inclusion 
disease, a severe congenital disease associated with a characteristic owl’s eye 
cytopathology 
HCMV is transmitted from one person to another through contact with infected 
bodily fluids, such as urine or saliva, including sexual transmission. HCMV is the 
most common cause of congenital infection and can be transmitted to the foetus at 
any trimester of pregnancy (Cannon and Davis 2005; Kagan and Hamprecht 2017).  
HCMV infection is manifest as an exceptionally wide range of clinical conditions 
and thus, unlike MC, infections cannot be reliably diagnosed from its symptoms but 
requires laboratory tests. The vast majority of primary HCMV infections are 
subclinical, indeed most are thought to be mild or asymptomatic.  Nevertheless, 
HCMV is capable of causing disease in the immunocompetent, it is a significant 
cause of infectious mononucleosis and hepatitis. However, serious disease is most 
evident among immunocompromised persons, most notably persons with HIV 
infection and organ transplant recipients on immunosuppressive treatment. Infants 
who born with HCMV can suffer from permanent disabilities including hearing loss, 
vision loss, and mental retardation (Scholz et al. 2003; Scholz et al. 2004).   
Kenneson and Cannon reviewed studies that reported results of systematic 
cytomegalovirus screening on foetuses and/or live-born infants by comparing the 
incidence of live-born infants with HCMV in a series of 34 papers (Kenneson and 
Cannon 2007). Estimates of HCMV infection at birth ranged from 0 to 13.6%, with 
newborns from the Gambia having the highest prevalence (13.6%). However, they 
found the average of prevalence of congenital HCMV from 27 culture-based 
universal study groups was 0.64%. Another study carried in Germany found 0.2% of 
newborns had HCMV infection and one study from Brazil had a birth prevalence of 
0.10%. However, in this study the screening was conducted by testing for IgM in 
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dried bloodspot cards, a method known to have a lower sensitivity than PCR or 
culture. (Dollard et al. 2007; Kenneson and Cannon 2007). The extent of foetal 
damages depended on when virus was transmitted during pregnancy.  When the 
mother was infected for first time (primary infection) during pregnancy the disease 
in the foetus tends to be more severe infection than following HCMV reactivation in 
the mother.  Congenital infection can cause hepatomegaly, the CNS sequalae like 
cerebral calcification, vision and hearing losses, mental retardation etc, and hydrops 
fetalis. HCMV disease is also less severe when the virus is acquired later, indeed 
perinatal and early postnatal HCMV infection is ten times more common than 
congenital infection (Lubeck et al. 2010).  
The prevalence of HCMV in developing world higher than in developed world. The 
acquisition of HCMV in the developing world is nearly universal in early childhood, 
in South America, Sub-Saharan Africa, East Asia, and India more than 90% of 
preschool children are HCMV antibody positive (>90%). In contrast, in Great Britain 
and in certain populations in the United States less than 20% of children of similar 
age are seropositive. 60% of children 4 to 7 years of age in Chengdu, China were 
HCMV seropositive. In Taipei, Taiwan, 58% of children 4 to 12 years of age are 
HCMV seropositive. 61% of low-income population of hospitalised paediatric 
patients in Rio de Janeiro, Brazil are HCMV seropositive (Boppana and Fowler 
2007). Similarly, 56% of children aged 1 to 4 years in Jamaica were HCMV antibody 
positive. The HCMV prevalence rate in Finland increased from 27% in children 7 
months of age to 41% in children 8 years of age in 8 years study. In a population 
survey in Parma, Italy HCMV seroprevalence increased from 28% in two-year olds 
to 96% in 45–54-year-old. Similarly, in Spain, the HCMV seroprevalence rate in 
children 2 to 5 years of age was 42% increasing to 79% in adults 31 to 40 years of 
age. In studies included only blood donors in Asia and Africa continue to have 
HCMV seropositivity rates of 95%–100%, whereas, HCMV seropositivity rates in 
blood donors in Germany had lower ranging from 30% in 18 to 20-year olds to >70% 
in adults >65 years of age (Boppana and Fowler 2007). The prevalence of HCMV in 
the community is significant as it has a direct impact on the ratio of congenital 
infections that come from either a primary infection or a reactivation in the mother. 
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1.7.2 Cellular tropism of HCMV in vivo  
HCMV infects only humans. It can infect virtually any tissue because of its wide 
cellular tropisms. There are no animal models to study HCMV, studying patient 
samples and autopsy materials are the only source to interpret HCMV pathogenesis. 
Dynamic aspects of viral replication and spread have generally only been addressable 
within the blood compartment (Rice et al. 1984; Emery et al. 1999).   
When the route of transmission of infection by saliva in primary HCMV infection, 
the first cells to be infected are epithelial cells of the rhinopharynx.  With sexual 
transmission the epithelium of the genital tract is infected first. Historically, HCMV 
was sometimes transmitted in blood transfusion where endothelial cells of the 
vascular tree and circulating myeloid cells would be first exposed to infection. The 
haematogenous dissemination may be initiated by leukocytes recruited to the primary 
site of infection, which then take up virus spread through the blood and lymphatic 
systems. HCMV can establish systemic infections that can implicate virtually all 
organs in the body, the virus can commonly be recovered in the salivary glands, 
kidneys, liver and mammary glands. Accordingly, HCMV diagnosis can be achieved 
by detection (historically isolation) of the virus in secretion products from these 
organs including saliva, urine or milk. HCMV disease is routinely assessed by 
monitoring virus load in the blood by PCR (DNAemia), although measuring the pp65 
antigen (ppUL83) in peripheral blood polymorphonuclear leukocytes and monocytes 
(antigenemia), immediate early (IE) or late mRNA (RNAemia) provides direct 
evidence of active virus replication. Once the acute phase of primary infection is 
controlled by the immune response, HCMV enters a period of clinical latency where 
the virus is difficult detect and even more difficult to isolate (Gerna et al. 1990; 
Boeckh et al. 1992; Gerna et al. 1992; Boeckh and Boivin 1998). 
By using leukocyte-depleted blood in blood transfusion HCMV transmission by 
blood transfusion was significantly decreased (Yeager et al. 1981; Gilbert et al. 
1989); this provided an early indication that the virus could persist in peripheral blood 
leukocytes (PBL). Following up on this observation using recently developed 
sensitive PCR assay, it was revealed that a CD14+ monocyte population rather than 
a T cells, B cells or PMNL fraction of peripheral blood carried HCMV DNA (Taylor-
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Wiedeman et al. 1991; Taylor-Wiedeman et al. 1993). The monocytes derive from 
CD34+ haematopoietic cell precursors been shown to be carriers of the virus 
(Mendelson et al. 1996; Sindre et al. 1996). Infection of monocytes can be considered 
as ‘latent carriage’ as virus production is not observed until the cells differentiate into 
macrophages, DCs of Langerhan’s cells.  Long-term latency of HCMV DNA may be 
the bone marrow progenitors of the monocyte and myeloid lineage or an associated 
bone marrow stromal cell (Hahn et al. 1998; Sinclair and Sissons 2006). 
 
Endothelial cells (EC) and epithelial cells are important targets for HCMV infection. 
HCMV exploits EC as a means to disseminate the infection. EC are present in the 
microvascular of capillaries and venules of many organs which include the entire 
gastrointestinal tract, lungs, kidneys, liver, salivary glands and brain (Sinzger et al. 
1995). The macrovascular EC were also shown to be susceptible to HCMV lytic 
infection. (Maidji et al. 2002; Jarvis and Nelson 2007) . In addition to circulating 
cytomegalic EC, the HCMV can be circulating in blood by peripheral blood 
leukocyte, including PMNL and monocyte/ macrophages (M/M) (van der Bij et al. 
1988).  
 
1.7.3 HCMV replication 
HCMV can establish a lytic (productive) virus replication cycle that follows a set 
pattern of attachment, entry, DNA replication, capsid assembly, DNA encapsidation, 
nuclear egress, secondary envelopment and release or latent carriage where it is not 
readily susceptible to antivirals yet poised to reactivate (Reeves and Sinclair 2008). 
According to convention, the cascade of HCMV gene expression during productive 
infection is divided into three phases.  The IE genes are expressed in from the virus 
in the absence of de novo gene expression and are thus dependent on pre-existing 
host cell transcription factor and viral proteins that enter alongside virions. Early 
phase gene expression occurs in the absence of viral DNA replication whereas late 
genes are activated following replication of the virus genome. Infections can be 
performed in the presence of an inhibitor of protein synthesis (e.g. cycloheximide) to 
limit expression to IE genes and in the presence of an inhibitor of DNA replication 
(e.g. Ganciclovir) to limit expression to early genes. A less artificial means of 
following the cascade of virus (and cellular) gene expression was achieved using 
 34 
temporal proteomics to follow gene expression through the full course of a 
productive infection. This pattern in human fibroblast of all expressed genes could 
be each be classified into one of 5 temporal classes (TP1-5) based on proteomic 
analysis and illustrated in figure 1.7 (Weekes et al. 2014). 
HCMV is like many alphaherpesviruses, it initiates infection by attachment to cell 
surface by heparan sulphate (Compton et al. 1993). HCMV needs gB and gH/gL for 
entry to the cell. It was found that an HCMV gB-null mutant could assemble virus 
particles but was not able to enter cells, the defect could be overcome by treating 
virions with the chemical fusogen polyethylene glycol (PEG) (Isaacson and Compton 
2009). The mode of entry is different according to cell type. HCMV enters fibroblasts 
by direct fusion with the plasma membrane and requires gH/gL but not the 
pentameric complex of gH, gL and pUL128-131. However, HCMV requires the 
pentameric complex to enter into epithelial and endothelial cells where the complex 
promotes macropinocytosis and endosomal fusion. (Vanarsdall and Johnson 2012). 
Feire et al found that during HCMV entry, cellular morphological changes and 
signalling cascades are activated that are consistent with engagement of cellular 
integrins.  An integrin-binding disintegrin-like domain within gB that is conserved 
throughout Herpesviridae, HCMV may uses α2β1, α6β1, and αVβ3 integrins as entry 
receptors and to activate signalling during the penetration stage of the entry pathway 
(Feire et al. 2004).  
After attachment of viral envelope glycoproteins with cellular receptors on 
fibroblasts, the virion merges with cell membrane, in the cytoplasm, the HCMV 
releases its capsid and tegument proteins. After endocytosis in epithelial and 
endothelial cells the HCMV uses its envelop glycoprotein to survive in low pH 
endosomes. The nucleocapsid bind to microtubules travel to the nucleus while 
tegument proteins (e.g. pp65 and pp71) are released into the cytosol. Some tegument 
proteins remain in the cytoplasm while others access to the nucleus through nuclear 
pore along with viral genomic DNA (Kalejta 2008; Smith et al. 2014). The 
herpesvirus genome transcription and replication occur in the nucleus followed by 
assembly of the capsid, the encapsidated virion buds through the nuclear envelope. 
The virus finally assembled by adding additional tegument proteins and the final 
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virion envelope in the assembly compartment (AC) prior to egress using the cellular 
secretory apparatus (Smith et al. 2014).  
 
1.7.4 HCMV propagation in vitro  
The first in vitro propagation of virus from two neonates who had cytomegalic 
inclusion disease (CID) was in 1954 by Margaret Smith. The Davis strain was 
isolated by Thomas Weller from culture of liver biopsy with embryonic muscle cells 
from a patient with suspected toxoplasmosis, after that the strains Esp and Kerr were 
grown from patients with CID. The agent in the end was called human 
cytomegalovirus.  While Wallace Rowe was culturing adenoid tissue when the 169th 
sample, from a seven-year-old girl, the infection characterized by intranuclear 
inclusion bodies, this leads to isolation of the HCMV strain and they designated 
AD169 (Wilkinson et al. 2015). Plotkin and co-workers subsequently isolated 
HCMV strain Towne from the urine of infected infant, they deliberately sequentially 
passaged the virus 125 times in WI-38 fibroblasts in order to attenuated the virus to 
use as a potential live vaccine (Plotkin et al. 1975). 
Strain AD169 was the first HCMV genome to be sequenced completely (Chee et al. 
1990). Comparing the data of AD169 with other strain later revealed frameshift 
mutation in three genes (RL5A, RL13 and UL131A) and a deletion of 19 genes at 
the right end UL region (the UL/b region: UL133-UL150) that was substituted by an 
inverted duplication of a sequence from near the end of left genome, that leads to a 
substantial expansion of RL sequence (Cha et al. 1996). Furthermore, some stocks 
contain a deletion in genes UL42 and UL43 (Cha et al. 1996; Davison et al. 2003b). 
An effect of passaging HCMV strain Towne (ATCC VR-977) was to produce two 
variants, one exhibiting the loss of the UL/b′ and the other intact in this region. 
Nevertheless, both variants have mutations in genes RL13, UL1, UL40, UL130, US1 
and US9 (Bradley et al. 2009). Cultured AD169, Towne, and Davis strains of 
cytomegalovirus (CMV) are able to infect fibroblasts, but not endothelial cells. In 
contrast, the low passage Toledo strain can infect endothelial cells. However, the 
endothelial tropism was lost on passaged Toledo strain through fibroblasts yet 
retained on passage through endothelial cells.  Although the Toledo strain retains 
UL/b′ sequences, it was inverted in passage. Since this was not obvious  
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Figure 1.7: HCMV Gene Expression divided to four or five classes. The analysis is of temporal 
expression of all HCMV proteins detected in a time course of virus infection. (A) a computer analysis 
in which HCMV encoded proteins are classified into four or five temporal profiles.  The protein groups 
have parallels with the classical IE, early (E), delayed E, late (L) and true L classification.  Division 
into 5 temporal profiles (TP1-5) was considered optimal. (B) According to the distance of each protein 
from its cluster centroid number the temporal classes divided into two to fourteen classes, provides 
rational that 5 was the minimum number of classes that provided definition (C) Heat map illustrating 
the temporal regulation of expression of all HCMV proteins detected by proteomics and assigning 
their kinetics in fibroblasts (TP1-5). Figure reproduced from  (Weekes et al. 2014)  
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Figure1.8:  Life cycle of human cytomegalovirus. (A) First the virions attach the cellular receptors, 
then it gives access for tegument and capsid to enter the cells. (B) In the nucleus where the capsid 
travel to, the IE genes are expressed, after that the delayed early genes (DE) are expressed followed 
by late (L) genes. (C) In the nucleus, the capsid is assembled, and then reaches the cytoplasm, it 
followed by budding of the virion which acquire tegument and viral envelope into intracellular 
vesicles at the assembly compartment (AC). (D) It ends by egression of the enveloped virion from the 
cell. Figure and figure legends are adapted from (Jean Beltran and Cristea 2014).  
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when used to annotate these additional genes, it was responsible for genes between 
UL132-UL149 being annotated in reverse numerical order on genetically intact 
viruses. When HCMV strains are propagated in cell culture they change, losing 
properties of the HCMV clinical isolates.  Prolonged passage will result in a loss of 
virulence, as revealed by vaccine trials using strain AD169 and Towne, and 
decreased resistant of infected cells to NK cells (Quinnan et al. 1984; Plotkin et al. 
1989)  
In our laboratory the Merlin stain is in use, it was isolated from HCMV doing PCR-
positive urine sample from a neonatal, the sample kindly provided by Public Health 
Laboratories (Cardiff PHLS/NPHS). To generate sufficient DNA, the viruses were 
amplified using fibroblast cell culture and cloned into an M13 vector and fully 
sequenced using Sanger sequencing. Merlin strain was passaged three times, each 
passage of Merlin involved   infection of an uninfected fibroblast monolayer with cell-
free supernatant. The Merlin strain genome sequenced completely at passage 3 and 
saved in the GenBank with accession number AY446894, it is first World Health 
Organization (WHO) Inter- national Standard for HCMV (Davison et al. 2003b; 
Dolan et al. 2004; Wilkinson et al. 2015). The Merlin virus strain had mutations at 
two genetic loci, in RL13 and UL128, that occurred after limited replication in vitro 
proceeded by cloning. The premature stop codon in UL128 abrogated 
gH/gL/gpUL128/gpUL130 /gpUL131A. Stanton and co-workers test the complete 
wild-type HCMV gene complement was made by retaining back to the original 
clinical sample from which Merlin strain was made, they found that RL13 efficiently 
repressed HCMV replication in many cell types. Also, they found that RL13 mutants 
helped the reproducibility of the virus. The other virus mutation is in the UL128 locus 
that acquired mutations in genes UL128, UL130, or UL131A, it was noticed the virus 
growth was inhibited in fibroblast cells in wild-type form (Stanton et al. 2010).   
The use bacterial artificial chromosome (BAC) clones has major impact in studying 
HCMV. When Shizuya and co-workers developed BAC vector technology, they 
found it capable of capturing and stably maintaining human genomic DNA fragments 
of >300 kilobases (Shizuya et al. 1992). Messerle and co-workers were the first 
research group to adapt the BAC system to CMV studies by cloning mouse 
cytomegalovirus genome as BAC in E.coli then transfecting BAC plasmid into 
eukaryotic cells to generate infectious virus from the bacterial clone (Messerle et al. 
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1997). Borst et al were then able to apply BAC technology to clone the human 
cytomegalovirus (HCMV) strain AD169 (Borst et al. 1999). 
HCMV can be regenerated from BACs containing the virus genome, including the 
Merlin BAC (Stanton et al. 2010). BAC vectors are based on studying Escherichia 
coli F factor. The Replication of the F factor in E. coli is controlled to keep it at in 
low copy number and retained in bacterial cells (Borst et al. 1999). For cloning 
HCMV genomes into BAC constructs, BAC vectors are first engineered to contain 
arms of homology to viral genome sequences flanking the site of BAC insertion. 
Then, linearized BAC vectors are delivered into HCMV infected cells where they 
may capture integrated into the HCMV genome by homologous recombination. By 
maintaining HCMV genome in E. coli, it avoids in vitro selection of HCMV gene 
mutations, and the infectious virus can then be recovered by DNA transfection of 
permissive cells. The BAC vector-based cloning facilitates manipulation of viral 
genome and provides genetically defined virus (Borst et al. 1999).   
BAC clones are stable when propagated or manipulated in E. coli and not prone to 
spontaneous deletions or rearrangements. However, the manipulation of viral 
genome in BACs, can lead to large-scale engineered deletions, insertions, or other 
rearrangements which may have impact on the virus replication efficiency or genome 
stability has often been overlooked (Cui et al. 2009). With modern sequencing 
technologies it is now feasible to routinely sequence HCMV genomes to monitor 
sequence fidelity in BACs, following transfection and through passage. 
 
1.8 HCMV downregulation of MHC-1  
 
MHC class I molecules are found on the cell surface of most nucleated cells, but not 
on the red blood cells. The MHC encodes the human leukocyte antigen (HLA) gene 
complex and is found on the short arm of chromosome 6, band p21.3 (Kulski et al. 
2002). MHC class I molecules are heterodimers a 45 kDa heavy chain consists of a1, 
a2, and a3, and the smaller 12kDa β2-microglobulin (β2m) subunit. The two chains 
are linked non-covalently via an interaction between α3 domain and β2m. The α 
chain is polymorphic and encoded by a HLA gene, while the β2m subunit is constant. 
On the upper surface of the MHC class I molecule, the α1 and α2 domains form a 
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groove, the peptide-binding site, which binds antigenic peptides of 8–10 amino acids 
in length. Most peptides presented by HLA-I molecules are derived from translation 
products that have been degraded in the cytoplasm by the multisubunit proteasome 
complex (Jones 1997) (figure 1.9).  
MHC class I molecules consists of the classical (class Ia) HLA-A, -B, and -C and 
non-classical MHC molecules HLA-E, -F and -G, antigens. By comparing non-
classical HLA molecules, to classical HLA, the non-classical HLA molecules have a 
low genetic variability, their own expression pattern, particular structural 
organization and function (Koller et al. 1988; Bjorkman and Parham 1990; Geraghty 
et al. 1990). The assembly and folding of MHC class I occurs within the endoplasmic 
reticulum (ER) lumen and peptide binding is needed for assembly process. The 
transporter associated with antigen processing (TAP) is responsible for translocating 
peptide from cytosol, where they are generated, into the ER lumen by where they can 
bind HLA-I (Abele and Tampe 1999). In ER, the chaperones facilitate the folding of 
nascent HLA-I molecules heavy chain and β2m. The immature HLA-I HC and β2m 
dimeric complex binds to TAP along with the chaperones calreticulum and ERP57 
(Pamer and Cresswell 1998; Antoniou et al. 2003). Tapasin is important for HLA-I 
assembly, it acts as a bridging molecule between the HLA-I/chaperone complex and 
TAP. Also, it is crucial for high affinity peptide to bind to HLA- I molecules. Once 
the peptide is loaded onto the HLA-I HC, the complex dissociates and the newly 
formed trimeric HLA-I complex then traffics through the Golgi apparatus to the 
plasma membrane (Spiliotis et al. 2000; Williams et al. 2002).  The summary HLA -
I antigen presentation pathway is showed on figure 1.9. 
The MHC class I chain-related (MIC) genes are located in chromosome 6 within the 
MHC class I region. The MIC genes have seven loci (MICA–MICG) but only MICA 
and MICB are transcribed. MICA and MICB have molecular mass of 43kDa from 
383 amino acids polypeptide. MICA/B have 18–30% similarity to classical HLA 
class I and whilst also normally possessing three external domains (α1–3), a 
transmembrane domain and (usually) a cytoplasmic domain, MICA/B does not bind 
β2m or peptide.  MICA/B expression is thus TAP independent (Groh et al. 1996). 
MICA/B is expressed by monocytes, keratinocytes, fibroblasts, endothelial cells, 
epithelial cell lines and most epithelial tissues. (Bahram et al. 1994; Bahram et al. 
1996; Groh et al. 1996; Zwirner et al. 1999; Bahram 2000). MICA/B is a ligand to 
NK2GD, an activating receptor expressed on all NK cells, all γδ Τ cells and some αβ 
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CD8+ T cells. The activation of NKG2D in NK cell receptor occurs through the 
transmembrane adapter protein DAP10 (Bauer et al. 1999; Wu et al. 1999).       
MICA is polymorphic with more than 50 recognized human MICA alleles (Robinson 
et al. 2001). In comparison with MICA, MICB is less polymorphic with only 17 
different alleles (Fischer et al. 2000).   Due to stop codon MICA*008, MICA*023 
and MICA*028 alleles have truncated cytoplasmic tail. Studies have established that 
MICA*008 is the most common allele in North American with a frequency of 66.9% 
(Robinson et al. 2001; Zhang et al. 2001).  
The HCMV US6 gene family downregulates of HLA-I from the cell surface these 
inhibitors include US2, US3, US6 and US11. HCMV US3 is expressed during IE 
period of viral replication around 1–4 h post-infection and alters HLA-I antigen 
presentation. There are three transcripts produced by the US3 open reading frame 
through alternative splicing (Ahn et al. 1996; Liu et al. 2002). The largest transcript, 
producing a 22 kDa protein, it is able to retain the fully assembled MHC class I 
complexes in the ER (Ahn et al. 1996). The transmembrane and ER-luminal domains 
of US3 is needed to downregulate MHC I by binding chaperon tapasin and inhibiting 
peptide loading. Also, US3 uses US2 gene product to enhance degradation of MHC 
I. Interestingly US3 binds newly synthesized class II α/β heterodimers and prevent 
its assembly interfering with MHC II antigen presentation (Hegde et al. 2002; 
Chevalier and Johnson 2003; Noriega and Tortorella 2009). US2 and US11 genes are 
also expressed early in infection and prevent HLA-I cell surface expression by 
promoting their retrograde transport to the cytosol where they are rapidly degraded 
by proteasomes (Wiertz et al. 1996a; Wiertz et al. 1996b; Jones and Sun 1997). A 
single glutamine residue within the transmembrane domain of US11 is responsible 
for ubiquitination and degradation of HLA-I heavy chain, interestingly the 
cytoplasmic tail residues of US2 are important for HLA-I instability (Lilley et al. 
2003; Noriega and Tortorella 2008). Also, US2 downregulates MHC II by degrading 
the HLA-DR-alpha and DM-alpha molecules (Tomazin et al. 1999). US2 
downregulates HLA-A2, HLA-B27, and HLA-G gene products. However, it has no 
effect on HLA-B, -C or -E alleles or soluble HLA-G1. It was found that US11 
induced the degradation of HLA-A2 but not HLA-G (Barel et al. 2003a; Barel et al. 
2003b). This supports the hypothesis that US2 and US11 work in different ways even 
though their degradation pathways are similar (Soetandyo and Ye 2010). 
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Figure 1.9: The assembly of MHC class I. (1) In the cytoplasm protein is degraded to peptides by 
the proteasome. (2) By using TAP, the peptides are transported into the ER. (3) The heavy chain of 
HLA class I molecules binds to β2m in the ER lumen with help of the ER chaperones calnexin, 
calreticulum and ERP57. (4) The calreticulum and ERP57-HLA class I complex with TAP. The 
tapasin aids peptide binding. (5) After peptide binding to HLA class I molecules the TAP dissociated 
from the HLA-class I complex which then transported through the secretory pathway to presented on 
surface of plasma membrane.  The diagram is adapted from (Hewitt 2003). 
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Figure 1.10: Downregulation MHC I molecules by HCMV. The cartoon details the inhibition of  
HLA-I antigen presentation during HCMV replication. US3 (blue) retains HLA-class I in ER by 
making a complex with it. US3 blocks PLC complex interaction by binding to TAP1 and tapasin. US2 
(red) uses SPP/TRC8  pathways and US11 (yellow) uses Derlin-1/TMEM129 ERAD pathways to 
translocate HLA class I molecules to ERAD pathways which lead to its degradation in proteosomes. 
US6 (green) blocks  TAP -dependent peptide translocation into the ER. ER, endoplasmic reticulum; 
ERAD, ER-associated degradation; TRC8, translocation in renal carcinoma, chromosome 8 gene; 
SPP, signal peptide peptidase; PLC, peptide loading complex (Halenius et al. 2015). 
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The mode-of-action of HCMV US6 is quite distinct from US2, US3 and US11 in that 
it prevents cytosolic peptides being transported to the ER by the TAP complex 
(Lehner et al. 1997). GpUS6 binding to the ER luminal side of TAP1 causes a 
conformational change that prevents the binding of ATP (Ahn et al. 1997). It was 
found that just the peptide from 89 to 108 is sufficient to inhibit antigen presentation 
(Dugan and Hewitt 2008). US6 inhibits classical HLA- I alleles and non-classical 
alleles HLA-G (Jun et al. 2000). The effect of US6 family on MHC I is summarized 
in figure 1.10. 
UL142 encodes an MHC-I-related glycoprotein that inhibits the surface expression 
of full-length MICA but not the truncated MICA*008 allele (Chalupny et al. 2006; 
Ashiru et al. 2009). The luminal and transmembrane domains of UL142 sequesters 
the full-length MICA alleles in the ER and cis-Golgi apparatus. However, it has 
effects only on nascent MICA but not mature cell surface MICA (Ashiru et al. 2009). 
Fielding and co-workers recently showed that the US12 gene family played a major 
role in regulating MICA. Although both US18 and US20 were capable of acting 
independently to promote lysosomal degradation of MICA, they were more efficient 
when working together and in the context of a productive HCMV infection (Fielding 
et al. 2014; Fielding et al. 2017).  
 
1.9 HCMV NK evasion functions 
 
NK cells are derived from CD34+ hematopoietic progenitor cells, in the bone marrow 
and were first defined as large granular lymphocyte (non-T cells, lacking CD3) that 
were able to lyse tumour cell without any priming or prior activation (Farag et al. 
2003). NK cells are an innate immune cell capable of combating infections. NK cells 
unlike B or T cells do not require receptor rearrangement in order to recognise virus 
infected cells or tumour cells. Rather, NK cells are heterogenous group of cells that 
differentially express a wide range of activating and inhibitory receptors that 
determine their individual specificity (Long 1999; Bottino et al. 2005).  NK cells are 
responsive to cytokines and interferons and become activated when their surface 
receptors recognise an excess of activating over inhibitory ligands on the surface of 
infected cells (Santoli et al. 1978; Trinchieri et al. 1978; Lanier 2005).   
 NK cells, neutrophils, dendritic cells, and macrophages, act in concert to suppress 
virus infections, the neutrophils interact with natural killer cells, they help each other 
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in maturation, activation, and effector functions (Mocsai 2013; Scapini and 
Cassatella 2014). The NK cell  stimulated with IL-15 and IL-18 use IFN-γ 
and granulocyte macrophage colony-stimulating factor (GM-CSF) to sustain 
immune response and  modulate neutrophils activation and survival (Costantini et al. 
2010). Apoptosis of neutrophils is enhanced by NKp46 and Fas-dependant human 
NK cell functions, and this NK cells can restrain inflammation (Thoren et al. 2012). 
Interestingly, the neutrophils also modulate NK cell maturation and activation and 
have effect on NK cells function and homeostasis beside cytokine production and 
NK cell licensing (Jaeger et al. 2012). 
Macrophages control NK cells by the expression of ligands and cytokines secretion, 
at same time NK cells kill the virus infected macrophages to cease the virus infection 
(Michel et al. 2012). NK cells are regulated by interactions with dendritic cells. 
Interestingly, NK cells can activate dendritic cells (DC) and they influence on 
subsequent effector functions on DC. The mature DCs release IL-12 and IL-15 
cytokines that activate NK cells and induce their proliferation, the activated NK cells 
induce DCs maturation by secreting IFN-γ,  tumour necrosis factor-α (TNF-α ) and 
GM-CSF then NK cells eliminate autologous immature DCs  (Gerosa et al. 2002; 
Ferlazzo et al. 2004; Morandi et al. 2006; Goldszmid et al. 2012)   
NK cells are particularly important in the control of herpesvirus infections.  Genetic 
deficiencies in NK cell function are rare but often associated with increased incidence 
of herpesvirus infection, in particular by HCMV and EBV (Biron et al. 1989; Gazit 
et al. 2004). NK cells are one of the innate immune cells which react to a decreased 
levels of HLA class I expression on target cells, also they are sensitive to the release 
of proinflammatory cytokines. However, NK cell activation is the result of a 
summation of activation and inhibitory receptors. KIR constitute a family of NK 
receptor that primarily recognise MHC class I. Although the majority of KIRs are 
inhibitory, they are paired with a subset of activating receptors. Depending on 
signalling molecules recruited by their cytoplasmic domains, KIRs can provide either 
an activating or an inhibitory signal. LIR1 (LILRB1/ILT2/CD85j/PIRB) is another 
inhibitory NK cell receptors that recognises HLA class I, thus, normal self-
recognition acts to suppress killing by NK cells. As mentioned previously, the 
HCMV US6 family downregulates MHC I using multiple mechanisms, the 
consequence of MHC I downregulation is to release the repression on NK cells, a 
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well-recognised phenomenon known as ‘missing self’ (Wilkinson et al. 2008; 
Hoglund and Brodin 2010; Yokoyama et al. 2010; Pegram et al. 2011). 
HLA-E is non-classical HLA class-I molecules which binds the inhibitory receptors 
CD94/NKG2A, to inhibit NK cell-killing. However, HLAE also binds to 
CD94/NK2C, which is an activating receptor expressed on the surface of NK and T 
cells, albeit binding to the paired activating receptor is 6 times weaker than binding 
to the inhibitory receptor (Borrego et al. 1998; Braud et al. 1998; Kaiser et al. 2008). 
HLA-E is expressed on the surface of the cells of most tissues that express classical 
HLA-I, it binds to nonamers of conserved peptide that is derived from leader 
sequence of signal peptide of  HLA class I and  HLA-G (Braud et al. 1997). The 
signal peptide peptidase enzyme cleaves the signal peptide from HLA-I peptide and, 
following its release, the signal peptide is further processed by intramembrane 
protease (Lemberg et al. 2001; Weihofen et al. 2003). Following release into the 
cytosol, the residual peptide is further processed in the proteasome to produce shorter 
peptide that are transferred to the lumen of the ER by TAP where it can bind HLA-
E and promote its transport to the cell surface (Lee et al. 1998). US6 downregulates 
HLA-I by blocking TAP, but as a result of it also downregulates HLA-E. Both these 
properties of US6 can be expected to stimulate NK cell recognition. However, the 
signal peptide of gpUL40 is responsible for rescuing HLA-E cell surface expression 
by providing a nine amino acid sequence (VMAPRTLIL) to HLA-E in a TAP 
independent way, accordingly the UL40 protects HCMV infected cells from and lysis 
by CD94/NKG2A+ NK cells (Tomasec 2000; Ulbrecht et al. 2000). 
HCMV UL141 glycoprotein (gpUL141) is able to downregulate NK cell killing. 
gpUL141 downregulates surface expression of CD155 (nectin-like molecule 5; 
poliovirus receptor), which is a ligand for the NK cell activating receptors DNAM-1 
and TACTILE, also known as CD226 and CD96 respectively (Tomasec et al. 2005). 
gpUL141 acts by sequestering CD155 in the ER. CD155 is involved in cellular 
adhesion, motility, transendothelial migration, focal adhesions and endocytosis and 
only becomes exposed on the cell surface when normal cell-to-cell interactions are 
disrupted by virus infection or cell transformation. HCMV infection is able to disrupt 
normal intercellular interactions (Stanton et al. 2007).  CD112, also known as nectin 
2, is normally involved in adherent junctions but also becomes exposed when normal 
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intercellular interactions break down. Like CD155, CD112 is also a ligand for the 
NK cell activating receptor DNAM-1. HCMV gpUL141 downregulates CD112 from 
the cell surface then recruiting US2 to target the cellular protein for proteasomal 
degradation, gpUL141 thus removes two activating ligands for DNAM-1 from the 
surface of HCMV infected cells.  (Prod'homme et al. 2010; Hsu et al. 2015). 
HCMV-encodes UL142 glycoprotein that is able to neutralize NK cell killing in 
HCMV infected cell , gpUL142 has a  homology to HLA class I and in silico analysis 
reveals secondary structure prediction delineatation of  HLA class I alpha-1 and 
alpha-2 domains that in HLA class I which may have the  ability to bind peptide 
(Wills et al. 2005). It was found that UL142 down regulates cell surface expression 
of MICA NKG2D ligands of NK cells, by retaining MICA in the ER and the cis-
Golgi apparatus.  GpUL142 down-modulated surface expression full-length MICA 
alleles. However, the truncated allele MICA*008 is immune from attention of UL142 
(Chalupny et al. 2006; Ashiru et al. 2009).  
The US12 gene family of HCMV consists of a sequential array of 10 genes extending 
from US12 to US21 in a tandem arrangement (figure 1.4). Their encoded proteins 
each contain. a seven-transmembrane domain (7TMD) and homology with the BAX 
Inhibitor-1 (BI-1) protein, that function as apoptotic enhancer (Lesniewski et al. 
2006). Fielding and co-workers found that the US18 and US20, inhibit NK cell 
mediated cytotoxicity by downregulating full length MICA in HCMV infection, 
(Fielding et al. 2014). Another study performed by Fielding et al demonstrated that 
the HCMV upregulates the surface expression of B7-H6. However, NK cell killing 
is inhibited by HCMV US18 and US20 encoded protein by downregulating B7-H6 
surface expression, by sending them to endosomal degradation (Fielding et al. 2017) 
The UL18 glycoprotein has similarity to HLA class I molecules, that has ability to 
bind b2m and presenting peptide (Beck and Barrell 1988). GpUL18 is able to bind 
LIR-1 receptors 1000 times more efficiently than HLA class I (Beck and Barrell 
1988; Leong et al. 1998; Kaiser et al. 2008). Prod'homme and co-workers found that 
the gpUL18 able to inhibit cytotoxicity LIR1+ NK cells. However, it stimulates LIR-
1- NK cells (Prod’homme et al. 2007).       
HCMV also express a small, non-coding microRNAs, to date twenty-four miRNAs 
have been described to be encoded by HCMV during the lytic and the latent infection 
phase, they target certain viral and cellular transcripts which helps HCMV to evade 
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immune responses. They also affect viral replication, cell cycle, and mediate latency 
(Grey et al. 2007; Hook et al. 2014; Kim et al. 2015; Meshesha et al. 2016). miR-
UL112-1 is one viral miRNA that is expressed during latency in primary myeloid 
cells and during lytic infection, where it inhibits the activation of a stress ligand of 
the NK cell activating receptor NKG2D by targeting MICB transcript (Stern-
Ginossar et al. 2007; Meshesha et al. 2016). 
The glycoprotein UL16 is able to retain ULBP1, ULBP2, and MICB in ER, that is 
enables HCMV to evade immune response by inhibiting stress activating receptor of 
NK cells NKG2D (Cosman et al. 1997; Kubin et al. 2001; Spreu et al. 2006).  
 
1.10 HCMV MHC-I homologues UL18 & UL142 
The UL18 gene encodes UL18 glycoprotein which has homology to HLA class I,  
it was first discovered when AD169 genome was analysed. GpUL18 is a type I 
transmembrane, which is sensitive to endoglycosidase H with a 67-kDa protein 
molecular weight, it forms a trimeric complex with b2-microglobulin and is able to 
bind peptides (Beck and Barrell 1988; Browne et al. 1990).  UL18 gene encodes 
another form of  the UL18 glycoprotein which is Endo H resistant protein with a 
160-kDa molecular weight. In comparison with HLA class I, which has 1-3 
glycosylation sites, UL18 is heavily glycosylated with 13 N-linked glycosylation 
sites. Also, it is unlike the MHC I as it binds only LIR-1 (Beck and Barrell 1988; 
Cosman et al. 1997). GpUL18 binds to LIR-1 with 1000 times higher affinity than 
HLA class I molecules, gpUL18 also binds to CD94/NKG2C, with 1,000-times less 
affinity when compared to LIR1 (Chapman et al. 1999; Kaiser et al. 2008).  The 
crystal structure of LIR-1 indicates that binding to gpUL18 is mediated through 
similar interfaces as LIR-1 uses to interact with HLA class I molecules (Willcox et 
al. 2003).  
Whilst UL18 is relatively well studied, its function and regulation are not yet fully 
defined. Initially, based on the similarity between gpUL18 and MHC class I 
molecules, Fahnestock et al proposed that the viral glycoprotein could function as a 
molecular decoy for NK cells, inhibiting NK cell lysis (Fahnestock et al. 1995). 
Reyburn et al found that gpUL18 was expressed in MHC class I negative cell line 
and it elicited protection against killing by NK cells (Reyburn et al. 1997). In 
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another study, gpUL18 was reported to enhance NK cell killing compared to control 
cells (Leong et al. 1998). These apparently contradictory findings were explained 
by Prod'homme et al, who studied NK cell degranulation from multiple donors 
targets and found that gpUL18 inhibit LIR1+ NK cells but stimulates LIR-1− NK 
cells (Prod’homme et al. 2007). The capacity of gpUL18 to stimulate LIR-1- NK 
cells has yet to be explained satisfactorily. The explanation proposed is that gpUL18 
may also stimulate an activating receptor.  Since the effect was observed in all 
donors, such a receptor would not be expected to be donor specific. Moreover, the 
observation that gpUL18 also selectively binds the HLA-E binding peptide donated 
by the UL40 signal peptide was unexpected (Prod’homme et al. 2007; Prod'homme 
et al. 2012). What purpose may be served in binding this peptide? UL40 does 
provide the peptide in a TAP-independent manner, so it does provide a source of 
peptide that is immune to the effects of US6. However, the peptide-binding region 
of gpUL18 is not involved in LIR1 binding so its role may lie elsewhere, possibly 
in recognition by an activating receptor. In this context it is interesting to note that 
KIR recognition of MHC-1 does tend to involve the peptide binding domain of 
MHC-1, and can be dependent on the nature of the peptide bound.  
UL142 ORF is encoded by one of genes within the UL/b’ region that is present in 
HCMV clinical isolates and low passaged strains virus which absent from the 
laboratory strains AD169 and Towne. The sequencing of UL142 reveals similarity 
between gpUL142 and gpUL18, both of them comprise the HCMV MHC gene 
family (Davison et al. 2003b). In silico analysis of UL142 reveals that UL142 
encodes MHC-I-related α1 and α2 domains, but not α3 domain. UL142 glycoprotein 
is a heavily glycosylated protein with 17 potential N-linked glycosylation sites, 
gpUL142 inhibits NK cell killing when expressed in isolation but not with all donors 
(Wills et al. 2005; Prod’homme et al. 2007). Chalupny and co-workers found that the 
gpUL142 has the capacity to evade immune response by inhibiting NK killing by 
downregulate the cell surface expression of full-length MICA. However, it fails to 
downregulate the truncated allele of MICA, MICA*008 (Chalupny et al. 2006). 
Another study was performed by Ashiru et al demonstrated that UL142 was mainly 
localized to the ER and cis-Golgi apparatus.  Also, they demonstrated that the ER 
localization of gpUL142 was mediated by also transmembrane domain, while its cis-
Golgi localization was mediated by the luminal domain. In agreement with the study 
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performed by Chalupny et al, they demonstrated that UL142 downregulated surface 
expression of full-length MICA alleles while having no effect on the truncated allele 
MICA*008. In addition, their data demonstrate that the UL142 retains full-length 
MICA alleles in the cis-Golgi apparatus and gpUL142 luminal and transmembrane 
parts were involved in recognition and intracellular sequestration of MICA. They 
suggested that UL142 has no effect on mature MICA on the cell surface, but interacts 
with nascent MICA and sequestered in the ER (Ashiru et al. 2009). Whilst the effect 
of UL142 on MICA is potentially extremely important, it is also somewhat redundant 
as the US12 family has now been shown to be highly effective at targeting full length 
MICA(Fielding et al. 2014; Fielding et al. 2017).  
1.11 MOCV MHC I homologues genes -MC033 and 
MC080. 
 
The mc033L and mc080R  are MHC-I homologues encoded by MOCV (Senkevich 
et al. 1997). mc080R was studied by Senkevich and Moss in 1998, who demonstrated 
in this study that MC080R protein was glycosylated and localised predominantly 
within the ER and Golgi compartments. MC080R was predicted to have a 
transmembrane domain and shown to bind to β2m in ER, however, it could not be 
detected on the cell surface (Senkevich and Moss 1998). The role of MC033L has 
not been previously studied. 
 
1.12 Aims 
 
The mc33L, mc80R, UL18 and UL142 are all recognised MHCI homologues 
encoded by large DNA viruses. Both HCMV genes have been functionally 
implicated in regulating NK cell recognition. There is indirect evidence that MOCV 
may downregulate cell surface expressions of MHC I as cell surface expression of 
ß2-m is reduced on MC lesions. It is also recognised that the downregulation of 
MHC-I renders HCMV infected cells more vulnerable to NK cell attack, and thus a 
similar situation may hold with MOCV. Thus, building on findings with HCMV, it 
was hypothesised that the MOCV MHC-I homologues may also be involved in 
modulating NK cell function. Moreover, whilst UL142 appears to downregulate full 
length MICA, that function has also been assigned to the US12 gene family.  In 
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studying the MHC-I homologues of two large yet unrelated DNA viruses, the aims 
of this thesis were to: 
1. Generate reagents to characterise the expression and function of MC033 
and MC080 
2. Investigate whether MC033 and MC080 modulate the cellular immune 
response. 
3. Investigate the effect of optimally-expressed UL142 on NK cell 
recognition both when expressed in isolation and in the context of a 
productive HCMV infection.  
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2-METHODS AND 
MATERIALS  
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2.1 SOLUTIONS  
 
All formulated bacterial culture media was sterilized by autoclaving. Prior to addition 
of supplements, media was tempered to 50°C.  
Double-distilled ultra-pure water (ddH2O) used for the preparation of solutions, 
buffers, and media was delivered from a Purelab Ultra water system (Elgin).  
The tissue culture reagents used were from the Gibco product line of Invitrogen/Life 
Technologies (Fisher Scientific, Loughborough, UK) and the analytical grade 
chemicals and bacterial culture reagents used were from Sigma and/or Fisher unless 
otherwise stated. 
 
Ampicillin stock: Ampicillin (Sigma-Aldrich, Poole, UK) was dissolved in H2O at 
50mg/ml and stored at -20°C. 
Bicarbonate Buffer: 2% (w/v) sodium bicarbonate in H2O.  
Block solution: PBS-T containing 5% dry milk powder  
3.5 M CsCL solution: 1.45g/ml CsCl in 5mM Tris HCl, pH7.8 
 
1.6M CsCl solution: 1.33g/ml CsCl in 1mM EDTA, 5mM Tris HCl, pH7.8 
 
Chloramphenicol stock: Chloramphenicol was dissolved in ethanol at 12.5mg/ml 
and stored at -20°C.  
Dialysis buffer for 5 liters:  1mM MgCl2, 135mM NaCl, 10mM TRIS HCl 
pH7.8, 10% glycerol, Make up to 5 litres with water		
DNA loading buffer (6X): 30% glycerol in de-ionised water with 0.25% (w/v) 
bromophenol blue (Sigma-Aldrich) in 0.25% (w/v) xylene cyanol FF (Sigma- 
Aldrich).  
Freezing media: 90% foetal calf serum (FCS) and 10% (v/v) dimethyl sulphoxide 
(DMSO). 
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2x Hepes Buffered Saline (HBS) for 100mL: 274 mM of NaCl, 10 mM KCl,                          
1.4 mM Na2HPO4, 15 mM D-glucose, 42 mM HEPES (free acid), at pH 7.05-7.06 
(by using NaOH) 
  
Immunofluorescence (IF) wash/block buffer: PBS, 1% (w/v) BSA. Depending 
on use, IF buffers differed on the inclusion or exclusion of sodium azide. For 
IE1 immuno-staining, 0.01 % (w/v) sodium azide was added to IF buffer.  
Immunoblot block/stain buffer: PBS-T, 5% (w/v) fat-free milk proteins 
(Marvel)  
Isopropyl β-D-1-thiogalactopyranoside (IPTG): 23.8mg Isopropyl P-D-l-
thiogalactopyranoside (IPTG) (Melford, Ipswich) dissolved in 1ml water to generate 
a l00mM stock solution.  
 
Luria Bertani (LB) broth: 1% (w/v) tryptone, 1% (w/v) sodium chloride 0.5% yeast 
extract dissolved in H2O then autoclaved.  
LB agar: As for LB broth but with 1.5% (w/v) agar added before autoclaving. 
Antibiotics were added before setting in plates.  
LB sucrose selection plates: 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 5% (w/v) 
sucrose 1.5% (w/v) agar dissolved in water then autoclaved. 1:1000 chloramphenicol 
stock, 1:500 X-gal stock and 1:500 IPTG stock were added before setting in plates.  
2x medium (Per 100 ml): 50 ml sterile water, 20 ml 10x DMEM (Gibco 21430), 20 
ml FCS (Invitrogen, 10500), 6 ml sodium bicarbonate (Gibco 25080), 4 ml Pen/Strep 
(Gibco15070063), 2 ml glutamine (Gibco 25030024). 
NK media: 10% of FCS and 5% of Human AB serum were added to RPMI media, 
the media was supplemented with 100 U/mL penicillin, and 100 µg/mL streptomycin, 
and 1% L-glutamine, then 100U/ml of IL-2 and 10ng/ml of IL-15 were added to the 
mix.  
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Phosphate buffered saline (PBS): One PBS tablet (Oxoid, Hampshire, UK) was 
dissolved in 100ml dH2O for making the buffer. It contains 8% (w/v) sodium 
chloride, 0.2% (w/v) potassium chloride, 1.15% (w/v) disodium hydrogen phosphate 
and 0.2% (w/v) potassium dihydrogen phosphate at pH 7.3.  
PBS-T (per 1 L): PBS, 0.5 ml TritonX-100 (Fisher, BP151- 500), 0.5 ml Tween 20 
(Fisher, BP337500) in water  
4% Paraformaldehyde (PFA) solution: PBS, 4% (w/v) paraformaldehyde.  
TBE (10X): 108 g Tris, 55 g boric acid dissolved in deionised H2O to a final volume 
of 920 ml and then 80 ml 0.5 M EDTA pH 8.0 added.  
TE: 10 mM Tris (pH 7.5), 1 mM EDTA sterilized and DNAases inactivated by 
autoclaving.  
Transfer buffer: (per 500 ml): 50ml 20x NuPAGE® Transfer Buffer, 50 ml 
methanol, 400 ml deionised water  
TRIS buffer: 10ml of 1M Tris-Cl pH7.4 was mixed with 2ml 0.5M EDTA, pH8.0 
with water added to a final volume of 1 liter 
1M TRIS-HCl: 121.1g Tris base was dissolved in 1 liter of d H2O and adjusted to 
pH 7.8 with hydrogen chloride.  
X-gal stock: 5-bromo-4-chloro-3-indoyl-p-D-galactopyranoside (X-gal) was 
dissolved in N, N-dimethyl formamide (DMF) to generate a 40mg/ml stock solution. 
Aliquots were stored at -20°C.  
2.2 Antibodies  
 
The used antibodies are listed in table 2.1 
Table 2.1:  The used antibodies in this thesis. 
Antibody Supplier Clone Cataloug number  
 
A- Western Blot    
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1- V5 (mouse, 
monoclonal) 
BioRad SV5-Pk5 
 
MCA2895GA 
 
2- HC10 (mouse) Kindly provided 
by Dr Hidde 
Ploegh 
 
hybridoma 
 
(Stam et al. 1986) 
3- Actine (rabbite) Sigma  Polyclonal  A2066 
B- Flowcytometry     
1- V5 (mouse, 
monoclonal) 
BioRad SV5-Pk5 MCA2895GA 
2- Human HLA-E 
(PE conjugated) 
Biolegend 3D12 342604 
3- human HLA A, 
B, C (Alexia 
flour @ 647) 
Biolegend W6/32 311414 
4- FITC-
conjugated 
CD107 
BD Biosciences H4A3 555800 
5- PE-Cy7-
conjugated CD3 
Biolegend 17A2  100220 
 
6- APC- 
conjugated CD8 
Biolegend HIT8a 
 
300911 
 
7- PE- conjugated 
CD56 
Beckman Coulter N901 
 
IM2073U 
 
8- Isotype 
antibodies: 
- PE conjugated 
mouse IgG1 k 
 
BD Bioscience 
pharmingen 
MOPC-21 
 
555749 
- Mouse IgG2a k alexea           
flour @ 647 
Biolegend  MOPC-
173 
 400234 
- Mouse IgG Sigma    15381 
- FITC-
conjugated IgG1  
BD Biosciences MOPC-21 
 
 555748 
C- Imunofluoresce
nce  
   
1- V5 (rabbite) Abcam ab 9116 GR116421-19 
2- Calnexin 
(mouse) 
Millipore C8.B6  2274261 
3- Giantin (rabbit) Abcam Polyclonal  Ab24586 
4- V5 (mouse, 
monoclonal) 
BioRad SV5-Pk5 
 
MCA2895GA 
D- Secondary  
antiboday  
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1- Alexia flour 
@488 (goat anti-
rabbit) 
Invitrogen 
 
F(ab)2, 
IgG(H+L) 
A11070 
2- Alexia flour @ 
594 
           ( goat anti-
mouse) 
Life technology F(ab)2, 
IgG9H+L) 
A 1102 
3- Alexia flour 
@647  
(goat anti-
mouse) 
Life technology  F(ab)2, 
IgG (H+L) 
A-21235 
 
4- Anti mouse HRP BioRad   
5- Anti- rabbit 
HRP 
BioRAd   
 
Table 2.2: Lasers, excitation wavelength and emmision spectra of 
flourochromes used   for flow Cytometry 
Fluorochrome  Laser (nm)  Emission  
FITC  Argon Laser 488nm  525nm  
PE  Argon Laser 488nm  575nm  
PE-Cy7  Argon Laser 488nm  767nm  
APC  Diode Laser 633nm  660nm  
 
2.3 Cells  
 
2.3.1 Cell lines 
 
The human cervical epithelial cell line, HeLa, were obtained from the American Type 
Culture Collection (ATCC). Human foetal foreskin fibroblasts (HFFFs) were kindly 
provided by Dr Graham Farrar (Porton Down). HF-TERT were made by 
immortalising HFFF cells by transducing them with the human telomerase reverse 
transcriptase (hTERT), provided by Sian Llewelyn-Lacey (McSharry et al. 2001),  
HF-CAR cells were made from HFFF-hTERTs after engineering them to express the 
human Coxsackie adenovirus receptor (hCAR) that facilitates adenovirus infection, 
provided by Dr J. DeGregori (University of Colorado Health Sciences Centre, 
Denver, USA) (Stanton et al. 2008). 293 cells expressing the tetracycline repressor 
protein (293-TREX) were purchased from Invitrogen (Invitrogen, R71007).  
HEK293 cells transduced to express the Adenovirus E1 genome region (Graham et 
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al. 1977), were used for the propagation of AdZ-5 vectors. NPi cells are fibroblast 
cell line derived from a TAP deficient patient (N.P) that are MHC class I and HLA-
E deficient (provided by V. Cerundolo, University of Oxford). Chinese Hamster 
Ovary cells expressing CAR (CHO-CAR) were obtained from ATCC. 
Table 2.3: HLA and MICA genotypes of the donors 
The Donor HLA-A 
genotype 
HLA-B 
genotype 
HLA-C 
genotype 
MICA genotype 
D007 HLA: -A2 -A24 HLA: -B44 -
B44 
HLA: - Cw10 -
Cw10 
MIC-A*00801 
A*00804 
D008 HLA: -A2 -A24 HLA: -B60 -
B60 
HLA: - Cw5 -
Cw5 
MIC-A*00801 
A*00804 
D009 HLA: -A1 -A24 HLA: -B8 -
B44 
HLA: - Cw5 -
Cw7 
MIC-A*00801 
A*00804 
HFFF HLA: -A1 -A24 HLA: -B8 -
B13 
Have not done MIC-A*016 A*027 
 
2.3.2 Tissue culture media 
 
The standard tissue culture conditions for the growth of human cells were 37°C, in 
an environment of 5% CO2.  Dulbecco’s modified Eagle’s medium (DMEM, 
Invitrogen) were used to grow the cells. Media was supplemented with 100 U/ml 
penicillin, and 100 µg/ml streptomycin, and 10% FCS, referred as complete medium 
in text.  The cells were routinely maintained in 150 cm2 flasks, they were allowed to 
reach around 70 to 90% confluency before cells were passaged. Adherent cells were 
passaged by first removing media, then the cells monolayer was washed by using 10 
ml of PBS, then 5ml of trypsin (Trypsin-EDTA (0.05%), phenol red, Gibco by life 
technology) was added and incubated at 37°C with 5% CO2 until the cells detached. 
After that 5ml of complete medium were added to the detached cells, then the cells 
suspension was divided into fresh flasks. 
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2.3.3 Cell counting  
 
The cells were counted using a glass haemocytometer (Fisher, MNK-790-M). The 
counting chamber was loaded with 10 µl of homogenous cell suspensions, and the 
number of cells within grids that held 0.1 µl (1 x 10-4 ml) was counted. Cells counted 
under x10 magnification, and the average number from three grids was obtained. The 
averaged cell count was multiplied by a factor of 10,000 (104) to determine the 
number of cells in 1 ml of the original suspension.  
2.3.4 Cryopreservation of cell lines 
 
The suspension of adherent cells was made as described in section 2.3.2, then the 
cells were centrifuged and resuspended in 1 ml of freezing media and transferred 
immediately to a cryovial tube and placed in freezing container contain isopropanol 
(Nalgene 5100 Cryo 1°C freezing container) (Merck, West Drayton). After that the 
container was transferred to a -80°C freezer for overnight before transfer the cryovial 
tubes to liquid nitrogen freezer.  
2.3.5 Thawing cells  
 
To resurrect cells from liquid nitrogen, the cryovial was transferred in dry ice, then 
thawed rapidly in a 37°C H2O bath. The thawed cells were suspended in 10 ml of 
complete medium. Then they were centrifuged at 470 x g for 5 minutes, then the cells 
were resuspended for counting before using them.  
2.4 Viruses  
 
Table 2.4: The viruses used in thesis 
 
Viruses Source /Reference 
 
RAd-mc080 
 
Genotype 1 molluscum contagiosum mc-080-codon 
optimized with C terminal V5 tag. Made by Hana Elasifer   
RAd-mc033 
 
Genotype 1 molluscum contagiosum mc-033-codon 
optimized with C terminal V5 tag. Made by Hana Elasifer   
vWR293-mc080 Genotype 1 molluscum contagiosum mc080 cloned into the 
replication-competent vaccinia virus Western Reserve (WR) 
strain and designated v293. Made by by Dr Subuhi Sherwani 
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RAd-UL18 
 
Strain Merlin UL18 ORF with a C-terminal V5 tag amplified 
by PCR and cloned in to AdZ vector system. Constructed by 
Dr Sepehr Seirafian and Dr James Davies 
RAd-1253 
 
AdZ-5 vector without insert. Made by Dr Richard Stanton 
RAd-UL142 
 
Strain Merlin UL142 ORF with a C-terminal V5 tag 
amplified by PCR and cloned in to AdZ vector system. 
Constructed by Dr Sepehr Seirafian and Dr James Davies 
RAd961-mc080 
 
Genotype 1 molluscum contagiosum non-codon optimized 
mc080. Made by Virginie Dr Prod’homme and Dr Rich 
Stanton 
1812 
 
The HCMV strain Merlin genome (1111) deleted UL142. 
Made by Dr Peter Tomasac 
1656 
 
The HCMV strain Merlin genome (1111) deleted 
US18+US20. Made by Dr Ceri Fielding  
1111 
 
The HCMV strain Merlin genome was cloned in to a BAC at 
passage 5. Derived from the prototype RL13-, UL128- Merlin 
BAC described in Stanton et al (2010) 
RAd-UL141 
 
Strain Merlin UL141 ORF with a C-terminal V5 tag 
amplified by PCR and cloned in to AdZ vector system 
Constructed by Dr Sepehr Seirafian and Dr James Davies 
RAd-UL142-1A 
 
Strain Merlin UL142 synthesised de novo to contain UL142 
ORF with the signal peptide in the N terminus removed and 
replaced with a signal peptide from preprotrypsin (PPT). It 
has N terminal V5- epitope tag;. Constructed by Dr Rebecca 
Aicheler   
RAd-UL142-2A 
 
Strain Merlin UL142 synthesised de novo to contain UL142 
ORF with the signal peptide in the N terminus removed and 
replaced with a signal peptide from preprotrypsin (PPT). It 
has C terminal V5- epitope tag. Constructed by Dr Rebecca 
Aicheler   
RAd-UL142-3C 
 
Strain Merlin UL142 synthesised de novo to contain the 
UL142 ORF with HCMV endogenous signal peptide. It has 
C terminal V5- epitope tag. Construced   by Dr Rebecca 
Aicheler   
RAd-Soluble UL142 Strain Merlin UL142 synthesised de novo to contain UL142 
ORF, the transmembrane part was cut and it has   C terminal 
V5- epitope tag linked to Bir A Construct. Constructed  by  
Dr Sepehr Seirafian 
 
 
2.4.1 Propagation of Recombinant Adenovirus (RAd) 
stocks  
 
RAd stocks were propagated in 293TREX cells, the used RAd viruses are shown in 
table 2.4. 150cm2 tissue culture flask with 70% confluent 293TREX cells were 
infected by adding virus at an MOI of 0.1 in 1ml of complete medium and incubated 
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at 37°C in 5% CO2. The virus was monitored for Cytopathic effect (CPE), the 
complete medium was changed when it needed. The infected cells were detached 
from the flask and resuspended in complete medium then they were centrifuged at 
470 x g for 5 minutes then the cell pellet was suspended in PBS and centrifuged at 
470 x g for 5 minutes, after that the cell pellet was transferred to -80°C freezer.  
2.4.2 Adenovirus purification by Caesium Chloride  
 
As the virus collected in section 2.4.1 contained cellular debris, a Caesium-Chloride 
(CsCl, Sigma, C3011-500G) gradient was used to purify the virus. 
5ml of PBS was added to the adenovirus infected cell pellet and same volume of 
tetrachloroethylene then was added, the mixture was shaken vigorously then 
centrifuged at 836 x g for 25 minutes to release the virus from infected cells. The 
mixture was separated into three layers, the upper layer contains the virus, the middle 
layer contains the cell debris and the lower layer contains tetrachloroethylene, the 
upper layer was collected in 15ml falcon tube. To make CsCl gradient, 1.6 ml of 
3.6M CsCl solution was pipetted into a 14x 89 mm ultra-clear Beckman centrifuge 
tube (331372, Beckman Coulter), overlaid with 3 ml of 1.6M CsCl solution drop by 
drop, to cause minimal disturbance in the bottom layer. The collected virus then was 
added to the CsCl gradient. The tubes were centrifuged at 90,000 x g for 2 hours 
(SW41 Ti rotor, Ultra Beckman L8-M ultracentrifuge), after centrifugation the 
opalescent virus band in the middle of the tubes was collected using a 19G needles 
and syringes. To remove CsCl from collected virus, it dialysed against a buffer 
solution, the sterile dialysed buffer was added to collected virus to up 2 ml total 
volume which then added to dialysed tubes (Medicell International Ltd, 
DTV12000.01.000). Then it was clipped from both sides and placed in 1 to 2 L of 
dialysed buffer then it rocked at 4oC, the dialysed buffer was changed after 4 hours 
with fresh dialysed buffer, then it rocked at 4oC for overnight. Next morning the 
dialysed pure adenovirus was collected and sterile dialysed buffer was added up to 
5ml total volume and then aliquoted into 500 µl volume in each tube and stored in    
-80°C freezer 
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2.4.3. Adenovirus titration  
 5x105 293 TREX cells were seeded into one well of a 12 well plate (Fisher, TKT-
520-070H). The following day 10-4 and 10-5 virus dilutions were made. 100 µl of each 
dilution was pipetted drop by drop in wells in duplicates. After 48 hs incubation at 
37°C in 5% CO2 the media were removed from infected well, and the cells dried by 
keeping them in the hood for 10 mins. 500 µl of ice cold 1:1 methanol and acetone 
were added to each well and incubated at -20°C for 10 minutes to fix the cells. The 
cells then were washed using PBS containing 1% BSA for 3 times then polyclonal 
goat-adenovirus antibody (Abcam, AB1056) was diluted 1:5,000 in PBS containing 
1% BSA then 0.5ml added to each well and incubated for 1hr at 37°C under constant 
rocking. The cells then were washed using PBS containing 1% BSA 3 times, then 
donkey anti-goat HRP (Santa Cruz Biotechnology, SC- 2056), 1:1000 dilution was 
added and incubated for 30 minutes at 37°C under constant rocking. The cells then 
were washed using PBS containing 1% BSA 3 times, the infected cells detected by 
the ImmunoPure metal enhanced DAB Substrate kit (Thermo Scientific, 34065). 
DAB substrate was used according to manufacturer’s instructions. Substrate was 
applied to cells that were then incubated for sufficient time for signal development 
before counting stained cells. Titres were calculated using the below formula:  
Titre (pfu/ml) = (average of infected cells per field) X (number of fields per well)  
                                                (Virus volume (ml)X (dilution factor) 
 
2.4.4 Growth of HCMV stocks 
To grow HCMV from the stock with known titre, 70% to 90% confluent HF-TERT 
cells in Cell Factories (TKT-175-020M, Fisher scientific) were infected with 50 ml 
of complete medium containing HCMV at an MOI 0.1. The infected cells were 
monitored for CPE and when 70% to 80% of CPE was observed the media was 
collected in 250 ml polycarbonate centrifuge bottles (Fisher, CFS-300-520C) and 
then centrifuged at 30,000 x g for 2 h. Fresh media was added to cell factory and then 
the media was collected again every 48 h, until the monolayer cells had detached. 
After centrifugation the supernatant was discarded and the 1ml of DMEM was added 
to the dislodged pellet and collected in a sterile tube, 0.5 ml of DMEM was added to 
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remaining pellet then it was added to previous collection. The collected virus was 
dissociated using a 19G needle and syringe, the collected virus was centrifuged at 
16060 x g (Biofuge Fresco, Heraeus) for a minute, then the supernatant was 
transferred to sterile tubes and stored at -80°C freezer.  
2.4.5 HCMV titration by plaque assay 
3x105 of HF-TERT were seeded into a single well of a 6 well plate, the next day the 
10-6, 10-7 and 10-8 virus dilutions were made. The media were removed from the wells 
and 1ml of virus dilution was added to each well in duplicates, then they rocked for 
2 hs at 37°C in 5% CO2. After removing the virus, the 10ml of overlay media was 
added to infected cells which is a mixture of 1:1 of 2% avicel and 2x media then 
incubated at 37°C and 5% CO2 for 2 weeks. The overlay used to restrict free transfer 
of released virus from the infected cells and prevent cell to cell infection 
transmission. After 2 weeks the overlay media was removed, and the cells were 
washed for 2-4 times with PBS. Plaques were counted in each duplicate using a light 
microscope, titres were calculated using the below formula:  
Titre (pfu/ml) = Average number of plaques per well   
                            Dilution factor x virus volume (ml)  
 
2.4.6 Lentivirus  
 
2.4.6.1 Making lentivirus expressing mc080 and mc033 by transfection 
by calcium phosphate DNA precipitation  
 
45µg of mc033 or mc080 pHAGE plasmids, 32 µg of p8.91 plasmid and 13µg of 
pMDG plasmid (p8.91 and pMDG plasmids were kindly provided by Dr Katja 
Finsterbusch) were added into HEPES buffered dH2O (2.5mM) to a final volume of 
750µl then they were mixed gently and incubated at room temperature for 5 minutes. 
Then the DNA-water mix was added to 750µl of 500mM CaCl2, the DNA-CaCl2 
mixture was added drop by drop, into a tube containing 1.5ml of 2x HBS, while 
continuing to vortex the tube. The mixture was incubated at room temperature for 30 
minutes, 3mls of DNA-CaCl2-HBS mixture was added drop by drop using a transfer 
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pipette, for each culture flask of HEK293 cells then placed in the 37°C 5% CO2 
incubator. The medium was removed from each flask 6 hours post transfection then 
they were washed gently with 20mls sterile PBS, and then 25mls of fresh, warm 
complete DMEM was added to each flask and incubated at 37°C and 5% CO2. 
 
2.4.6.2 Lentivirus packaging 
 
The second-generation lentiviruses were made by using the plasmids p8.91 and 
pMDG along with pHAGE plasmids (Kindly provided by Dr Richard Mulligan) 
expressing MC033 or MC080.  Early passaged 293TREX cells were counted and 
seeded at 15x106 cells per T150 cm2 culture flask in 15mls of complete DMEM. The 
next day the cells were transfected by calcium phosphate DNA precipitation (section 
2.4.6.1), 28 hs post transfection the cell supernatants were harvested and filtered 
using a 0.45µm sterile filter. The collected filtered virus was kept in the fridge (2-
8°C) and complete DMEM was added to the cells and incubated at 37°C, 5% CO2. 
The second harvest of viral particles was collected at 72 hs post transfection, filtered 
and added to the first virus harvest. 3ml 20% sucrose in PBS was placed in an ultra-
centrifuge tube then the filtered supernatant was added gently to the sucrose solution. 
The tubes were spun at 90,000 x g at 4°C for 90mins (SW41 Ti rotor, Ultra Beckman 
L8-M ultracentrifuge), the viral pelleted in the bottom, the supernatant and sucrose 
layer was aspirated, the tubes were inverted for 10 minutes to dry the pellet. The 
pellet was suspended in100µl of complete DMEM and stored in the -80°C freezer  
 
2.4.7 Single infection of cells for assays 
The cells were counted and seeded the day before infection (5×105 cells for a 25 cm2 
flask, 2.5×105 cells per well for a 6-well plate, 5×104 cells per well for a 24-well 
plate) and incubated at 37°C in 5% CO2 overnight to allow cell adherence. The virus 
(adenovirus or HCMV) was removed from -80°C, then transferred to a 37°C H2O 
bath. The defrosted virus was mixed by pipetting it gently, the cells were infected 
with virus at the required MOI in complete media for adenovirus and only DMEM 
for HCMV (2 ml for a 25 cm2 flask, 1 ml per well for a 6-well plate, 250 µl per well 
for a 24-well plate). The infected cells were incubated for 2 hs at 37°C in 5% CO2 in 
a rocking incubator. The virus was removed, and complete medium was added to 
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infected cells (5 ml for a 25 cm2 flask, 4 ml per well for a 6-well plate, 1 ml per well 
for a 24-well plates) and the cells were incubated at 37°C in 5% CO2 for a required 
time 
2.4.8 Co-infection of cells for assays 
The cells were counted and seeded the day before infection and were allowed to 
adhere overnight. The viruses were removed from -80°C, and transferred to a 37°C 
water bath, the defrosted virus mixed by gentle pipetting. For NPi cells HLA-E 
experiments, the cells were infected on day 1 with RAd-HLA-E at an MOI 350 
PFU/cell, and RAd mc080 or RAd US6 at an MOI 350 PFU/cell then on day 2 the 
cells were infected with RAd-UL40 at an MOI  350 PFU/cell, the infected cells 
incubated for a further 48 hs prior to analysis. In HLA-A2 experiment the NPi cells 
infected with RAd mc080 or RAd US6 at an MOI 350 PFU/cell, next day the cells 
infected with RAd-HLA-A2 at an MOI 350 PFU/cell and incubated for a further 48 
hs prior to analysis. For MICA assay in CHO-CAR cells, the cells were co-infected 
with RAd expressing MICA*008 or RAd expressing MICA*002 at an MOI 50 
PFU/cell and RAd mc080, RAd vector or RAd expressing UL142 at an MOI 50 
PFU/cell and incubated for 72 hs prior analysis. 
2.5 MOLECULAR BIOLOGY 
 
2.5.1 PCR 
The gene was amplified by PCR from the plasmid, the primers designed then they 
delivered from Eurofin, the Biometra T3000 Thermal cycler was programmed. The 
temperature, number of cycles, and concentration of template DNA and time are 
adjusted according the amplified DNA length, the DNA amount and polymerase 
type.  All reagents were defrosted in water bath except dNTP which was defrosted at 
room temperature, PCR programs are presented in appendix.  
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 2.5.2 Agarose gel electrophoresis 
In order to asses that the correct DNA was present at each stage of the cloning or 
recombineering process, the samples were separated by gel electrophoresis. 0.8% to 
1% of agarose containing gel was used, the separation of PCR products based on 
their size, the visualisation of the bands on the gel were enhanced with ethidium 
bromide. The band visualized by UV light using an Autochemi Bioimaging system 
(UVP) and LabWorks software (Perkin Elmer), or a bench-top transilluminator 
(Spectroline). Gels were cast using trays taped at either end and accompanying well-
forming combs, and allowed to set prior to submersion in excess TAE running buffer. 
0.2 volumes of 6X DNA loading buffer was added to each sample, 10µl of molecular 
weight marker and test samples were pipetted into the wells of the gel and 
electrophoresis was run for 2-3 hours at 100 V.  
2.5.3 Isolation of DNA form an Agarose gel 
UV light (Spectroline transilluminator, model TVC-312A) was used to visualize the 
DNA bands, then DNA bands were cut, and then DNA purified from PCR reactions 
using the Illustra GFX DNA and Gel Band purification Kit (28-9034-70, GE 
Healthcare) following manufacturer’s instructions. In brief, nucleic acids and other 
macromolecules were first denatured in the presence of a chaotropic buffer (supplied) 
and by using the heat blocker heated to 60°C, the solution was transferred to a column 
and placed in Eppendorf tube after 30 seconds it was centrifuged at 16060 x g for 30 
seconds. After discard of flow-through, 500µl of washing buffer was pipetted onto 
the column then it was centrifuged at 16060 x g for 30 seconds. The column was 
transferred to a fresh Eppendorf tube and 30µl of sterile deionized H2O was pipetted 
onto the column and after 30 seconds incubation the tube was centrifuged for 1 
minutes at 16060 x g.  
2.5.4 Determination of DNA concentration  
The DNA concentration of the samples were determined using a Nano-drop ND-
1000 spectrophotometer (ThermoScientific). The spectrophotometer was initialised 
with 2µl dH2O the loading pedestal was wiped. The instrument was then blanked by 
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loading 2µl of the relevant solvent buffer and performance of a measurement. The 
loading pedestal was again wiped before loading 2 µl of analyte sample to be 
measured. The concentration was obtained in ng/µl.  
2.5.6 Plasmid DNA minipreps 
The Qiagen 27104 miniprep kit was used, the colonies were inoculated and grown 
overnight in 5 ml of LB containing ampicillin (50µg/ml). The bacteria cells were 
harvested by centrifugation at 5400 x g for 5 minutes. The supernatants were 
discarded and 250µl of buffer P1 (Qiagen, 27104) was used to resuspend the cells, 
250µl of buffer P2 was added, the tubes were inverted 4-6 times to lyse the cells and 
denature their DNA. 350µl N3 buffer was added to neutralise the reaction. The 
samples were mixed by inversion and centrifuged at 17,900 x g for 10 minutes at 
room temperature. The supernatants were transferred to the QIAprep spin column by 
decanting and centrifuged at 17,900 x g for a minute, the flow-through was discarded. 
To remove the trace of nuclease activity the QIAprep spin column was washed twice 
by 0.5ml of PB buffer and centrifuged at 17,900 x g for a minute and the flow-through 
was discarded. Then the QIAprep spin column was centrifuged at 17,900 x g for a 
minute to remove the residual of washing buffer. The QIAprep column was placed 
in a clean 1.5 ml Eppendorf tube and DNA was eluted by adding 50 µl dH2O to the 
centre of each QIAprep spin column, and it was let to stand for 1 min, and centrifuged 
at 17,900 x g for 1 min.  
2.5.7 Plasmid DNA maxiprep 
In order to obtain transfection quality DNA, recombinant DNA was purified 
following the protocol of low copy plasmid purification (Max/Bac) plasmid DNA 
purification nucleo-Bond by Machery-Nagel. The bacteria colonies containing the 
plasmid of interest was inoculated into 250 ml LB media containing antibiotics and 
incubated overnight at 37oC with shaking. Cultures were centrifuged at 6,000 x g for 
15 minutes at 4°C. 24 ml of S1 buffer was added to bacteria pellets. Then 24 ml lysed 
buffer (S2 buffer) was added to the tubes which then was inverted 6–8 times, the 
tubes were incubated for 3 minutes at room temperature. 24 ml of cooled neutralising 
buffer was added to the mixture, the tubes inverted 6-8 times, then the tubes were 
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incubated in ice for 5 minutes which then centrifuged at 6000 x g for 15 minutes at 
4°C. In mean time the equilibration buffer (6 ml) was added to a NucleoBond® 
Column, and the column allowed to empty by gravity flow. Then the supernatant was 
added onto column which had emptied by gravity flow. 18 ml of buffer N3 was added 
twice to the column and the DNA was eluted by adding 15 ml of elution buffer heated 
to 50°C to the column and the DNA was collected in fresh tubes. 11 ml of isopropanol 
was added to the eluted DNA then the tube was centrifuged at 4,500 x g at 4°C for 
30 minutes. The DNA precipitate was washed with 70% ethanol and centrifuged at 
4,500 x g, at 15 minutes. After ethanol evaporation the DNA was resuspended in 100 
µl sterilised dH2O, the solution DNA was stored -20°C 
2.5.8 Restriction enzyme digest for pHAGE plasmid 
cloning 
 
The restriction enzyme digestion was used to generate compatible ends capable of 
being ligated together. 5 µl of PCR product and 5 µl of plasmid vector were each 
purified from an agarose gel using a Qiagen gel extraction kit (section 2.5.3). Both 
the PCR product and plasmid vector were digested with the compatible restriction 
enzymes (2 µl each; 10 U/µl) in 10X SURECUT buffer A (5 µl; ROCHE) in a total 
volume of 50 µl, they were incubated at 37oC for 2 h. This was mixed with 15 µl 
loading buffer and analysed on a gel. The bands were again gel purified (section 
2.5.3), to remove small DNA fragments, and ligated following the protocol in section 
2.5.9.  
 
2.5.9 Ligation  
 
To ligate the digested PCR product and the vector, 5 µL of the digested PCR product 
was mixed with 1 µl of the digested plasmid vector, and 2 µl glycogen with 100 µl    
-20oC ethanol. Then the mixture was centrifuged for 15 minutes at 16060 x g, to 
pellet the DNA and bring the vector and insert into close proximity. The supernatant 
was discarded and the pellet was incubated at 50oC for 5 minutes to dry, then it was 
resuspended in 10 µl ligation mix which consisted of 1 µl T4 DNA ligase 
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(Invitrogen), 2 µl 5X T4 DNA ligase buffer (Invitrogen) and 7 µl sterile injection 
water. The ligation reaction was stored at 4oC for overnight. 
 
2.5.10 Transformation  
The chemically competent Top10 bacteria (One Shot TOP10 chemically competent 
E.Coli; Life Technologies) were transformed using heat shock to carry the ligated 
product (section 2.5.9). The bacteria were thawed slowly on ice, then 5 µl of ligated 
DNA (section 2.5.9) was added to the cells on ice.  After that the tube was placed on 
a heat block at 37oC for 5 minutes and transferred to ice for 5 minutes. 250 µl of SOC 
media was added to the cells which were left to recover on the heat block at 37oC for 
one hour. 100 µl of transformed bacteria were spread onto an Ampicillin LB agar 
plate (Sigma; 1 µl/ml of 100mg/ml stock). The plates were incubated overnight at 
37oC, next day, colonies were picked from the plate and grown up in 10 ml of LB 
containing Ampicillin at 37oC overnight. Plasmid from the remaining 9 ml of bacteria 
was purified using the MiniPrep kit (Qiagen) and one ml of the transformed bacteria 
having the right ligation were frozen for storage at -20oC.   
2.5.11 Amplification and Purification of Plasmid DNA  
All plasmids were purified using the Qiagen® MiniPrep kit (section 2.5.6), the 
diagnostic restriction digest was done to verify the integrity of vector and also the 
presence/size of genes cloned into related vector. Bacteria were cultured in LB 
containing Ampicillin at 37oC overnight in a shaking incubator and purified using 
miniprep kit as described in section 2.5.6. 
2.6 Transfection of cloned plasmids  
The plasmid was used to transfect HeLa cells in 12 well plates with coverslips, for 
transfection, 50µl of OptiMEM (Life technologies) was used to dilute 0.3mg of 
plasmid DNA.  2µl Lipofectamine 2000 (Life technologies) was then added to diluted 
DNA. The transfection mix was incubated at room temperature in the dark for 15 
minutes, the medium was removed from HeLa cells and 100µl of transfection mix is 
 70 
added to each well and incubated at 37oC in 5% CO2 for overnight. The following 
day the transfection mix was replaced by complete DMEM.  
2.7 Recombineering 
Recombination mediated genetic engineering (Recombineering) of BAC-cloned 
AdZ-5 genomes, for the insertion of transgenes into the AdZ-5 vector was performed 
as previously described (Stanton et al. 2008). The SW102 bacteria was used in 
recombineering which has the lambda red genes expressed from a defective phage 
which mediate homologous recombination between DNA sequences as short as 50bp 
homology. The lambda gene is under temperature control expression, it is induced 
by raise the temperature from 32 °C to 42°C for 15 minutes. The bacteria were 
induced on the day of experiment because they do not survive freeze-thawing 
process. The recombineering start by PCR the mc033 and mc080 from plasmids 
(pEX mc080 myc opt and pEX mc033 ha opt (ordered from Eurofins MWG)) using 
primers had homology to the CMV promoter & polyA (see the appendix). The 
SW102 E.coli colonies which have BAC-cloned RAZ-5 genomes inoculated in 5 ml 
LB contained  50µg/ml ampicillin and 12.5µg/ml chloramphenicol. The day after 500 
µl of grown bacteria were added to 25 ml of LB contained 50µg/ml ampicillin and 
12.5µg/ml chloramphenicol. The bacteria incubated at 32°C in shaking incubator for 
around 3 hs which needed for bacteria to reach the optical density (OD) of 0.6 at 
600nm (Ultraspec 3000, Pharmacia Biotech spectrophotomer). The lambda phage 
genes were induced by incubating the bacteria on ice for 15 minutes then the bacteria 
were centrifuged at 3,345 x g for 5 minutes at 0°C. After that the pellet was suspended 
in 1 ml of sterile ice-cold H2O. The sterile ice-cold H2O was added to bacteria up to 
25 ml and they were centrifuged at 3,345 x g for 5 minutes at 0°C, the washing step 
was repeated. Then 400 µl ice cold H2O was added to the pellet and 25 µl of the 
suspension were mixed with 4 µl PCR DNA, the mix were transferred to 0.2 cm gap 
electroporation cuvettes (Bio-Rad, 165-2082) on ice. Then, they were incubated for 
5 minutes before the mix was electroporated at 2.50 kV using the Biorad Micropulser, 
then 5ml of LB containing 12.5µg/ml chloramphenicol was added to electroporated 
bacteria and incubated for 4 hs in shaking incubator at 32°C. 50µl of bacteria were 
plated on selective media containing 5% sucrose at 32°C for 30 to 48 hs. Four 
colonies from each plate were miniprepped (section 2.5.6) then tested for the right 
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insert by using BamHI as restriction enzyme (section 2.9). The inserted genes were 
sequenced as described in section 2.10 and they were 100% identical to original 
genes for both mc033 and mc080. For large scale plasmid preparation and for 
transfection-quality DNA, maxipreparation for both mc033 and mc080 were done 
using Qiagen kit (section 2.5.7). The mc033 and mc080 adenoviruses were made by 
transfection of circular maxipreped DNA using Polyfect (Qiagen) as described in 
section 2.8. 
2.8 Transfection of 293-TREX cells with adenovirus BAC 
DNA  
It was not necessary to digest the Ad vectors genome before transfection, the circular 
maxiprepped DNA was used in transfection. E1 gene was deleted from Ad-vector. 
However, 293-TREX cells express E1 gene in trans beside expression of the tet-
repressor gene, that prevents transgene expression. Transfection was performed 
using Polyfect (301105, Qiagen), transfection kits. 2x106 293-TREX cells were 
seeded in a cell bind T25 cm2 flask (Fisher, TKV-123-031L), the next day 4µg vector 
DNA was added to 100µl DMEM, 40µl polyfect was added to the DNA in DMEM 
and incubated for 10 minutes at room temperature. During the incubation, the media 
was changed on the cells and 3mls DMEM was added. 1ml DMEM was added to 
DNA complex and then they transferred to cells. After 24 hs the media was changed 
and then the media changed whenever went yellow, after 7-10 days the plaques were 
visible. When the cells were totally infected, the detached infected cells were 
collected in 2 ml of DMEM, the collected virus was used to infect 80% confluent of 
293TREX cells in T150cm2 cell bind flask. 
2.9 Restriction enzyme digest of BAC 
 
For verifying the integrity of adenovirus vector and testing if the transgenes (mc033 
and mc080) were intact, a diagnostic restriction enzyme digest from miniprep DNA 
was performed.  
By using BamHI restriction enzyme on the miniprepped DNA of BAC of adenovirus 
vector, the integrity and presence of mc033 and mc080 was confirmed. When BamHI 
restriction enzyme used for restriction digest AdZ-5 vectors, it gave bands of 18, 11, 
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7.7, 2.5, 1.7, 0.8 and 0.6 Kbp. However, the 2.5 & 1.7 Kbp bands (from the 
Sac/LacZ/Amp cassette) were replaced with mc033 or mc 080 DNA band. The 
miniprepped DNA (8 µl) was added to with buffer E (Promega, R005A) (1 µl) and 
BamHI enzyme (Promega, R6021) (1 µl), the mixture was incubated at 37°C for 2 
hours. The mix was loading in agarose gel and the electrophoresis was performed at 
150V for 90 minutes.  
 
2.10 Sanger sequencing 
Sequencing analysis of short genome regions or PCR products was performed by the 
Sanger sequencing services offered by Eurofins (MWG). Sequencing primers were 
designed to bind about 100 bp upstream of either end of the region to be validated. 
The concentration of DNA was also determined as previously described in section 
2.5.4. All DNAs and primers were sent in volumes and at concentrations as required  
2.11 Analysis of protein expression  
 
2.11.1. Immunofluorescence  
4x104 HF-CARs were seeded in 12 well plates with coverslips. The day after, the 
cells were infected with adenovirus as described in section 2.4.7. 48 hs after infection, 
the media was removed, and the cells were then fixed using 500µl of 4% PFA and 
incubated for 10 minutes at room temperature. The cells were washed with PBS and 
permeabilised using wash buffer (1% BSA and 0.2% saponin in PBS). All antibody 
incubations and washes were carried out in the wash buffer unless stated otherwise. 
Primary antibody incubation was performed for an hour at 37°C in 50 µl, in order to 
chase nascent protein in ER the cells incubated with primary antibodies, rabbit anti 
V5-tag, (Abcam, GR116421-19) and/or mouse anti-calnexin clone 
(Millipore,2274261). For Golgi complex double staining immunofluorescence was 
performed, by use mouse anti V5 tag (AbD Serotec, MCA1360) and/or rabbit anti 
Giantin. The cells in coverslips were then washed 5 times, then the appropriate 
secondary antibodies (table 2.1) were applied at 1/500 dilution for 30 minutes at 37°C 
in a total volume of 50 µl, the cells were then washed 5 times. 4,6-Diamidino-2-
Phenylindole, Dihydrochloride (DAPI) (Thermo Fisher, D1306) was added to 
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coverslips and then they were left in dark overnight, then examined using Zeiss 
fluorescence microscope (Carl Zeiss Microscopy, Germany). 
2.11.2 Immunoblot detection of proteins  
Semi-quantitative detection of proteins was performed by immuno-blot techniques, 
with targeted proteins first resolved and isolated from mixed samples using the 
NuPage Novex protein isolation kit (Invitrogen/Life technologies).  
2.11.2.1 Sample preparation 
 
The media was removed from HF-CAR infected cells then washed using PBS, excess 
PBS was removed using pipette then 400µl of lithium dodecyl sulfate sample loading 
buffer (LDS) (100 of 4XLDS, 40µl of 10 mM DTT and 260µl ddH2O) was added to 
each T25 cm2 flask, the cells were resuspended in the buffer using a cell scraper, and 
then the mix was transferred to an Eppendorf tube. Proteins in all samples were 
denatured by incubation at 100°C for 10 mins using a heating block. 
 
2.11.2.2 Western Blot 
 
20 µl or 30 µl of the samples were loaded in 10% Nu-PAGE polyacrylamide gels 
(Invitrogen) by SDS-PAGE, and 10 µl of prestained protein markers (Invitrogen, 
LC5800) and electrophoresed for 2 hs at 100V. After that they were transferred to 
Hybond-C nitrocellulose (GE Life Science) by semi-dry blotting using Trans-Blot 
SD semidry transfer cell (Bio-Rad) for 2 hs at 10 Volts. They were then blocked in 
5% milk in Phosphate-buffered saline containing 0.05% TWEEN-20 (PBS-T) 
overnight at 4°C. The membranes were then incubated with primary antibodies 
diluted in 5% milk in PBS-T at room temperature for an hour, followed by washing 
in PBS-T, and incubation with anti-mouse or anti-rabbit IgG-HRP conjugate for an 
hour at room temperature. Membranes were then washed in PBS-T and incubated in 
SuperSignal West Pico Chemiluminescent substrate (Fisher Scientific) before being 
imaged using Syngene imaging system (UK, Cambridge) with GeneSys software. 
Where appropriate, the blots were stripped in Pierce Stripper buffer (Fisher 
Scientific) for 10 min, washed in PBS-T, reblocked using block buffer, and reprobed. 
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2.11.2.3 Deglycosylations  
 
The EndoH and PNGase deglycosylations was performed by incubation of EndoH 
(New England Biolabs, P0702S) or PNGaseF (New England Biolabs, P0704L) 
enzymes in presence of G3 buffer (New England Biolabs, B1702S) in the EndoH 
digestion, and G2 (New England Biolabs, B3704L) and 10% NP40 (New England 
Biolabs, B270S) buffers in PNGase reaction with samples for overnight at 37°C. The 
amounts of buffers and enzymes are included in table 2.5.  
For running the samples using Western Blot (section 2.11.2.2), 5µl of 4x LDS sample 
buffer (Invitrogen, NP0008) was added to 1 µl of 1M DTT and 14 µl of digested 
sample and incubated for 10 minutes, and centrifuged for a minute at 16060 x g.  
Table 2.5: Deglycosylation mixture 
 Mock digested 
(µl) 
EndoH digested 
(µl) 
PNGase digested 
(µl) 
Sample  22 22 22 
EndoH  2  
PNGase   2 
G2   3 
G3 3 3  
NP40   3 
ddH2O 5 3  
Total volume 30 30 30 
 
2.12. Flow cytometry  
 
After seeding and infecting the cells in T25cm2 flasks, the media were first aspirated, 
then the cells rinsed with PBS, one ml of trypsin was used to detach the cells, then 5 
ml complete media was added to neutralise trypsin. The mixture was spun at 470 x g 
for 5 minutes. The cell pellet was suspended in 800-1000 µl of PBS with 1% BSA 
(wash buffer), then 100 µl of each sample was transferred to a V bottomed 96 well 
plate and centrifuged at 470 x g for 5 minutes, at 4°C. The pellet was washed with 
cold wash buffer and centrifuged at 4°C for 470 x g, for 5 minutes. The cells were 
incubated with primary antibody for 20-30 minutes, after that the samples were 
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centrifuged, and supernatants discarded. The cells were washed twice in wash buffer 
to remove excess primary antibody. The cells were incubated with the secondary 
antibody for 20-30 minutes, then they were washed twice using washing buffer. The 
cells then fixed in 2% of PFA at least for 10 minutes. The BD AccuriTM C6 flow 
cytometer (BD Biosciences) was used to detect fluorescence, and results were 
analysed using C-flow software (BD Biosciences, Oxford, UK). 
 
2.13 Intracellular staining of fixed cells by flowcytometry 
 
After 72 hours of infection of HF-CARs with desired virus the media was removed, 
and the cells rinsed with PBS and trypsinised then 10ml of DMEM was added to 
T25cm2 flask. The mix of infected cells were spun at 301 x g for 3 minutes, the 
supernatant was discarded, and the pellet was resuspended in complete DMEM and 
aliquoted in V bottomed 96 well plate. The cells were washed with PBS then fixed 
using 4% PFA for 10 minutes, then they were washed twice with PBS. The cells were 
permeabilised using washing buffer (1% BSA and 0.2% saponin in PBS) for 30 
minutes, all antibody incubations and washes were carried out in the wash buffer 
unless stated otherwise. The cells were incubated with primary antibody for an hour 
at 37°C after washing the cells were incubated with secondary antibody for 30 
minutes, after that the cells were washed using PBS and fixed in 2% PFA and 
examined using BD Accuri™ C6 and analysed using C-flow software (BD 
Biosciences, Oxford, UK). 
 
2.14 Isolation of PBMC  
Blood was collected into tubes containing preservative-free heparin (Monoparin) (CP 
Pharmaceuticals Ltd., Clwydd) (5 IU/ml blood) and layered onto Histopaque-1077 
in a 3:2 volume ratio (15 ml blood to 10 ml Histopaque) in a 30 ml universal container 
(Greiner). Tubes were centrifuged for 20 minutes at 1100 x g without braking. The 
interfacing layer of mononuclear cells was removed into a universal container and 
diluted with PBS. The cells were washed with PBS first at 1100 x g for 6 minutes 
followed by 2 washes of 350 x g for 4 minutes. The cells were re-suspended in 
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appropriate media, counted and diluted to the required concentration for use. 
Generally, 1 x 106 PBMC were collected per ml of blood from healthy donors.  
2.15 NK degranulation assays 
 
NK degranulation assays were performed in a similar manner to that described 
previously (Prod'homme et al. 2007b; Prod'homme et al. 2010) , PBMC were 
harvested as described in section 2.14 and incubated overnight with IFN-α (1000 
IU/ml). PBMC (0.5×106) were incubated for 5hr with 5×104 fibroblast targets per 
well in a V bottomed 96 well (effector:target ration of 10:1) with the addition of 1 µl 
per well FITC-conjugated anti-CD107 antibody or 1 µl per well FITC-conjugated 
isotype control. 0.5 µl/well BD GolgiStop (BD Biosciences) was added an hour after 
the beginning of the assay. After 5 hs incubation the 96 well plate was centrifuged at 
470 x g for 5 minutes, at 4°C. The pellet was washed with cold wash buffer and 
centrifuged at 4°C for 470 x g, for 5 minutes. The cells were stained with PE-Cy7 
conjugated antibodies against CD3 and PE conjugated CD56 then they were 
incubated for 30 minutes at 4°C. Then the pellet was washed twice with cold wash 
buffer and centrifuged at 470 x g, for 5 minutes at 4°C, after that the cells fixed in 
2% PFA before analysis by flow cytometry AccuriTMC6 flow cytometer (BD 
Biosciences), C-flow software (BD Biosciences, Oxford, UK). 
 
2.16 CD8+ T cell CD107a mobilization assays: 
 
D007 human skin fibroblast (HSF) infected with RAd mc033, RAd mc80, RAd US6 
or RAd control were coated with 1µg/ml, 0.2µg/ml or 0.04µg/ml concentration of 
HCMV VLE peptide or 1µg/ml, 0.2µg/ml, 0.04µg/ml or 0.008µg/ml concentration 
of HCMV pp65 peptide in 1ml of RPMI-10 for an hour at 37°C. Then, two washes 
with RPMI-10 were applied to remove excess peptide. 1x105 CD8+ T cells (kindly 
provided by Mihil Patel (Cardiff)) were incubated in quadruplicate with 1x104 target 
cells and anti-CD107a-FITC mAb (1µl/well) or one well with 1µl/well of an isotype 
control containing IgG1κ-FITC was used. 0.5 µl/well of BD GolgiStop (BD 
Biosciences) was added to the cells after an hour then they were incubated for 4 hs 
more. The plate was centrifuged at 470 x g for 5 minutes, at 4°C, the pellet was 
washed with cold wash buffer and centrifuged at 4°C for 470 x g buffer. The cells 
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were stained with PE-Cy7conjugated antibodies against CD3 and APC conjugated 
antibody against CD8 for 30 min at 4°C. Cells were washed twice in cold wash 
buffer, the pelleted cells were fixed in 2% PFA before analysis by flow cytometry 
AccuriTMC6 flow cytometer (BD Biosciences), C-flow software (BD Biosciences, 
Oxford, UK). 
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mc080 and mc033 in different 
viral gene expression systems 
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3.1 Introduction 
 
Molluscum contagiosum virus (MOCV) and Human Cytomegalovirus (HCMV) are 
two large human DNA viruses that both express MHC-I homologues. MOCV 
encodes two potential MHC class I homologues: hypothetical proteins MC080 and 
MC033. MC080 exhibits closest sequence similarity to human HLA A2 and rat MHC 
class I homologous while MC033 has homology to Xenopus class I 
histocompatibility antigen (Senkevich et al. 1997; Senkevich and Moss 1998). 
HCMV encodes MHC class I homologs UL18 and UL142 (section 1.10). UL18 has 
been shown not only to be a viral MHC I homologue but to act as a MHC-I mimic 
by suppressing the cytotoxic responses of NK cells through a direct interaction with 
the inhibitory receptor LIR1 (Prod'homme et al. 2007a). The second HCMV MHC I 
homologue, UL142, has similarity to UL18 and together they constitute the HCMV 
MHC I gene family (Davison et al. 2003b). UL142 glycoprotein (gpUL142) has been 
reported to downregulate the polymorphic full-length NK ligand MICA, but not 
truncated MICA*008 (Chalupny et al. 2006; Ashiru et al. 2009). The situation 
became more complicated when recent studies indicated that HCMV genes US18 
and US20 may be primarily responsible for cell surface downregulation of MICA 
(Fielding et al. 2014; Fielding et al. 2017).  
The goal of my PhD project is to compare and contrast the roles of these MOCV and 
HCMV MHC-I homologues using UL18 as the paradigm. 
Our understanding of MOCV is limited by a lack of appropriate in vitro systems 
because the virus can not readily be propagated in cell culture. The inoculation of 
primate cells with MOCV taken from clinical lesions results in an abortive infection 
with the cells initially inducing a cytopathic effect manifesting as clumping and 
rounding, only to revert to normal growth after 48 hours (Barbanti-Brodano et al. 
1974; McFadden et al. 1979). Buller et al have achieved replication of MOCV by 
engrafting human foreskin into athymic mice and inoculating the skin with extract 
from patient lesion (Buller et al. 1995). However, this complex system is not readily 
compatible with studies of gene function. Since it is not possible to grow MOCV in 
vitro, it was necessary to look at MOCV genes in isolation. Although clinical HCMV 
strains also cannot readily be propagated in vitro, the virus readily adapts in culture 
due to the selection of mutants in RL13 and the UL128 locus; thus, systems have 
been developed to propagate tissue culture adapted HCMV strains in vitro (Dargan 
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et al. 2010). Therefore, the potential exists to examine the function of HCMV genes 
both in isolation and in the context of virus replication. 
In this thesis, vaccinia, lentiviral and adenoviral systems have been used as 
expression vectors to study the MOCV genes, mc033 and/or mc080. 
 
3.2 Analysis of mc080 expression using Vaccinia and 
Adenovirus Vector  
 
Vaccinia virus (VV), a prototype member of the Poxviridae family, has a large DNA 
genome with virus DNA replication and virion assembly taking place entirely in the 
cytoplasm of the host cell (Gallego-Gomez et al. 2003). VV has been widely 
employed as an expression vector capable of carrying large inserts of foreign genes 
and producing proteins that undergo the normal post translational modification 
associated with human cells (Perkus et al. 1985; Coupar et al. 1988). The shutoff of 
the host cell protein synthesis by VV early genes results in expression of cloned genes 
being favoured.  The broad host range of vaccinia virus allows a wide array of 
primary and transformed tissue culture cell lines to be utilized (Broder and Earl 
1999). Prior to initiating this study, mc080 gene had been cloned into the replication-
competent VACV Western Reserve (WR) strain and designated v293 (vWR293-
mc080; by Dr Subuhi Sherwani) and into a replication-deficient Adenovirus (RAd) 
vector and designated RAd961 (RAd961-080; by Dr Rich Stanton). Both viruses 
showed poor growth characteristics in infected cells, resulting in low titre virus 
stocks.  The first goal was to test the suitability of existing reagents to investigate the 
function of MC080.  
 
3.2.1 Western Blot of cells infected with recombinant 
adeno and vaccinia viruses 
 
To test the expression of MC080 by the recombinant viruses, using Western blot, 
HeLa cells were infected with recombinant adenovirus RAd961 and vaccinia virus 
v293 at an MOI of 1. A peptide derived from MC080 
(CDSWKSSWRARWEEGKRRVAT; Charles River 2518/10 1+2) was used as a  
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Figure 3.1:  Expression of mc080 from vaccinia and adenovirus vectors. Western blot of cell 
lysates prepared from HeLa cells infected with an MOI 1 of either vWR293-080 or RAd961-080.  10 
µl of each lysate was subjected to electrophoresis by SDS PAGE then transferred electrophoretically 
to a nitrocellulose membrane. Samples were run in triplicate: M were molecular weight markers 
highlighted by Magic Mark and of the indicated sizes; (1) the MC080 peptide used to raise the 
polyclonal antibody; (2) vWR293-080 infected cell lysate and (3) RAd961-080 infected cell lysate. 
The membrane was cut into three parts and probed using different dilutions of rabbit polyclonal anti-
MC080 (1:300, 1:500, 1:1000) as shown. The secondary antibody was anti rabbit Ab HRP 
(Chemiluminescent kit-Amersham™, ECL™ PRIM) diluted 1:5000. The image was captured after 
2min using a LAS- 3000 (FUJIFILM).  
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positive control (McGuigan, Hinsinger, Farleigh, Pathirana).  There were no specific 
bands for mc080 (calculated molecular weight 42 kDa); the peptide control, running  
below the molecular weight marker for 20kDa, was detected with high affinity (figure 
3.1). The apparent lack of expression of MC080 was noted, which was then ascribed 
to a possible toxic effect of mc080 on the HeLa cells. 
After initial experiments with vaccinia expression systems, it was concluded that the 
gene mc080 was not well expressed, and may even have a toxic effect on cells, 
possibly due to the high GC content (~60%) of the original MOCV sequences used 
for the construction of the recombinant viruses v293 and RAd961, leading to low 
titre virus recombinants and no detection of recombinant proteins in Western blot 
(figure 3.1). 
Following this line of thought, if mc080 gene expression has a toxic effect, the strong 
promoters used in poxviral and adenoviral constructs, or the location of gene 
transcription in these expression systems may exacerbate this effect.  In order to test 
this possibility, it was decided to clone codon optimized MOCV MHC homologs into 
a lentiviral vector expression system, which has weaker promoters and may offer an 
advantage with a possibly toxic gene expression product.   
 
3.3 The Lentivirus vector 
 
Lentivirus vectors reverse transcribe their RNA genomes into a double-stranded 
DNA, which is stably integrated into the genome of the host cell so that it will also 
be passed to daughter cells (S. and R. 1997; Gillet et al. 2009). Human 
Immunodeficiency Virus 1 (HIV-1) is the most extensively studied human lentivirus 
and also provides the backbone to many lentiviral vectors. Second generation 
lentiviral vectors have improved safety compared to first generation vectors, because 
of the removal of the accessory genes vif, vpr, vpu and nef  (Naldini et al. 1996) 
(figure 3.2). In addition, the vector is pseudotyped with the vesicular stomatitis virus 
glycoprotein (VSV-G) which enhances virion stability and broadens viral tropism 
(Miyoshi et al. 1997; Palu et al. 2000; Escors and Breckpot 2010). Three plasmids, a 
packaging plasmid, a transfer plasmid and an envelope-encoding plasmid are used to 
reduce the possibility of recombination to replication-competent virus (Wei et al. 
1998; Freed 2015).  
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Figure 3.2: The second-generation lentivirus system. The graphic illustrates the second-
generation lentiviral vector system. The lentiviral genome is divided into three plasmids, the 
packaging plasmid, encoding a number of non-structural lentiviral proteins including the polymerase 
(GAG, POL, TAT, REV), the transfer plasmid, with long terminal repeats and promoter 
(subsequently called pHAGE), and the envelope plasmid, encoding the envelope protein 
(ENV).  Figure provided by Addgene. (https://www.addgene.org/viral-vectors/lentivirus/lenti-guide/ 
12/02/2018) 
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3.3.1 Cloning of mc033 and mc080 into a Lentivirus vector 
In an attempt to enhance expression levels of mc080 and reduce potential toxicity 
associated with the high GC content of MOCV, it was decided to synthesis a codon 
optimised version of mc033 and mc080 by MWG Eurofins-Gene. 
The codon optimized genes were cloned into the plasmids pEXmc033 internal lab 
reference number (ILR) 476 and pEXmc080 (ILR 474) (figure 3.3). The genes were 
synthesised with C-terminal epitope tags to facilitate their detection and remove 
dependence on the polyclonal peptide antibody.  
The lentiviral pHAGE transfer plasmid (ILR 445) was prepared by restriction digest 
with BamHI and NotI.  Genes of interest with tag epitopes (mc033-ha; mc080-myc) 
were excised using the same restriction enzymes, then ligated into the pHAGE NotI-
BamHI vector backbone, and transformed into TOP10 E.coli. Ampicillin resistant 
colonies were grown up, DNA extracted and digested. Plasmids with inserts of the 
appropriate size were selected for DNA sequencing, and their inserts found to be 
identical to the synthesized sequences (figure 3.4). The expression was confirmed by 
transfection of HeLa cell with pHAGE ILR482 (mc080) and pHAGE ILR485 
(mc033).  In the selected cells shown in figure 3.5, a strongly apple green signal in 
adherent and dividing cells, clearly distinguishable from background or artefacts, 
indicates expression of mc080 and mc033. The cells transfected with ILR482 
(MC080) appear deformed which suggest that expression of MC080 is toxic (Figure 
3.5).  
3.3.2 Cloning of pHAGE mc080 neo and pHAGE mc033 
neo  
 
The lentiviral donor plasmid pHAGE was further modified, using a neomycin 
resistance cassette, to allow for efficient expression in stably transfected cell lines. 
The IRES - ZsGreen gfp cassettes were replaced by IRES Neo (derived by PCR from 
pIRES2EGFP- Clontech; ILR17) using restriction enzymes BamHI and ClaI (figure 
3.6). Plasmids were produced and confirmed as described above. The expression was 
confirmed by transfection of HeLa cell with pHAGE ILR498 (mc080) and pHAGE 
ILR500 (mc033). In the selected cells shown in figure 3.7, a strongly apple green 
signal in adherent and dividing cells indicates expression of mc080 and mc033. These 
plasmids were used for lentivirus package (transgene plasmid).  
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Figure 3.3: vNTI virtual constructs of pHAGE plasmids. (A) The codon optimized mc033-ha was 
placed under the control of CMV promotor (ILR485); (B) the codon optimized mc080-myc construct 
(ILR482). Both MOCV gene inserts are followed by an IRES controlled GFP cassette (ZsGreen) from 
the original pHAGE plasmid.  
  
 
 
 
                                                           
Figure 3.4: Cloning of mc033 and m080 into the retrovirus vector pHAGE. Diagnostic restriction 
endonuclease digest of plasmids with NotI and BamHI derived from ligation (pHAGE opt mc033-ha) 
and (pHAGE opt mc080-myc: top pHAGE (7717). Anticipated size of mc033-ha was 1780bp and 
mc080-myc was 1231bp.  All clones had inserts of the appropriate size except mc080 clones 8, 9. The 
molecular weight standard was a 1kb ladder.   
                                   
B A 
       mc033   
       mc080 
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Figure 3.5: The expression of pHAGE plasmids ILR482 (mc080), ILR485 (mc033) and ILR489 
rtTA. The figure showed immunofluorescent picture of HeLa cell transfected with pHAGE plasmid 
mc080(ILR482) (A, B); plasmid mc033 (ILR485) (D, E) or plasmid rtTA (ILR489) (C, F). At 48 
hours posttransfection they were fixed and permeabilized then stained using 1:100 rabbit anti Ha 
antibody for ILR485; rabbit anti myc antibody for ILR482 or mouse anti ha antibody for ILR489, then 
immunostained with 1:1000 chicken anti-rabbit AlexaFluor - 488(green) or donkey anti-mouse 
AlexaFluor-594(red).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: vNTI virtual constructs of pHAGE IRES neo plasmids. (A) using the pHAGE-opt 
mc033-ha plasmid, IRES ZsGreen (GFP) was replaced with IRES neo (ILR500); (B) same construct 
derived from pHAGE-opt mc080-myc (ILR498). Both MOCV gene inserts are now followed by an 
IRES controlled neo cassette from pIRES2EGFP.  
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Figure 3.7: Expression of ILR 500 (mc033) and ILR498 (mc080) plasmids. The HeLa cells 
transfected with either ILR498 (mc080) (A, B) or ILR500 (m033) (C, D) plasmids. At 48 hours post 
transfection, the cells were fixed, permeabilized and stained with either anti Ha (ILR500 mc033) or 
anti myc (ILR598, mc080) then immunostained with chicken anti-rabbit AlexaFluor-488. 
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At this point in the project expression by recombinant lentiviral plasmid constructs, 
both in transient transfections and in stably expressing cell lines was weak, and 
toxicity seemed a possible explanation. Therefore, the tet- inducible expression of 
mc080/m033 coded proteins, using tetracycline induction of gene expression either 
in stably transfected cell lines, or following production of recombinant lentiviral 
particles without gene expression during the growing up of recombinant lentiviruses.   
 
3.3.3 TRE controlled and rtTA constructs  
 
To control gene expression in an inducing system, the genes need to be controlled by 
a minimal promoter that has a very low baseline expression and inducer elements 
that increase the promoter strength upon addition of the inducer substance. In the 
tetON tetracycline regulated expression system, this is tetracycline or related drugs, 
and it requires the rtTA regulator to be co-expressed with tetracycline responsive 
element (TRE) controlled proteins (figure 3.8). The TRE, including the minimal 
CMV promoter, was derived by PCR from pTRE2shuttle (Clontech; ILR19) adding 
restriction sites SpeI-NotI, resulting in a 443bp product. The PCR product was cloned 
into the respective restriction sites of pHAGE opt-mc033-ha/neo and mc080-myc/ 
neo, deleting the full length CMV promoter in the process (figure 3.9).  Plasmids 
were produced and confirmed as described above.    
 
 
 
 
 89 
                           
Figure 3.8: The tetON system. On the top panel, the transactivator is unable to bind to PTRE3GS 
because of absence of doxycycline that necessitates binding. When doxycycline is supplied in the 
culture medium, it binds to transactivator, enabling it to bind to PTRE3GS, and activate transcription of 
the transgene cloned downstream, panel 
(http://www.clontech.com/US/Products/Inducible_Systems/TetSystems_Product_Overview/Tet-
One_Overview 12/02/2018) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: vNTI virtual constructs of pHAGE (Neo IRES) plasmids. (A) mc033 was tagged with 
ha epitope and produced under control of TRE promotor, CMV promotor was replaced with replaced 
with TRE promotor; (B) the mc080 was tagged with myc epitope and produced under control of TRE 
promotor, CMV promotor was replaced with replaced with TRE promotor (Table 3.1). 
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In order for provide for inducible expression, the tet regulator has to be provided in 
trans by the cell line. To achieve this, the rtTA cassette was derived by PCR from 
the AdOn adenovirus (Clontech) adding restriction sites NotI and BamH along with 
a C-terminal ha-epitope tag, resulting in a PCR product of 1040bp. pHAGE rtTA-ha 
(ILR 489) was made by ligation of rtTA into the pHAGE-original plasmid (ILR445), 
allowing selection by GFP expression, as the rtTA cassette is followed by IRES-
ZsGreen (GFP) (figure 3.10). Plasmids were produced and confirmed as described 
above. The expression of rtTA plasmid (ILR489) was confirmed by 
immunofluorescence as shown in figure 3.5.  
The expression of mc033/mc080 from the stably transfected plasmids upon addition 
of the tet inducer, was low and only small numbers of cells showed fluorescence in 
these experiments, indicating low induction efficiency or further toxicity in this 
system. A limitation of the lentiviral gene expression system is that expression tends 
to be limited to a small proportion of genes and the act of delivery can be cytopathic.   
Since the ultimate aim was to study these genes in immunological assays, it was 
decided to utilise Adenoviral and lentiviral vectors. 
 
3.3.4 Expression using recombinant lentiviral virions 
 
Second generation Lentiviruses vector particles were produced by using the plasmids 
p8.91; pmdg kindly provided by Katja Finsterbusch and transfer plasmids (ILR498 
(mc080) and ILR500 (mc033)). Confluent T150 flasks of early passaged 293TREX 
cells were transfected using Calcium phosphate DNA perception, two days post 
transfection cell supernatants were filtered and concentrated using 20% sucrose as 
described in section 2.4.6 
These experiments were only conducted in preliminary fashion. To test the 
expression of MC080/MC033 using lentiviruses, the HeLa cells were infected using 
lentivirus stocks, only very small numbers of cells showed fluorescence in these 
experiments, indicating low titre of lentiviral stocks. The selected cells shown in 
figure 3.11 were strongly apple green, in adherent and dividing cells, clearly 
distinguishable from background or artefacts. 
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Figure 3.10: vNTI virtual constructs of pHAGE plasmid ILR489.  the rtTA-ha was placed under 
the control of CMV promotor  
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Table 3.1: Summary of pHAGE plasmid constructs 
 
ILR number 
(gene number) 
Ligation number 
(clone) TRE, tag, 
and selection 
marker 
Sequencing 
results 
Transfection of 
HeLa cell line 
474 (080 opt) pEX mc080 myc 
opt 
Eurofins 
 
476 (033 opt) pEX mc033 ha opt Eurofins 
 
482 (080) L322 (1) myc gfp 100% identical GFP positive  
483 (080) L322 (4) myc gfp 100% identical 
 
485 (033) L323 (1) ha gfp 100% identical GFP positive 
486 (033) L323 (2) ha gfp 100% identical 
 
488 (rtTA) L 325 (1) ha gfp 100% identical 
 
489 (rtTA) L 325 (5) ha gfp 100% identical GFP positive 
498 (080) L340 (1) (myc neo) Seq over insert 
/tag 
IF positive anti 
myc/ anti-80 
499 (080) L340 (2) (myc neo) Seq over insert 
/tag 
 
500 (033) L341 (1) (ha neo) Seq over insert 
/tag 
IF positive anti ha 
501 (033) L341 (2) (ha neo) Seq over insert 
/tag 
 
503 (080) L345-3 (TRE myc 
neo) 
100% identical  IF positive anti 
myc/ anti-80 
504 (080) L345-6 (TRE myc-
neo) 
100% identical 
 
505 (033) L346-1 (TRE ha-
neo) 
100% identical  IF positive anti ha 
506 (033) L346-2(TRE ha-
neo) 
100% identical 
 
 
Following discussions regarding functional assays available in Cardiff to test MHC 
class I homologs it was decided at this point to also clone the codon optimized mc080 
and mc033 sequences into the adenoviral expression system.  While expression in 
the lentiviral system was observed, it appeared rather weak in immunofluorescence 
assays. Also, the subsequent functional assays available in Cardiff are all established  
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Figure 3.11: Analysis of expression from Lentivirus particles. The representative microscopy is 
image of immunofluorescent staining of lentivirus mc080 (A, B) and lentivirus mc033 (C, D). The 
HeLa cells where infected using lentiviruses described above, at 48 hours post infection the cells were 
permeabilized and stained using rabbit anti-ha (mc033) or rabbit anti-myc(mc080), then they were 
immunostained using chicken anti-rabbit AlexaFluor @488. 
 
 
 
 
 
 
 
 
 
A B
C D
 94 
using adenoviral expression vectors (Tomasec 2000; Prod’homme et al. 2007), and 
HCMV genes to compare the MOCV homologs to are all only available in adenoviral 
vectors.  
So, while the functional testing of mc080/033 expressed from lentiviral vectors may 
be academically interesting to confirm results obtained in the adenoviral system, for 
practical reasons and in order to allow direct comparisons to HCMV proteins 
characterized by the Wilkinson group, adenoviral constructs using the codon 
optimized mc080/mc033 gene sequences would be required.   
3.4 Cloning and expression mc033 and mc080 using 
adenovirus vector- 5 (AdZ-5) 
 
Over sixty years have now passed since adenoviruses were first isolated. Adenovirus 
is non-enveloped virus with a ~36 kb double strand DNA genome. At least 83 human 
serotypes have been discovered, they divided into seven different species (A- F) 
(McConnell and Imperiale 2004; Espinola et al. 2017). Prior to the initiation of this 
study, attempts to clone mc080 in to an AdEasy1 vector were unsuccessful, efficient 
expression on mc080 appeared to be incompatible with vector replication. Work was 
therefore switched to an ‘inhouse’ species C serotype 5 replication-deficient Ad 
vector designed to permit transgene insertion with ‘zero’ cloning steps (AdZ). AdZ 
was produced by Stanton et al (Stanton et al. 2008) by deleting both the E1 and the 
E3 regions of the Ad genome thereby allowing insertion of transgenes up to 8 kb in 
size. The E1 region is multifunctional and required for the activation of Ad late genes 
and thus essential for virus replication. The E3 encode immune evasions that are not 
essential for virus replication in vitro. Deletion of E1 means the AdZ vectors must be 
propagated on E1-expressing helper cells; 293 cells are the most commonly used 
(Stanton et al. 2008). The transgene is inserted directly into vector within E. coli 
strain SW102 utilizing recombination-mediated genetic engineering as described in 
section 2.7 (Graham et al. 1977; Stanton et al. 2008). A useful feature of the AdZ 
vector is that it contains two tetracycline responsive elements (TRE) downstream of 
the HCMV IE promoter. When the vector is propagated in 293 cells expressing the 
tet-repressor (293TREX), expression from the transgene is silenced, this device 
enabled cloning of the mc080 gene. 
 95 
3.4.1 Cloning mc033 and mc080 into AdZ5 
 
The codon optimized mc033 and mc080 genes were cloned into AdZ by 
recombineering in frame with a C-terminal V5-epitope tag already present in the 
vector, allowing their expression to be validated using an anti V5 antibody. Genes 
were amplified individually from pEX mc080 myc opt (ILR474) and pEX mc033 ha 
opt (ILR476) (synthesized by MWG Eurofins-Gene). The PCR-amplified DNA 
fragments were electroporated into E. coli SW102 then cultured on agar plates 
containing sucrose; the selective media ensures that bacteria where recombination 
did not happen failed to grow. Four white colonies of each plate were inoculated into 
5ml LB media containing chloramphenicol, grown overnight before miniprep were 
performed and tested to see if they had an acquired insert of an appropriate size.  
Digestion of the AdZ-5 vector with BamHI generates bands of 18, 11, 7.7, 2.5, 1.7, 
0.8 and 0.6 kb; replacement of the 2.5 and 1.7 kb Sac/LacZ/ Amp bands with the 
mc033 and mc080s genes of ~1.7 kb and ~1.2 kb respectively. The second, third and 
fourth mc033clones and all mc080clones contained inserts of the appropriate size 
(figure 3.12 and figure 3.13). The inserted genes were sequenced and found to be 
100% identical to original genes for both mc033 and mc080.  
3.4.2 Optimizing expression of recombinant deficient 
adenovirus of mc033 and mc080  
 
Western blot was performed using lysates of HF-CAR cells infected with 
recombinant adenoviruses RAd mc080 and RAd mc033 at an MOI 5. The MC033 
protein was estimated to have an apparent molecular weight of 64 kDa, which is 
consistent with its predicted mass of 64.415 kDa. MC080 protein detected at 40 kDa, 
ran faster than the predicted primary translation products (44.55 kDa) (figure 3.14), 
this may be the caused by incomplete denaturation of protein by SDS (Rath et al. 
2009)  
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Figure 3.12: Virtual construct of MOCV genes cloned into the AdZ vector. (A) plasmid pAL1141; 
(B) pAL1141-opt-mc033 and (C) pAL1141-opt-mc080.  The amp-lacZ-SacB selection cassette was 
replaced to put the opt-mc033 and opt-mc080 in to the replication deficient Ad vector under the control 
of the HCMV IE promoter and with a C-terminal V5 epitope tag. 
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Figure 3.13:cloning mc033 and mc080 into AdZ vector. Diagnostic BamHI restiction endonuclease 
digest of of pAL1141-opt-mc033 lane 1-4 ( 1.7 kb), and pAL1141-opt-mc080 lane 5-8 (1.2 kp). All 
clones had an insert of the appropriate size except the first clone of pAL1141-opt-mc033. 
   
 
 
                              
Figure 3.14: Expression of RAdmc033 and RAdmc080. Lysates were prepared from of HF-CAR 
cells infected with RAdmc033; RAdmc080 or an AdZ vector control (empty vector) (MOI 5) for 72h. 
25µl of each sample was loaded onto 10% NuPAGE Bis-Tris gel, electrophoresis performed then 
transferred to nitrocellulose membrane. The blot was probed first with a mouse V5 monoclonal 
antibody then the anti-mouse IgG HRP (1:2000) was used. The MC033 band was calculated at 64.415 
kDa and MC080 at 44.55 kDa using justbio. 
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3.4.3 The time course expression of RAdmc033 and 
RAdmc080 
 
 RAdmc033 and RAdmc080 encode the MOCV MHC-1 homologues under the 
control of the constitutive HCMV major IE promoter. The expression of MC033 and 
MC080 proteins from HF-CAR cells infected with the Ad recombinants were tested 
at 48, 72, 96 hours p.i. by using Western Blot analysis. MC033 ran as single band at 
around 64 kDa with its expression increasing gradually over time. In contrast, 
MC080 was observed to migrate as 2 band, the faster migrating species estimated at 
~40 kDa and the heavier more diffuse band at around 42 kDa. MC080 expression 
was slightly lower at 96 h than at 72 h p.i. (figure 3.15). Moreover, some cellular 
cytotoxicity was observed at the later time point.  In view of these observation, future 
experiments were performed at 72 h p.i. unless otherwise indicated. 
Senkevich and Moss found that MC080 was not present on the cell surface 
(Senkevich and Moss 1998). To test for the intracellular expression of mc080 and 
mc030, HF-CARs were infected with RAdmc080, RAdmc033, RAdUS6 (positive 
control) or RAd control (negative control) at an MOI  5 PFU/Cell. Forty-eight hours 
post infection cells were fixed, permeabilized and stained for V5 then analysed by 
flow cytometry. The displacement of the peak for MC033 and MC080 to the right 
compared with the negative control (1253), shown in red signifies the expression 
mc033 and mc080. However, there was a displacement of the peak for RAd negative 
control to the right compared to isotype control, which potentially due to cross 
reaction between of V5 antibody and adenovirus protein. The expression levels of 
MC033 and MC080 exceeded the scale as shown in figure 3.16.  
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Figure 3.15: Time point expression of RAdmc033 and RAdmc080HF. HF-CAR cells were 
infected with RAdmc033, RAdmc080, RAdUS6 (positive control) or RAd1253 (negative control) at 
an MOI 5 for 48, 72 and 96 hours. Equivalent amount of samples were applied into 10% NuPAGE 
Bis-Tris gel, then they were electroblotted to nitrocellulose membranes and probed by mouse 
monoclonal V5 (1:10000) for corresponding V5 tagged protein then the anti-mouse IgG HRP (1:2000) 
was used. 
 
 
 
 
Figure 3.16: Flowcytometric analysis of MC033 and MC080 expression. For expression of MC033 
and MC080 from the recombinant adenoviruses, HF-CAR cells were infected with RAdmc033, 
RAdmc080, RAdUS6 (positive control) or RAd1253 (negative control) at an MOI 5 for 72 hours 
followed by intracellular staining for V5 using mouse monoclonal V5 and IgG1 was used as isotype 
control 
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3.5 Summary 
 
The expression of the codon optimized mc080 and mc033 was undertaken using 
RAd5Z vector, DNA transfection of HeLa cells using different pHAGE plasmids and 
a second-generation lentiviral vector. However, the lentiviral vectors grew to poor 
titre, giving low expression of mc080 and mc033 and for this reason the they were 
not progressed. I failed to observe any expression from mc080 using vaccinia vector, 
potentially due to toxicity of the virus and possibly due to the high GC content of the 
original MOCV sequences, leading to low titre virus recombinants and no detection 
of recombinant proteins. 
From previous experiments cellular cytotoxicity was observed at the later time point 
when using RAdmc080.  In view of these observation, future experiments were 
performed at 72 h post infection unless otherwise indicated. 
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4- Functional assay of mc033 
and mc080 
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4.1: Introduction 
  
The only previous study on mc080R used a VACV virus vector to express the gene 
and found that it encoded a glycoprotein that formed a complex with β2 
microglobulin and was not presented on the cell surface but retained in the ER 
(Senkevich and Moss 1998). Neither the role or the expression of MC033L has 
previously been studied. Although the selection of another poxvirus vector to express 
mc080R was rational, the use of a lytic system hindered the detailed analysis the 
MOCV gene. Replication-deficient Ad vectors express only the gene of interest, 
provide efficient and reliable expression of the codon optimized MOCV genes and 
are compatible with functional assays already established in the laboratory. This 
thesis therefore preferentially used expression using replication-deficient Ad vectors 
as the basis for further studies.  
HLA class I heavy chains form a trimeric complex with ß-2m and peptide that are 
assembled in the ER before being processed through the Golgi apparatus and 
presented on the cell surface.  A subset of endogenous cell proteins is degraded by 
proteasomes into short peptides which are actively transferred into the lumen of the 
ER by the transporter associated with antigen processing (TAP). During virus 
infection, a subset of viral proteins will also enter and be processed by this pathway. 
After binding peptide in ER, the peptide-MHC I complex are further processed in the 
Golgi apparatus before being presented on the cell surface (Androlewicz 2001). 
Virus-derived peptides may be recognised as foreign by TCR present on CD8+ 
cytotoxic T lymphocytes (CTL) and result in killing of virus infected targets. HCMV 
encodes at least four functions that act together to impede the MHC I antigen 
processing pathway and thereby to avoid activating CTLs. US6 one of those genes, 
inhibits the function of TAP, blocking the translocation of peptide from cytosol to 
ER lumen (section 1.8) (Lehner et al. 1997). Endogenous MHC-I molecules are 
however the chief inhibitory ligands for Natural Killer cells (section 1.8). Although 
suppressing cell surface expression of MHC-I renders HCMV-infected cells resistant 
to CTL attack, it has the potential to make them more vulnerable to NK cells 
(Wilkinson et al. 2008). This vulnerability is combated in part by HCMV gpUL18, 
acting as a class I mimic by binding the inhibitory receptor LIR-1. Furthermore, a 
peptide donated by the UL40 signal peptide upregulates HLA-E in a TAP-
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independent manner; HLA-E bind the NK cell inhibitory receptor CD94:NKG2A 
(Prod’homme et al. 2007). MOCV infection is also thought to downregulate MHC-I 
from the cells surface, as indicated by the loss of ß-2m from the surface of MOCV 
lesions (Viac & Chardonnet - 1990). The goal of the study was to first characterise 
the MOCV mc033L and mc080R MHC-I homologs expressed from the Ad virus 
vector and then investigate whether MC033 and MC080 modulate the cellular 
immune response. 
 
4.2 Intracellular localisation of mc033 and mc080 and their 
effect on total MHC I 
 
The expression of MC033 and MC080 were each readily detected by 
immunofluorescence in HF-CAR cells infected with the Ad recombinants encoding 
mc033 or mc080, respectively.  In analysing these data, it is prudent to remember 
MC033 and MC080 are being expressed in isolation; in the context of an MOCV 
infection, the proteins may interact with other virus-encoded proteins and the act of 
productive infection can be expected to impact on cellular organelles.  
To investigate trafficking of the proteins, cells were co-stained with a second 
antibody specific for either calnexin (an ER marker) or giantin (a marker for the 
Golgi apparatus). DAPI was included in merged images to identify the cell nucleus. 
The overall distribution of the V5 tagged MC033 and MC080 was similar to calnexin 
and thus consistent with both proteins being localised to the ER (figure 4.1 A). (This 
correlation was supported by the dual exposure image where co-localisation was 
produces a yellow colour.)  The distribution of Golgi marker was quite distinct being 
found in a globular structure adjacent to the nucleus. While it is clear from the images 
that MC033 did not localise exclusively to the Golgi, there was some overlap (that 
results in some yellow colour associated with the Golgi) in the merged image with 
MC080 and giantin (figure 4.1 B). It is possible that MC080 may be in the Golgi, has 
to be confirmed by confocal microscopy.   
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FIGURE 4.1: MC080 and MC033 are localized predominantly to the ER.  HF-CAR cells were 
infected with RAdmc033 or RAdmc080, at an MOI 5 for 48 hours followed by cellular 
permeabilization and stained with (A) a rabbit monoclonal anti-V5 and Alexia Flour@488 goat anti-
rabbit to detect either MC033 or MC080 (green). The ER was labelled using a mouse monoclonal 
anti-calnexin (1:200), they were immune-stained with and Alexia Flour@594 goat anti-mouse 
antibody(red) or both. (B) The Golgi was labelled with rabbit giantin antibody and Alexia Flour@594 
goat anti-rabbit (red) and a mouse monoclonal anti-V5 and Alexia Flour@488 goat anti-mouse to 
detect either MC033 or MC080 (green) or both. DAPI was included in merged images to illustrate 
cell nuclei. Cells were examined by a Zeiss immunofluorescence microscope. 
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4.3 Effect of MC033 and MC080 on NK Cell Activation 
 
The hypothesis was that MC033 and MC080 were acting as MHC-I mimic, i.e. they 
were expressed on the surface of infected cells and binding directly to inhibitory 
ligands on NK cells. Although the localisation of both MC033 and MC080 to the ER 
appears inconsistent with that model, both HCMV gpUL18 and gpUL142 were found 
predominantly in the ER when expressed from an Ad vector, yet both NK evasion 
functions can be detected on the cell surface and gpUL18 is known to bind directly 
with the NK inhibitory receptor LIR-1 (Griffin et al. 2005; Prod’homme et al. 2007)  
The first series of experiments sought to explore the effect of MC080 and MC033 on 
NK cell activation in a CD107a mobilisation assays that provides a direct 
measurement of NK cell degranulation assay. HCMV UL141 is recognised to elicit 
robust protection against NK cell activation not only through downregulating 
activating ligands CD112 and CD155 from the cell surface but also by targeting the 
death receptor TRAIL-R2 (Tomasec et al. 2005; Prod'homme et al. 2010; Smith et 
al. 2013b);  UL141 was therefore included as a positive control.  
NK assays are primarily performed from PBMC purified from the blood from 
volunteer donors or blood bags provided by the Welsh blood transfusion service. 
Overnight interferon stimulated PBMC were used in NK cell functional assays as an 
approach that minimises in vitro culture and thus provide as close to a physiological 
source of NK cell for in vitro assays as practical.  
The PBMC from donor 008 and donor 009 and two NK lines from donor 007 (kindly 
provided by Dr Rebecca Aicheler) and from blood donor 5 (BD5) (kindly provided 
by Dr Simone Forbes and Dr Virginia-Maria Vlachava) were tested in autologous 
(when applicable) and allogenic setting.  
Peripheral blood mononuclear cells (PBMC) were freshly isolated from volunteer 
donor 008 and donor 009, and the BD5 NK line and donor 007 NK line, the PBMCs 
were incubated for 16h with a-interferon. Interferon-stimulated PBMC were 
incubated with HF-CARs or autologous HSF infected with RAd-mc080, RAd-
mc033, RAd-UL141 or the control vector at an effector:target ratio of 10:1 and 
incubated for 5 h in a CD107a assay (section 2.15). NK cell degranulation was 
assessed by flowcytometry. 
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In an allogeneic setting, MC080 did not protect against NK cell degranulation in 
PBMC in D009 and D008. However, in NK lines D007 and BD5, mild inhibition of 
NK cells killing were noticed (figure 4.2). In an autologous setting MC080 was able 
to either activate in PBMC from donor 008 and NK line donor 007 or inhibit NK cell 
degranulation in cells of donor 009 (figure 4.2) this difference NK cell 
responsiveness may have related to KIR/HLA genotype difference between donors  
(Ahlenstiel et al. 2008). It was found that MC033 had no effect in either D009 
allogenic or autologous setting, that is why it was not included in other NK 
experiments. It is suggested that MC080 is effective in supressing NK cell activation 
in certain individuals and MC033 has no effect in NK cell activity (figure 4.2). 
In seeking an explanation for the observed results, NK cells constitutively express 
the killer immunoglobulin-like receptors (KIR), which are specific and highly 
polymorphic, they are dividing into inhibitory and stimulatory depending upon the 
expression of either a long (L) or a short (S) cytoplasmic tail, respectively. 
The KIR gene content may vary between individuals, and to date there are more than 
a twelve KIR genes that have been described. KIR and leukocyte inhibitory receptor 
(LIR-1) are ligands for MHC class I (Moretta et al. 2001; Martin et al. 2004; Parham 
2005). 
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Figure 4.2: MC080 modulates NK cell activity. The effect of MC080 and MC033 on NK cells 
degranulation was assessed by measuring the proportion of CD107a+ cells within the CD3- and 
CD56+ population. UL141 is a recognised HCMV NK cell evasion function that was included in the 
assays as a positive control. (A) HF-CARs and autologous skin fibroblasts cells infected at an MOI 
5 or 500 respectively with RAd-mc080, RAd-mc033, RAd UL141 or Ad vector (RAd-control) for 
72 hs. Infected cells were incubated with D009 PBMC with effector:target 10:1 ratio for 5 h with 
FITC conjugated CD107a or FITC IgG1 isotype control in presence of Golgi stop. (B) HF-CARs 
and D007 or D008 fibroblast cells infected at an MOI 5 or 500 respectively with RAd-mc080; RAd-
1253(vector control); or RAd-UL141. After 72 hs, the D007 NK cells or D008 PBMC and infected 
cells with 10:1effectors:target, incubated for 5 hours with FITC conjugated CD107a or FITC IgG1 
isotype control in presence of Golgi stop. NK degranulation assessed by %CD107a+ within the 
CD3- and CD56+. (C) HF-CARs cells infected at an MOI 5 with RAd-mc080, RAd-1253(control), 
or RAd-UL141 for 72 hs. Infected cells were incubated with BD5 NK cells with effector:target 10:1 
for 5 hs in presence of FITC conjugated CD107a or FITC IgG1 isotype and Golgi stop. The data 
was analysed using one-way anova and the virus constructs were compered versus RAd control 
using Dunnett test	(*P<0.05, **P<0.01, ***P<0.001).  
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4.4 MC080 down regulates cell surface MHC class I 
expression 
 
The complex pattern of NK cell modulation encouraged further characterisation of 
MC033 and MC080 expression. To analyse the subcellular localisation of MC033, 
MC080 and gpUS6 lysates were treated with endoglycosidase H (Endo H) and 
Peptide-N-Glycosidase F (PNGase F) and analysed by immunoblotting. HCMV US6 
is known to be ER resident and to downregulate MHC-I and was included as a 
positive control (Lehner et al. 1997). The MC033 mock treated sample ran as two 
bands, a high molecular form (64 kDa) that was sensitive to Endo H and PNGase F, 
consistent with retention of MC033 in the ER (figure 4.1). The resistance of the faster 
migration MC033 species implied it was not N-glycosylated. The MC080 mock 
treated sample ran as three bands; a slow migrating form (~46kDa), an intermediate 
form (~42kDa), and a faster migrating form (~40kDa). Both heaviest and 
intermediate forms are sensitive to Endo H and PNGase F which may indicate a 
prolonged glycosylation and/or a longer retention in the ER, the fast migrating form 
was not sensitive to de-glycosylation (figure 4.3). MC080 forms stable intracellular 
complexes with ß2-m, a protein required for the expression of mature MHC-I heavy 
chains (MHC-I HC) on the cell surface (Senkevich and Moss 1998). Therefore, we 
examined the effect of both MC080 and MC033 on MHC class I expression. MC033 
has no obvious effect on the protein levels or glycosylation status of MHC-I HC 
(figure 4.3). In contrast, in the presence of MC080, the protein levels of MHC-I HC 
are diminished, and MHC-I HC become sensitive to Endo H, suggesting that MC080 
retains MHC-I HC in the ER and reduces total MHC-I HC in the cell (figure 4.3). 
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Figure 4.3: MC080 downregulates total MHC I. To investigate the intracellular localization of 
MC033 and MC080 and their effect on MHC-I, HF-CAR cells were infected with RAdmc033, 
RAdmc080, RAdUS6 (positive control) or RAd1253 (negative control) at an MOI 5 for 72 hs. Prior 
to Western blotting, denatured protein lysates were mock treated or were treated with either Endo H 
or PNGase F following the manufacturer’s protocol, overnight at 37°C. The plotted membranes were 
immuno-probed with mouse monoclonal anti-V5 (1:10000), Heavy chain HC10 (1:600) or rabbit anti-
actin antibody (1:3000). 
 
 
 
 
 
 
 
Figure 4.4: Flow cytometric analysis of effect of MC033 and MC080 on surface expression 
MHC-I. To investigate the surface expression of MHC-I, HF-CAR cells were infected with 
RAdmc033, RAdmc080, RAdUS6 or RAd1253 (Ad vector) at an MOI 5 for 72hs. The cells were 
stained using the APC conjugated W6/32 antibody (1:50), which detects the expression of MHC-I on 
the cell surface. 
 
 
 
RAd control 
RAd-mc033 
RAd-US6 
Isotype-stained RAd control 
RAd control 
RAd-mc080 
RAd-US6 
Isotype-stained RAd control 
 112 
As the immunoblot data indicated that MC080 reduced total protein levels of MHC-
I HC and rendered MHC-I HC susceptible to Endo-H digestion. Since 
immunofluorescence studies already indicated MC080 localised to the ER (Section 
4.1), it was possible that MC080 could be retaining MHC-I in the ER. I therefore 
sought to investigate whether MC080 was able to downregulate MHC-I from the cell 
surface.  Cell surface expression of MHC class I on HF-CAR cells infected with 
RAdmc080, RAdmc033, RAdUS6 or the appropriate Ad vector control was 
monitored by flow cytometry. MC080 reduced the levels of MHC class I surface 
expression at an equivalent efficacy through the time course to that observed with 
HCMV US6, a recognised inhibitor of TAP.  MC033 did not exert an effect on the 
surface expression of MHC-I molecules (figure 4.4). Since only the EndoH-sensitive 
glycoform of MHC-1 can be detected in cells expressing MC080, it seems likely that 
MC080 is acting to retain MHC-I in the ER. The reduced levels of MHC-1 detected 
in the presence of MC080 suggests that it is being targeted for degradation rather 
than being retained as a stable complex (figure 4.3).  
 
4.5 MC080 Downregulates HLA-E 
 
Human histocompatibility leukocyte antigen-E (HLA-E), a non-classical MHC class 
Ib molecule, has limited sequence polymorphism. HLA-E normally binds a 
nonameric peptide derived from a conserved sequence present in the leader sequence 
of many conventional MHC HCs. Peptide binding is required for the maturation of 
HLA-E and its transit to the cell surface (Braud et al. 1997). Once the cell surface 
HLA-E binds the NK cell inhibitory receptor CD94/NKG2A and thus as a sensor of 
classical MHC-1 expression and an inhibitory ligand.  To investigate the effect of 
MC080 on surface expression of HLA E, the HF-CARs were infected with RAd-
mc080, RAd-mc033, RAd-US6 or RAd-1253 (control) with an MOI 5 PFU/cell. The 
level of HLAE expression was analysed at 24, 48, 72 and 96 hours, the mAb 3D12 
was used for flow cytometry, normal IgG1 was used as negative control. The flow 
cytometric data in figure 4.5 showed that, at all time points, low level of HLAE were 
expressed on cell surface upon expression of MC080, in contrast, MC033 did not 
alter surface expression of HLA-E. Although the effect is consistent over the time 
course,  the low level of HLAE expression in human fibroblast makes the impact of 
mc080 on HLA-E difficult to resolve (figure 4.5), the US6 is known to block the 
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peptide transporter TAP as a result it downregulate HLAE in a TAP dependent way 
(Braud et al. 1997; Tomasec 2000) 
Efficient cell surface expression of HLA-E and classical MHC-I proteins require 
peptides to be loaded in a TAP dependent manner (Braud et al. 1997). Two 
herpesvirus proteins, HSV ICP47 and HCMV US6, have been shown to impede 
classical MHC-I expression by interfering with TAP and HHV-7 U21 downregulates 
HLA-E expression (Fruh et al. 1995; Hill et al. 1995; May et al. 2010) complex 
molecules from the cell surface. As our data indicated that MC080 and MC033 reside 
in the ER, where TAP primarily resides, and that MC080 can downregulate MHC-I 
and HLA-E, I sought to determine whether MC080 was able to hinder peptide 
loading by interfering with TAP and therefore reduce MHC-I and HLA-E surface 
expression. The NPi fibroblast cell line is derived from a patient with a genetic defect 
in TAP, and these cells exhibit extremely low levels of cells surface MHC class I and 
HLA-E expression. NPi cells were infected with Ad vector encoding HLA-A2 in 
conjunction with either RAd-mc080 or RAd-US6. The peptide binding groove in 
HLA-A2 binds hydrophobic peptides, many of which are able to reach the lumen of 
the ER in a TAP-independent manner. The HCMV inhibitor of TAP, US6, had no 
effect on HLA-A2 expression in TAP deficient cells while, in contrast, MC080 
resulted in a striking reduction in HLA-A2 surface expression. This result implies 
that MC080, unlike US6, downregulates classical MHC-I via a TAP independent 
mechanism (figure 4.6). Next, we asked whether MC080 could interfere with cell 
surface expression of the non-classical MHC-I molecule HLA-E. NPi cells are 
negative for TAP and are therefore are not able to present HLA-E on their surface, 
therefore peptide was supplied from the HCMV strain Merlin UL40 protein which 
presents peptide to HLA-E in a TAP independent manner (Tomasec 2000).  NPi cells 
were co-infected with recombinant adenoviruses expressing HLA-E*0101 (RAd-
HLA-E) and UL40 (RAd-UL40) as well as RAdMC080 or RAdUS6. As previously 
reported, cell surface expression of HLA-E was increased in cells co-infected RAd-
HLA-E and RAd-UL40 and here we show that co-infection of these cells with RAd-
MC080 resulted in downregulation of HLA-E (FIG 4.6). These data indicate that 
MC080 downregulates classical MHC-I and HLA-E in a TAP independent manner.  
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Figure 4.5: Flow cytometric analysis of effect of MC033 and MC080 on surface expression 
HLAE. To investigate the surface expression of HLAE, HF-CAR cells were infected with 
RAdmc033, RAdmc080, RAdUS6 or RAd1253 (vector control) at an MOI 5. 24, 48, 72 hours post 
infection, the HF-CAR cells were immune-stained using the PE conjugated 3D12 (1:50) antibody, 
which detects the expression of HLAE on the cell surface. 
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Figure 4.6: MC080 downregulate MHC I and HLAE in a TAP independent way. (A) fibroblast 
from a TAP deficient patients (NPi) were co-infected at an MOI 350 with RAd control expression 
HLA-A2 and RAd-mc080 or RAd-US6 (control) or NPi cells infected with HLA-A2 only. After 72 
hs from infection, the cells fixed and stained with APC conjugated W6/32 or isotype control IgG2a, 
then fixed and analysed using Accuri flow cytometry. (B) The NPi cells co-infected at MOI 350 with 
RAd expressing HLA-E*0101and RAd-UL40 alone or in conjunction with either RAd-mc080 or 
RAd-US6. 72 hs p.i the cells fixed and stained with PE conjugated 3D12 or PE isotype control. The 
fixed cells analysed using Accuri flow cytometry.  
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4.6 Effect of mc080 on MICA 
So far seven genes making the major histocompatibility complex class I chain-related 
molecule, they are from MICA to MICG. However, only MICA and MICB are 
functional genes, MICA looks very similar to its classical class I but does not bind 
β2-microglobulin (β2-m)  (Bahram et al. 1996; Fodil et al. 1996; Li et al. 1999). More 
than 50 alleles of MICA have been described, the most common allele in North 
American Caucasoid with allele frequencies higher than 50% is MICA*008.  The 
hallmark of this allele is that, it has an insertion that generates a premature stop codon 
in exon 5 which makes the transmembrane domain shorter, and also lacks the 
cytoplasmic tail (Petersdorf et al. 1999; Zhang et al. 2001; Stephens 2002). MICA is 
recognized by the C-type lectin NKG2D which is expressed on all NK cells, gd T cell 
and some ab T cells (Bauer et al. 1999). Since MC080 was capable of 
downregulating both MHC class I and HLA-E, the question was if it was able to have 
effect on expression MICA. MICA is a stress ligand; normal fibroblasts do not 
normally express significant amounts of MICA on the cell surface hence I used 
Chinese Hamster ovary (CHO)-CAR cells which lack endogenous MICA was used. 
To test the effect of MC080 on surface expression of MICA, CHO-CAR cells were 
infected at an MOI 50 with RAd-mc080 or RAd-control in combination with MOI 
50 of full length MICA (RAd*002) or truncated MICA (RAd*008) all at an MOI of 
50, for 72 hours. The cells were as stained with MICA antibody to test for surface 
expression of MICA, IgG2b was used as isotype control. It was noticed that MICA 
expression of MC080 was equal to expression MIC*002 or MIC*008, then it was 
concluded that MC080 had no effect on the cell surface expression of either full-
length MICA*002 or truncated MIC*008 (Fig 4.7).  
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Figure 4.7: MC080 has no effect in surface expression MICA. CHO cells co-infected at MOI 50 
with RAd vectors encoding the genotype MICA*002 or truncated MICA*008 genotype alone, or in 
combination with MOI 50 of either RAd-mc080 or a control RAd vector as indicated, CHO cells 
infected with MOI 50 of RAd control only was used as a control. After 72 hs cells were stained with 
PE conjugated anti-MICA or an PE conjugated IgG2b isotype control antibody analysed by flow 
cytometry.  
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4.7 Effect of MC080 on T-cell Activation 
 
Cytotoxic CD8+ T lymphocytes (CTL) play a critical role in the immune control of 
viruses. CTL recognize cells presenting viral peptides bound to surface MHC class I 
molecules (Kagi et al. 1994). Since the number of cell surface, peptide loaded on 
MHC class I molecules required for CTL recognition is very low, the question is 
whether MC080 was capable of decreasing levels of MHC-I sufficiently to alter CTL 
recognition of MC080 expressing cells. HLA-A2-specific T cells lines from donor 
007 specific for the HCMV IE1 -restricted VLEETSVML (VLE) epitope in the major 
IE1 protein and the NLVPMVATV (NLV) epitope in the tegument protein pp65 were 
kindly provided by Mihil Patel (Cardiff university).  Both cell lines were expanded 
in vitro, before being used in CTL functional assays against peptide pulse target cells. 
Donor 007 HSF was infected with RAd-mc080, RAd control, RAd mc033 or RAd 
US6, Targets were coated with an appropriate concentration of peptide (VLE; 
1.0µg/ml, 0.2µg/ml, 0.04µg/ml peptide and for NLV;1.0µg/ml, 0.2µg/ml, 0.04µg/ml, 
0.008µg/ml) for 1 hour. Excess peptide was washed, CD8+ T cells were incubated in 
triplicate with targets, with effector:target ratio of 10:1 and incubated for 5 h in a 
CD107a assay (section 2.16). CD8+ T cell degranulation was assessed by flow 
cytometry. For first time it was noticed that MC080 had the ability to protect against 
T-cell degranulation at a range of peptide concentrations and it was similar to US6 
(the positive control). However, mc033 had no effect on CD8+ T activity. Also, it 
was found that lower peptide concentration has more impair of CD8+T cells activity. 
This is indicating that downregulation of MHC class I by MC080 provides MOCV 
with a mechanism for evading T-cells degranulation (figure 4.8).   
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Figure 4.8: MC080 downregulate CD8+T cells. CD8+T cells lines generated from donor 007 
restricted epitope (A)VLEETSVML (VLE) and (B) NLVPMVATV (NLV) were expanded. 
Autologous skin fibroblast cells were infected with at (A) RAd-mc080, RAd-mc033 and RAd-control; 
(B) RAd-mc080, RAd-US6 and RAd-control at MOI 500. 72 hours post infection, (A) the cells at 
were coated with VLE; 1.0µg/ml, 0.2µg/ml, 0.04µg/ml peptide, (B) the cells were coated with 
pp65;1.0µg/ml, 0.2µg/ml, 0.04µg/ml, 0.008µg/ml peptide for 1 hour at 370C. Excess peptide was 
washed off, then CD8+ T cells were incubated in triplicate with targets, with effector:target ratio of 
10:1. Following 5 hours incubation with FITC CD107a antibody or FITC IgG1 in presence of Golgi 
stop, then the cells were stained with PE/Cy7 conjugated CD3 and PE conjugated CD8. The cells 
fixed and then analysed using flow cytometry for CD3+ and CD8+.  
 
 
 
 
 
0.1 1
0
10
20
30
40
50
60
70
Empty RAd
RAd-mc033
RAd-mc080
Peptide Conc (µg/ml)
A 
B 
 120 
4.8 Summary 
 
Both MC033 and MC080 are glycoproteins sequestered in the ER.  For first time, it 
was observed that MC080 is effective in supressing NK cell activation in certain 
individuals and this difference NK cell responsiveness may be related to KIR/HLA 
genotype difference between individuals. Also, MC080 down regulates surface 
expression of MHC-I and total protein levels of MHC-I and may degrade or retain 
MHC-I in the ER. Furthermore, mc080 downregulates surface expression of HLA-E 
in a TAP independent way. In contrast, MC033 has no effect in MHC-I and HLAE. 
MC080 has ability to protect against degranulation by CD8+ T cells.  
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5-Characterisation of HCMV 
MHC-I Homologues UL142. 
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5.1 Introduction 
 
The HCMV UL18 ORF  was first identified as a MHC class I homolog during 
analysis of the strain AD169 genome (Beck and Barrell 1988) and subsequently 
shown to encode for a 67-kDa endoglycosidase H-sensitive glycoprotein capable of 
forming a trimeric complex with β2-microglobulin and endogenous peptides (Browne 
et al. 1990). HCMV strain AD169 gpUL18 was shown to bind to the inhibitory 
receptor LILRB1 (LIR1) with 1,000-fold higher affinity than MHC class I; the 
affinity of UL18 in other strains may differ (Cosman et al. 1997; Bauer et al. 1999; 
Chapman et al. 1999; (Cerboni et al. 2006; Chen et al. 2016). The role of gpUL18 in 
virus infection is complicated as while it inhibits LILRB1+ NK cells, it also activates 
LILRB1- NK cells (Cosman et al. 1997; Bauer et al. 1999; Chapman et al. 1999; 
Davison et al. 2003b; Prod'homme et al. 2007).  UL18 and UL142 together form the 
HCMV gene family of MHC I homologues (Davison et al. 2003b). UL142 also 
encodes a glycoprotein that exhibits amino acid sequence homology with MHC class 
I and secondary structure prediction delineate MHC class I alpha-1 and alpha-2 
domains that in MHC class I play a role in binding to peptide and other ligands 
(Davison et al. 2003b; Wills et al. 2005). However, the alpha-3 domain which  is 
necessary for MHC I stability, is truncated in UL142 (Davison et al. 2003b; Wills et 
al. 2005).  
HCMV UL142 is contained within the UL/b′ gene region that is missing from 
commonly used high passage laboratory strains Towne and AD169. However, it is 
intact in the low passage strain Merlin (Tomasec et al. 2005; Stanton et al. 2010). 
HCMV strain Merlin, isolated in Cardiff, was initially sequenced at passage 3 and is 
genetically intact except for mutations identified in UL128L and RL13; these 
mutations are required for efficient growth in fibroblasts (Dolan et al. 2004; Stanton 
et al. 2010). UL142 is expressed late in infection and is heavily glycosylated in line 
with the prediction that it contains 17 potential N-linked glycosylation sites (Wills et 
al. 2005). Like UL18, HCMV UL142 has been demonstrated to be involved in NK 
cell evasion. However, unlike UL18,  UL142 only inhibits NK cells in a proportion 
of donors (Wills et al. 2005). Current research demonstrates that HCMV UL142 can 
suppress NK cell activation by modulating expression of a ligand (MICA) for the 
ubiquitous NK cell activating receptor NKG2D  (Wills et al. 2005). NKG2D is also 
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expressed on gd T cells and subsets of ab T cells (Bauer et al. 1999). NKG2D is 
remarkable in recognising at least 8 different ligands that are induced by cellular 
stress, such as virus infection or genotoxic shock. HCMV encodes multiple functions 
that retain and degrade NKG2D Ligands, thus preventing their presentation on the 
cell surface.  HCMV UL16 targets MICB, ULBP1, ULBP2, and ULBP6 (Cosman et 
al. 2001; Chalupny et al. 2003; Bacon et al. 2004), while  recently the US12 gene 
family, most notably US18 and US20, have been shown to reduce MICA expression 
extremely efficiently (Fielding et al. 2014; Fielding et al. 2017).  HCMV UL142 has 
been shown to down regulate cell surface expression of MICA, re-localising and 
retaining MICA in the ER and the cis-Golgi apparatus (Chalupny et al. 2006; Ashiru 
et al. 2009).  While MICA is highly polymorphic, there is particular interest in the 
MICA*008 allele. MICA*008 is found in 20% of the population and is C-terminally 
truncated such that it does not code for a transmembrane domain. Rather MICA*008 
is expressed with a GPI anchor (Glycosyl-Phosphatidyl-Inositol) (Ashiru et al. 2013). 
MICA*008 appears to be immune from the attentions of UL142 and the US12 family.  
This led to the proposal that MICA*008 is an HCMV-resistant "escape variant" that 
has been selected during human evolution to circumvent the effects of HCMV UL142 
and the US12 family. However, recently MICA*008  has been shown to be targeted 
by US9, indicating a dynamic co-evolution of the human immune system with 
HCMV infection (Seidel et al. 2015).  
While more research has been conducted on the HCMV MHC-I homologues than on 
the comparable genes in molluscum contagiosum, our understanding of HCMV 
UL18 and UL142 is far from complete. The observation that the US12 family targets 
MICA post-dates the identification of UL142 as a gene that downregulates MICA. 
Although ectopically expressed gpUL142 had been shown to suppress MICA 
expression, this function of UL142 had not yet been investigated in the context of the 
virus genome. The observation that UL142 only functions in selected donors is not 
consistent with MICA being its target. The NKG2D-MICA interaction is a major and 
ubiquitous mechanism of NK cell recognition (Wills et al. 2005) and NKG2D is 
expressed on nearly all NK cells (Bauer et al. 1999). However, these disparities could 
potentially be attributed to MICA polymorphism. In light of the observation that the 
US12 family targeted MICA efficiently, my hypothesis was that MICA may not be 
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the primary target for UL142 in lytic infection and that gpUL142 may be suppressing 
NK cell activation by an independent mechanism.  
In this chapter the expression of UL142 and the effect of UL142 on truncated 
MICA*008 and non-truncated MICA*002 expression was tested in isolation by 
expressing UL142 in an Ad vector. The effect of UL142 on MICA expression was 
also tested in the context of HCMV by studying the effect of the HCMV strain Merlin 
with deletion of UL142. 
 
Table 5.1: The viruses used in this chapter 
Viruses 
 
Information details 
RAd-UL141 
 
Strain Merlin UL141 ORF amplified by PCR with a C-
terminal V5 tag and cloned in to AdZ vector system 
Constructed by Drs Sepehr Seirafian and James Davies 
RAd-UL142-1A 
 
Codon optimised versions of strain Merlin UL142 
synthesised de novo to contain UL142 ORF with the 
signal peptide in the N terminus removed and replaced 
with a signal peptide from preprotrypsin (PPT). It has 
N terminal V5- epitope tag. Constructed by Dr Rebecca 
Aicheler   
RAd-UL142-2A 
 
Codon optimised versions of strain Merlin UL142 
synthesised de novo to contain UL142 ORF with the 
signal peptide in the N terminus removed and replaced 
with a signal peptide from preprotrypsin (PPT). It has 
a C terminal V5- epitope tag. Constructed by Dr 
Rebecca Aicheler   
RAd-UL142-3C 
 
Codon optimised versions of strain Merlin UL142 
synthesised de novo to contain the UL142 ORF with 
HCMV endogenous signal peptide. It has a C terminal 
V5- epitope tag. Constructed by Dr Rebecca Aicheler  
RAd-Soluble UL142 Codon optimised versions of strain Merlin UL142 
synthesised de novo to contain UL142 ORF, the 
transmembrane part was cut and it has a C terminal V5- 
epitope tag linked to BirA.  Constructed by Dr Sepehr 
Seirafian 
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5.2 Expression of UL142 using an adenovirus vector  
 
When the endogenous UL142 ORF with a V5 tag was cloned into the AdZ vector 
(RAd-UL142), gpUL142 expression could not be detected by immunofluorescence 
and was only weakly by western blot (Seirafian 2012). Optimisation of codon usage 
can be used to increase protein translation efficiency and changes in mRNA sequence 
can overcome issues with secondary structure and control signals in mRNA.  Three 
codon optimised versions of UL142 designed by Dr Rebecca Aicheler were 
synthesised commercially and provided as PCR-amplified DNA fragments for the 
generation of RAd-UL142-1A, RAd-UL142-2A and RAd-UL142-3C (see Table 
5.1). RAd-UL142-3C contains a codon optimised, full length version of UL142 with 
a C-terminal V5 tag. UL142 expression was previously shown to be more readily 
detectable when its endogenous signal peptide was replaced with the signal peptide 
from preprotrypsin (PPT) (Ashiru et al. 2009). To this end, the RAd-UL142-1A was 
made with the PPT signal peptide upstream of a N-terminal V5 tag; this construct 
was designed to test whether gpUL142 was expressed on the cell surface. Since 
signal sequences may help determine the cellular location of proteins, the PPT signal 
sequence could potentially target gpUL142 to a different cellular compartment. To 
control for this, RAd-UL142-2A was also produced with the PPT signal sequence 
but the V5 tag was inserted on the C-terminus. Any effects of the PPT signal 
sequence on UL142 localisation and expression levels can therefore be controlled for 
by comparing RAd-UL142-2A and RAd-UL142-3C. 
The BAC DNA for three constructs (RAd-UL142-1A, RAd-UL142-2A and RAd-
UL142-3C) was electroporated into E. coli SW102 then cultured on agar plates 
containing sucrose. The selective media ensures that bacteria where recombination 
did not happen failed to grow. For large scale plasmid preparation of transfection-
quality DNA, maxi-preparations of the three constructs were performed. Fresh DNA 
for the BAC constructs were transfected into the 293TREX helper cell line to 
generate replication-deficient recombinant adenoviruses and the infections were then 
expanded into six tissue culture flasks (150 cm2) to produce a virus stock.  
 
Dr Sepehr Seirafian also generated a soluble version of UL142 (RAd-Soluble 
UL142) in an AdZ vector in which the C-terminal transmembrane domain was 
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removed to encourage the protein secretion. A C terminal V5 epitope tag was added 
to allow for expression analysis and a recognition sequence for a biotin ligase BirA 
was inserted to enable biotinylation of UL142 with a view to generating tetramers or 
UL142 complexes for identifying potential binding partners.  A BAC plasmid of this 
construct was sequenced for this project. DNA for the BAC construct was transfected 
into 293TREX cells to generate infectious virus RAd-soluble UL142 and the 
infection was then expanded into six tissue culture flasks (150 cm2) to produce a virus 
stock.  
 
To test intracellular expression of gpUL142 from each of these constructs, human 
fibroblasts (HF-CAR) were infected with RAdUL142-1A, RAdUL142-2A, 
RAdUL142-3C, RAd-soluble UL142, or RAdUL18-V5 (served as positive control) 
at an MOI 10 PFU/cell for 72 h, then cells were fixed, permeabilized, stained for V5 
and analysed by flow cytometry (figure 5.1). These data demonstrate that expression 
of gpUL142 could be detected from cells infected with RAdUL142-1A, RAdUL142-
2A and RAdUL142-3C at levels similar to that observed for RAdUL18. 
Paradoxically, the version of UL142 (RAd-soluble UL142) engineered to be secreted 
gave the highest levels of intracellular expression. 
Ashiru and co-workers claim that gpUL142 is predominantly localised to the ER and 
Golgi apparatus along with MICA, yet a small amount of protein did reach the cell 
surface (Ashiru et al. 2009). Since the cellular localisation of gpUL142 has 
implications for its function, I next sought to investigate surface expression of 
gpUL142 when expressed in the Ad vector. HF-CARs cells were infected with the 
RAd-UL142-1A construct (codon optimised, PPT signal peptide, V5 N-terminal tag), 
RAd-UL142- 2A and RAd-control at an MOI 10 PFU/ml for 72 hours after which 
time, cells were stained with mouse V5 antibody or IgG1 isotype control (figure 5.2). 
By inserting the tag at the N-terminus of UL142 (downstream of the signal peptide), 
the tag should present externally rather than intracellularly. While expression could 
not be detected from RAd-control, the RAd-UL142-2A gave small shift in 
immunofluorescence compared to the RAd-control due to weak binding of V5 
antibody to C terminal V5. When flow cytometry was performed on non-
permeabilised cells, expression of gpUL142 was detected from the RAd-UL142-1A 
construct. This result is consistent with a proportion of gpUL142 being present on 
the surface of cells infected with RAd-UL142-1A. 
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Figure 5.1: Intracellular Expression of UL142. HF-CARs cells were infected with RAd-UL142-
1A, RAd-UL142-2A, RAd-UL142-3C, RAd-soluble-UL142 or RAd-UL18 (positive control) at an 
MOI 10 for 72 hs followed by permeabilization and intracellular staining for V5 using mouse 
monoclonal V5 antibody and IgG1 antibody was used as isotype control. Analysed by flow cytometry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RAd-UL18
RAd-UL142-2A
Isotype staining RAd-UL18
RAd-UL18
RAd-UL142-3C
Isotype staining RAd-UL18
RAd-UL18
RAd-UL142-1A
Isotype staining RAd-UL18
RAd-UL18
RAd-soluble UL142
Isotype staining RAd-UL18
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Figure 5.2: Surface Expression of UL142. HF-CARs cells were infected with RAd-UL142-1A, 
RAd-UL142-2A or RAd-control at an MOI 10 for 72 hs. Non permeabilised cells were stained with 
mouse monoclonal V5 antibody or IgG1 antibody, and analysed by flow cytometry. 
 
 
 
 
 
 
 
 
 
 
 
RAd-control
RAd-UL142-1A
RAd-UL142-2A
Isotype stained RAd-Control
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5.3 Western blot Analysis of UL142 expression 
 
Western blot analysis was performed to further characterise UL142 expression from 
the Ad recombinants. Codon optimisation increased expression of gpUL142 to a 
level that could readily be detected by flow cytometry. In the Ad vector expression 
of UL142 is under the control of the constitutive HCMV major IE promoter. 
Forskolin is known to stimulate expression from the CMV IE promoter in the context 
of the Ad vector (Jacobs et al. 1992; Wilkinson and Akrigg 1992) and was thus used 
here in an attempt to further enhance the expression of gpUL142. Samples were 
prepared from infected-cell lysates and denatured prior to electrophoresis then 
analysed by Western blot. Supernatants from infected cells were also assessed for 
secretion of the “soluble” engineered version of gpUL142 and for release of the 
membrane-bound version (figure 5.3).  
GpUL142 expression was readily detected from all four constructs and generally 
increased over time except where toxicity was observed in cells late in infection (72-
144 h p.i.). Forskolin enhanced the expression of UL142 in the lysates of all 
constructs, except for RAd-UL142-soluble where expression was unexpectedly 
lower.  Compared to the other recombinant viruses the RAd-soluble UL142 virus 
engineered to express soluble protein expressed higher levels of intracellular 
gpUL142 (figure 5.1). The increased intracellular expression of gpUL142 from the 
RAd-soluble UL142 virus is associated with increased toxicity as reflected by a 
decreased actin signal in the absence of forskolin which was further increased in the 
presence of forskolin (figure 5.3 D). High levels of gpUL142 expression appear to 
be associated with cytotoxicity (figure 5.3 A&D).  
GpUL142 has 17 potential N-linked glycosylation sites and the N-linked glycans 
have been shown to account for approximately half the apparent molecular mass of 
the ~70-80kDa protein  (Wills et al. 2005). GpUL142 expressed by RAd-UL142-1A 
and RAd-soluble UL142, consisted of multiple species with the heaviest form 
estimated to be around 105kDa whereas the fastest migrating form (~36kDa) may 
correspond to the immature ‘naked’ unglycosylated form (Figure 5.3 B & C); the 
calculated molecular weight for gpUL142 is 34,693 kDa.  
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Figure 5.3: Western Blot of expression of UL142 expression from Ad recombinants. (A) HF-
CARs cells were infected with RAd-UL142-1A at an MOI 10 for 24, 48, 72 and 144 hours for lysate. 
To analyse supernatants, the cells in T 25 flasks were washed twice with PBS, 72 hours post infection 
2ml of DMEM was added to the flasks (with and without forskolin). Subsequently gpUL142 
expression was examined at 24, 48 and 72 hs post wash. 20µl of lysate and 30µl of supernatant was 
applied into a 10% NuPAGE Bis-Tris gel, electroblotted to nitrocellulose membranes and probed with 
mouse monoclonal antiV5 (1:10000) for V5 tagged protein; then anti-mouse IgG HRP was applied.  
Membranes were washed twice with PBST, stripped and stained with anti-Actin antibody (1:3000(-). 
(B) HF-CARs cells were infected with RAd-UL142-2A and cell but not secreted gpUL142 expression 
was analysed. (C) HF-CARs cells were infected with RAd-UL142-3C and cell extracts were analysed 
for expression. (D) HF-CARs cells were infected with RAd-Soluble UL142 as described above and 
UL142 expression in cell extract and supernatants was analysed. In each case, 20µl of lysate and 30µl 
of supernatant (where examined) was applied in sample buffer to a 10% NuPAGE Bis-Tris gel, 
electroblotted to nitrocellulose membranes and probed with mouse monoclonal anti-V5 (1:10000) 
then the anti-mouse IgG HRP.  Subsequently membranes were washed using twice with PBST twice, 
stripped and stained with actin antibody.  
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GpUL142 produced in RAd-UL142-2A and RAd-UL142-3C infected cells had a 
molecular mass of around 105kDa.  Higher levels of gpUL142 expression were 
detected in cells infected with RAd-UL142-1A and RAd-soluble UL142.  This 
difference in expression was consistent (reproducible) as can be observed when the 
UL142-1A, UL142-2A and UL142-3C were run next to each other in figure 5.4A. 
The PPT leader peptide was selected because it has been reported to enhance 
expression of gpUL142, and this result is consistent with the observations of higher 
expression of the target protein from adenoviral vectors incorporating this leader 
sequence. It is also possible that anti-V5 antibody may detect N terminal V5 tagged 
proteins more readily than C-terminal tagged fusion proteins. The lower molecular 
weight proteins visible on long exposure of RAdUL142-1A and Rad-soluble UL142 
suggest limited proteolytic degradation of these samples. An obvious limitation of 
using a C-terminal epitope tag to track expression is that the tag could be removed 
by post-translational processing. With RAdUL142-1A the N-terminal tag would 
escape C-terminal processing. The data is consistent with limited proteolysis of 
gpUL142 impacting detection of the C-terminal more than N-terminally tagged 
variants. With RAd-UL142-soluble, the cytosolic and transmembrane domains have 
been deleted and thus the truncated form of gpUL142 was released directly into the 
lumen of the ER, and thus this species would not be subjected to the same proteolytic 
processes.  
Generally, forskolin stimulated gpUL142 expression levels, but there were 
exceptions.  Most noticeably forskolin did not enhance expression of secreted 
gpUL142 from RAd-UL142-1A and RAd- soluble UL142 infected cells (figure 
5.3a). It is possible that forskolin treatment may be suppressing the secretion of 
gpUL142, although this effect was not observed with other constructs (Jacobs et al. 
1992). When membranes were stained for actin, the forskolin treated samples had 
lighter bands compared to non-treated samples. In these cells, the addition of 
forskolin dramatically reduced the levels of UL142 detectable in the supernatant. 
UL142 expression was readily detected in the supernatant and cell lysates of cells 
infected with RAd-soluble UL142 (figure 5.3d).   
A high molecular weight UL142 glycoform was detected in the supernatant of RAd 
UL142-1A infected cells (around 105kDa) (figure 5.3A). Although the strength of 
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the signal in the supernatant fraction was less than with the cell lysate, it should be 
borne in mind that only 30µl of total 2ml (0.15%) supernatant was run in comparison 
with 20µl of 400µl (5%) for the cell lysate. The membrane was stripped and stained 
with actin as an assessment of cellular contamination. The faint actin bands just 
detectable in the forskolin-treated sample implied a low-level contamination with 
cellular proteins, possibly reflecting cytotoxicity. However, only gpUL142 was 
detected in the supernatant of cells and actin was not detectable in the supernatants 
of cells with no forskolin treatment. The results thus imply that gpUL142 was 
released/secreted from the cells.  The size of gpUL142 in the cell supernatant match 
that of the highest band of lysate sample of UL142-1A (figure 5.3A); this result 
supports that protein is secreted as the molecular weight is comparable with mature 
glycosylated forms of UL142 expressed in cells. It is possible that gpUL142 could 
be secreted by exocytosis or a comparable process.  
5.4 Glycosylation of secreted and cell-associated forms of 
gpUL142 
 
The data presented in figure 5.3 demonstrated that expression tended to be optimal 
at 72 h p.i and that forskolin was often able to enhance expression. I therefore selected 
this time point and conditions to investigate the glycosylation status of gpUL142 
expressed from the various Ad recombinants detailed in Table 5.1 by EndoH and 
PNGaseF digestion. Lysates prepared from cells infected for 72 hs with each 
construct were treated with EndoH or PNGase F and analysed by Western blot, and 
the V5 tag was used to monitor gpUL142 expression.  The absence of any toxicity 
under the conditions used is indicated by reproducibility of the actin loading control 
(figure 5.4). GpUL142 was detectable from RAd-UL142-1A infected cells in the 
absence of forskolin but, in contrast to the previous assay, was greatly enhanced by 
forskolin treatment (figure 5.4A).  RAdUL142-1A infected cells expressed more 
gpUL142 than UL142-2A and UL142-3C which is in agreement with the previous 
experiment (Figure 5.3A). Also, RAdUL142-2A infected cells expressed more 
gpUL142 than UL142-3C, which indicates PPT enhances the expression of 
gpUL142. When comparing figure 5.3 with figure 5.4, one should bear in mind that 
the Western blot membranes had different exposure times in the gel imaging system. 
‘Mock’ treatment in figure 5.4A refers to the control sample that did not receive 
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endoglycosidase treatment. A high molecular weight form of gpUL142 of 
approximately 105 kDa was detected in RAdUL142-1A, RAd UL142-2A and RAd 
UL142-3C infected cells.  Endo H treated samples were detected at 40 kDa and 
PNGase treated samples were detected at 36 kDa, which is consistent with gpUL142 
being highly glycosylated. The fact that the majority of gpUL142 expressed from all 
three viruses is EndoH sensitive implies that most of the proteins have not been 
processed by the Golgi apparatus, and thus are likely retained in the ER. However, 
the low abundance EndoH insensitive glycoforms detectable with RAd UL142-1A 
and RAd UL142-2A could represent a fraction that is fully processed and potentially 
presented on the cell surface (Figure 5.4A).  
The cell lysate of RAd-soluble UL142 was run with non-codon optimized 
RAdUL142 and RAdUL18 on the same membrane as presented in figure 5.4B. All 
of the RAd-soluble UL142 expressed protein in the cell lysate was sensitive to EndoH 
and PNGase bands (Figure 5.4B). GpUL142 was not detectable in cells infected with 
the non-codon optimised version of UL142 (RAdUL142), a result consistent with 
previous findings (Seirafian 2012) and indicates codon optimization improves 
UL142 expression. RAdUL18 was included as a control to check EndoH and PNGase 
treatments. GpUL18 is highly glycosylated and is expressed in two glycoforms, one 
is susceptible to Endo H digestion and the other slower migrating form is resistant; 
the result was compatible with studies described by Griffin and co-worker (figure 
5.4B) (Griffin et al. 2005). Forskolin significantly enhanced expression from 
RAdUL18. There are parallels between these HCMV MHC-I homologues: both are 
heavily glycosylated, both are expressed at low levels and although both are 
expressed at the cell surface, the majority of both proteins appears to be retained in 
the ER (as gauged by sensitivity to EndoH).  
The gpUL142 version engineered to lack a transmembrane domain (RAd-soluble 
UL142) was Endo-H sensitive when present within the expressing cell, yet the form 
secreted into the supernatant was EndoH resistant (figure 5.4 C).  EndoH appear to 
be able to trim some the glycans on this heavily glycosylated from but unlike the 
intracellular precursor, it was largely resistant. This result implies soluble gpUL142 
is rapidly secreted once it transits the Golgi apparatus.  In this experiment, forskolin 
stimulated expression of the secreted form of gpUL142.   
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The supernatant of RAd UL142-1A was tested because this version of gpUL142 has 
an N terminal V5 that allows the protein to be tracked if it is cleaved above the 
transmembrane domain and released; as indicated in figure 5.3A. Significant 
amounts of the N-terminally tagged version of gpUL142 were again detected in the 
supernatant. Actin could only be detected in samples treated with forskolin, 
indicating some cell toxicity. In the absence of forskolin actin was not detected, thus 
implying the low abundance gpUL142 detected in supernatants was not due to 
contamination by cell lysis. Moreover, the fact that it was completely EndoH resistant 
also argues against its presence being due to cellular contamination. The PNGase 
bands in supernatant UL142-1A and Soluble 142 run as two bands (more clearly in 
forskolin treated samples) ;the upper band at 46 kDa and the lower band at 36 kDa  
(figure 3.4C and D) may be related to N-glycans forms on unfolded/misfolded 
proteins which are more susceptible to PNGase than N-glycans on folded proteins 
(Ninagawa et al. 2015). In all samples from infected cell extracts, the EndoH treated 
bands were slightly lower than 40kDa indicating a loss of ~60-65 kDa of N-linked 
carbohydrate, implying that many of the predicted 17 glycosylation sites are 
functional. The presence of the fully glycosylated (EndoH-resistant) form of 
gpUL142 in the supernatant of AdUL142-1A-infected cells implies that it can be 
released from cells independently of any additional HCMV-encoded gene function. 
GpUL142 thus appears to be both expressed at the cell surface and released/secreted 
from cells.  
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Figure 5.4: UL142 is highly glycosylated. Biochemical analysis of the intracellular localization and 
glycosylation status of UL142; (A) Samples from HF-CAR cells infected with RAd-UL142-1A, RAd-
UL142-2A, RAd-UL142-3C at an MOI 10 PFU/ml for 72 hours were mock treated or treated with 
Endo H or PNGase F following the manufacturer’s protocol, overnight at 37°C. Membranes were 
immuno-probed with mouse monoclonal anti-V5 (1:10000), subsequently membranes were stripped 
and treated with anti-Actin antibody (1:3000); (B) Samples from HF-CAR cells infected with RAd-
solubleUL142-, RAd-UL142, RAd-UL18 (used as a control) at an MOI of 10 PFU/ml for 72 hours, 
were mock treated or treated with Endo H or PNGase F following the manufacturer’s protocol, 
overnight at 37°C. Membranes were immuno-probed with mouse monoclonal anti-V5 (1:10000) , 
subsequently membranes were stripped and treated with anti-Actin (1:3000); (C) HF-CARs cells were 
infected with RAd-soluble UL142 at an MOI 10 PFU/ml for 72 hours. Cells in a T25 flask were 
washed twice with PBS then 2ml of DMEM media was added and cells were further incubated for 72, 
prior to Western blotting analysis.  Supernatants were centrifuged twice then either mock treated or 
treated with Endo H or PNGase F following the manufacturer’s protocol, overnight at 37°C before 
analysis. Membranes were immuno-probed with mouse monoclonal anti-V5 (1:10000) then stripped 
and treated with anti-Actin (1:3000); (D) HF-CARs cells were infected RAd-UL142-1A at an MOI 
10 PFU/ml for 72 hours. Cells in a T25 flask were washed twice with PBS then incubated for a further 
72 hours in 2ml DMEM media, prior to Western blotting analysis. Supernatants were centrifuged 
twice then either mock treated or treated with Endo H or PNGase F following the manufacturer’s 
protocol, overnight at 37°C. Membranes were immuno-probed with mouse monoclonal anti-V5 
(1:10000) then membranes were stripped and treated with anti-Actin (1:3000). (-) indicates treatment 
without forskolin; or (+) indicates treatment with forskolin. 
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5.5 UL142 and Surface Expression of MICA 
 
I next sought to test whether UL142 expressed from any of the RAd constructs being 
characterised in this study was able to affect cell surface expression of MICA 
expression.  MICA is a stress ligand and its expression levels in normal fibroblast 
culture is low even though Ad vector delivery is able to provide some stimulation of 
NKG2D Ligands (Tomasec et al. 2007). HF-CAR cells were infected with RAd-
UL142-1A, RAd-UL142-3C, RAd-soluble UL142 or infected with both RAd-US18 
and RAd-US20 together, which have been shown to act synergistically to inhibit 
MICA expression (positive control). The expression of surface MICA was analysed 
by flow cytometry (figure 5.5). UL142 expressed from both viruses RAd-UL142-1A 
and RAd-UL142-3C were able to reduce surface expression of MICA, in contrast, 
soluble UL142 did not alter surface expression of MICA. Ectopic expression of 
UL142 was able to downregulate cell surface expression of MICA but required the 
transmembrane/cytosolic domains of gpUL142. 
 
 
Table 5.2: The HCMV viruses used in this chapter 
 
Viruses 
 
Information details 
RCMV1111 
 
The HCMV strain Merlin genome was cloned into a BAC at passage 
5. Derived from the prototype RL13-, UL128- Merlin BAC described 
in Stanton et al (2010) 
RCMV1656 
 
Deleted US18+US20 derived from MerinBAC1111 Constructed by Dr 
Ceri Fielding.  
RCMV1812 
 
Deletion of UL142 in HCMV, derived from MerinBAC1111 
Constructed by Dr Peter Tomasec  
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Figure 5.5: Effect of RAd UL142 on cell surface expression of MICA. HF-CARs cells were 
infected with RAd-UL142-1A, RAd-142-3C, RAd-soluble UL142, RAd1253 (vector control) or with 
RAd-US20 and RAd-US18 together (positive control) at an MOI 10. 72 p.i, the HF-CARs cells were 
immune-stained using the MICA-PE or isotype IgG2b-PE antibody. 
 
 
 
 
 
 
Figure 5.6: Effect of HCMV UL142 on surface expression of MICA. HF-TERTs were either 
mock infected or infected with Merlin∆UL142 (RCMV 1812), Merlin∆US18∆US20 (RCMV 1656) 
or HCMV strain Merlin (HCMV 1111) at an MOI of 10 for 72 h, then stained with MICA-PE or 
isotype IgG2b-PE antibody. 
RAd-control
RAd-US18+RAd-US20
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RAd-US18+RAd-US20
RAd-UL142-1A
Isotype staining RAd-control
RAd-control
RAd-US18+RAd-US20
RAd-soluble UL142
Isotype staining RAd-control
1111
1812
1656
HF-TERT
Isotype stained 1812
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An advantage of working with HCMV, relative to molluscum contagiosum, is that 
gene functions can be assessed in the context of an active infection. The impact of a 
gene responsible for controlling MICA cell surface expression is likely to be more 
pronounced in the context of a productive HCMV infection where MICA is known 
to be induced. The effect of UL142 on MICA expression was therefore assessed 
using the HCMV strain Merlin.  For this purpose, HCMV strain Merlin deletion 
mutant (Merlin∆UL142; RCMV1812) virus was kindly provided by Dr Peter 
Tomasec. Since US18 and US20 have been previously shown to downregulate MICA 
expression, HCMV US18 and US20 double deletion mutant (Merlin∆US18∆US20; 
HCMV 1656) was obtained from Dr Ceri Fielding for comparison. The ability of 
these mutant viruses to modulate MICA expression was compared to the parental 
virus, HCMV strain Merlin (HCMV 1111). Details of all HCMVs used are shown in 
table 5.2.  Cell surface expression of MICA was assayed by flow cytometry in HF-
TERTs at 72 hs p.i. (figure 5.6).  Infection with the Merlin∆US18∆US20 (RCMV 
1656) mutant resulted in substantial upregulation of MICA on the cell surface 
whereas Merlin∆UL142 (RCMV 1812) had no effect.                                        
UL142 has been reported to downregulate full length alleles of MICA, but not the 
truncated MICA*008 allele (Chalupny et al. 2006; Ashiru et al. 2009). In order to 
test whether UL142 is able to target only full-length alleles of MICA, Chinese 
hamster ovary cells (CHO) – CAR were infected with adenovirus constructs 
encoding either truncated MICA*008 or the full-length MICA*002 in combination 
with the various RAdUL142 constructs described in Table 5.1. CHO-CAR were used 
for this study because they do not express endogenous MICA that could potentially 
confound the analysis of the experiment. The levels of MICA*002 and MICA*008 
expression achieved by using the Ad vectors was not significantly altered by any of 
the UL142 variants (figure 5.7). Thus, expression of UL142 does not alter the surface 
expression levels of the full length (MICA*002) or truncated (MICA*008) alleles of 
MICA in CHO-CAR cells.  
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Figure 5.7: UL142 has no effect on surface expression of MICA in CHO cells. CHO cells were 
co-infected at an MOI 50 with RAd vectors encoding the MICA*002 and truncated MICA*008 
genotype or RAd vector alone, or at an MOI 50 of RAd vectors encoding the genotype MICA*002, 
truncated MICA*008 genotype in combination with an MOI 50 of RAd-UL142-1A, RAd-UL142-2A, 
RAd-UL142-3C or RAd-soluble UL142 or control RAd vector as indicated. After 72 h, cells were 
stained with PE-conjugated anti-MICA or an PE conjugated IgG2b isotype control antibody analysed 
by flow cytometry.  
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5.6 UL142 downregulates NK cell killing in an allogenic 
setting using a donor 007 NK line 
 
Ectopic expression of UL142 has been shown to suppress NK cell activation, 
although interestingly only in a subset of donors (Wills et al. 2005; Prod’homme et 
al. 2007). In order to assess UL142 function, I sought to test whether I could 
recapitulate its function as an NK cell evasion molecule. Initial experiments involved 
harvesting PBMC from blood bags obtained from the Welsh Blood Transfusion 
service and generating NK cell lines from them. While blood bags provide an 
abundant source of PBMC, their quality can vary depending on how long they have 
been stored before being released for research. Functional variability is not only a 
limitation of blood bags but moreover the option does not exist to revisit donors with 
interesting responses. PBMCs donated by laboratory volunteers are therefore an 
invaluable source of fresh blood where the processing of bloods can be completely 
controlled, the HCMV serostatus has been determined, the responsiveness of NK 
cells tends to be well characterised from previous assays and the option exists to use 
matched skin fibroblasts, so experiments can be performed in an autologous setting.  
However, demand to access the donor pool is high and their availability is limited.   
Consequently, the NK lines from blood donor 1 (BD1), blood donor 2 (BD2), blood 
donor 3 (BD3), and blood donor 005 (BD5) were generated and kindly provided by 
Dr Simone Forbes and Dr Virginia-Maria Vlachava and donor 007 (D007) was 
generated and kindly provided by Dr Rebecca Aicheler. HCMV UL141 elicits robust 
protection against NK cell activation and was therefore included as a positive control 
(Tomasec et al. 2005; Prod'homme et al. 2010; Smith et al. 2013b). In all assays 
UL141 was able to inhibit NK cell degranulation significantly (figure 5.8). Since the 
enhanced expression observed with the codon optimised versions of UL142 has the 
potential to influence the sensitivity of functional assays, the ability of different 
UL142 variants (Table 5.1) to modulate the NK cell responses was therefore 
compared. None of the UL142 constructs tested had an overt effect on NK cell 
function when cells from BD1, BD2 and BD3 were tested. Unexpectedly, UL142 
significantly increased NK cell degranulation in BD5 when expressed from the RAd 
recombinants UL142-1A, UL142-2A and UL142-3C but not the construct expressing 
the soluble-UL142 form. This result implies that when expressed on the cell surface 
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gpUL142 may stimulate an activating signal receptor on BD5 NK cells, or impede 
signalling to an inhibitory receptor. 
The NK cell line from D007 allows the function of UL142 to be assessed in both an 
autologous and an allogeneic setting.  In an allogenic setting, D007 NK cell 
degranulation was inhibited when target cells expressed either UL142-2A or soluble-
UL142, but not when the cells expressed the UL142-1A and UL142-3C variants 
(figure 5.8). When assayed in an autologous system using the RAd-UL142-1A and 
RAd- soluble UL142 constructs stimulated NK cell activation.  UL142 clearly had 
the capacity to modulate NK cell responses in lines derived from two out of the five 
donors tested. Interestingly, the same NK cell line was capable of being either being 
inhibited or activated depending on the properties of the target cell. 
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Figure 5.8: Effect of UL142 Expression of NK Cell Degranulation. The effect of UL142 on 
degranulation of NK cell lines was assessed by measuring the proportion of CD107a+ expression by 
CD3- and CD56+ NK cells. UL141 is a recognised HCMV NK cell evasion function that was 
included in the assays as a positive control. HF-CAR cells were infected at an MOI 10 with RAd-
UL142-1A, RAd-UL142-2A, RAd-UL142-3C, RAd-soluble UL142, RAd UL141 or RAd 1253 
(RAd-control) in allogenic setting for BD1, BD2, BD3, BD5 and D007 for 72h. D007 syngeneic 
fibroblasts were infected at an MOI of 500 with RAd-UL142-1A, RAd-soluble UL142, RAd UL141 
or RAd 1253 (RAd-control) for 72 hs. Infected cells were incubated with D007 BD1, BD2, BD3, or 
BD5 NK cells 10:1 effector:target cell ratio for 5 h with FITC conjugated CD107a or FITC IgG1 
isotype control antibody in the presence of Golgi stop. NK degranulation was assessed by measuring 
the %CD107a+ of CD3- CD56+ NK cells. The data was analysed statistically using one-way anova 
and a Dunnett test was used to compare NK cell responses with all the different RAd UL142 
constructs and RAd UL141 versus the RAd-control (*P<0.05, **P<0.01, ***P<0.001).  
. 
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5.7 Summary 
 
The expression of RAd-UL142 was improved by codon optimization of RAd-UL142 
constructs, and inclusion of a PPT leader peptide further enhanced expression of 
UL142. When expressed in isolation the majority of gpUL142 in the cell was 
detected in a highly glycosylated EndoH sensitive form, consistent with its 
association with the ER. Nevertheless, gpUL142 could readily be detected on the cell 
surface. Moreover, a mature Endo-H resistant form is released into the tissue culture 
supernatant, possibly as a result of proteolytic cleavage.  These results indicate that 
gpUL142 has the potential to act either at the cell surface or remotely.  By contrast 
with previous studies, Merlin UL142 had no effect on MICA expression when 
expressed by HCMV virus in infected fibroblasts or adenovirus in infected CHO-
CAR cells coexpressing MICA. However, in agreement with previous observations, 
expression of UL142 by adenovirus in HF-CAR cells downregulated MICA 
expression.  This observation may be due to the high levels of expression of gpUL142 
by adenovirus in this system. UL142-2A and soluble-UL142 adenoviral constructs 
inhibited NK cell killing in in allogenic fibroblasts in a donor-specific fashion. 
However, by contrast, UL142-1A, UL142-2A and UL142-3C adenoviral constructs 
activated NK cells in autologous fibroblasts in a donor-specific fashion. 
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6.1 Optimising expression of mc033L and mc080R using 
viral vectors 
 
In order to analyse expression of the MOCV genes mc033L and mc080R, I sought to 
express these genes individually using appropriate mammalian expression vectors. 
VACV has proved to be a highly efficient virus vector that is able to accommodate 
extremely large inserts and, following the infection of mammalian cells, provides for 
the expression of recombinant proteins with appropriate posttranslational 
modifications (Perkus et al. 1985; Coupar et al. 1988). Being a poxvirus, VACV was 
a natural vector to attempt the expression of MOCV genes. Adenovirus vectors have 
been developed and used very extensively as gene delivery vehicles by the research 
group in Cardiff to analyse gene function (Stanton et al. 2008).  Both vector system 
can readily be propagated to high tires and provide for efficient transgene delivery in 
both dividing and non-dividing cells. The AdZ vector allowed for direct insertion a 
transgene into the vector within E.coli with no requirement for a transfer vector. The 
DNA element encoding the transgene is introduced into recombineering bacteria that 
already carrying a BAC containing the AdZ vector (Stanton et al. 2008). 
In preliminary investigations performed prior to the initiation of this study, the 
natural mc080 ORF was cloned into both the replication-competent VACV Western 
Reserve (WR) strain by Dr Subuhi Sherwani to produce the recombinant virus v293 
(vWR293-mc080) and a replication-deficient Ad vector by Dr Rich Stanton to 
produce RAd961. Both recombinant viruses grew slowly and to low tires when 
propagated in vitro and critically, expression of MC080 could not be detected with 
either construct. Although the toxicity associated with these constructs was initially 
attributed to (low level) expression of the transgene, the later success with codon 
optimised versions of the gene makes it more likely that the extreme GC rich codon 
bias of the MOCV sequence may have been responsible for impeding vector 
propagation, inducing cytotoxicity and possibly also limited expression of the 
transgene. 
Codon usage adapted versions of the mc033 and mc080 genes were synthesized with 
a view to optimising translation speed (Sorensen and Pedersen 1991; Tuller et al. 
2010).  Codon usage adapted version of the MOCV genes were not inserted in to the 
VACV vector as it was apparent from preliminary studies that the lytic infection 
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produced by the replication-competent VACV vector was going to complicate 
studies of transgene expression and function. In order to select a vector that caused 
minimal perturbation to the target cell in functional assays, the lentiviral donor 
plasmid pHAGE was also adopted for expression of the MOCV genes and neomycin 
resistance cassette used to select vector transduced cells. Since there was a major 
concern over cytotoxicity associated with expression of mc080, conditional 
expression of the transgene was sought using a tet regulated promoter (tetON). The 
pHAGE plasmid vector used to express codon-optimised MC033L ORF and 
MC080R ORF. The expression of MC033/MC080 from the stably transfected 
plasmids upon addition of the tet inducer was low and only small numbers of cells 
showed fluorescence in these experiments, indicating low induction efficiency or 
further toxicity in this system. The lentiviral gene expression system can be limited 
by the fact that expression tends to be limited to a small proportion of genes and the 
act of delivery can be cytopathic.  The second-generation lentivirus system was used 
to express the MC033L and MC080R, these experiments were only conducted in 
preliminary fashion. While the expression of both genes by this approach was modest 
in immunofluorescence assays, there is clear potential to improve upon these levels, 
e.g by generating higher titre lentivirus stocks. These lentivirus recombinants could 
yet prove useful in future studies on the function of the MOCV genes. 
Many of the assays available in Cardiff University to investigate the viral 
immunomodulatory genes were set up to tests functions of genes cloned in to Ad 
expression vectors. For examples, the HCMV immunomodulatory function of UL18, 
UL40, UL135, UL141 and UL142 were discovered and/or characterised by using Ad 
vector systems (Tomasec 2000; Tomasec et al. 2005; Wills et al. 2005; Prod’homme 
et al. 2007; Stanton et al. 2014). The AdZ vector system is robust, straightforward, 
and suited to both sporadic and high-throughput applications (Stanton et al. 2008). 
MC033 and MC080 were expressed highly efficiently from adenovirus constructs, 
indeed the signals were off the scale when they were first analysed by flow 
cytometry. 
From a combination of immunofluorescence microscopy and western blot studies, 
MC033 and MC080 proteins were characterised as EndoH-sensitive glycoproteins 
that mainly co-localised with the ER marker calnexin. MC033 does not contain a 
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consensus ER localization signals; KDEL or K(X)KXX motifs that are frequently 
found in the cytoplasmic tail of ER resident proteins (Teasdale and Jackson 1996). 
The accumulation MC033 in ER may be mediated by a non-canonical ER retention 
signal, be a property of the transmembrane domain or MC033 may be retained 
through an interaction with another ER resident protein (Watson and Pessin 2001). 
My immunolocalization studies also detected the MC080 protein in the Golgi 
compartment, Senkevich and Moss also found MC080 protein accumulated in the 
Golgi compartments and ER (Senkevich and Moss 1998). 
The fact that MC080 was only detected as an EndoH-sensitive form implies that the 
vast majority of the protein was retained with in the cells. Interestingly, Senkevich 
and Moss were able to demonstrate that MC080 bound to ß2m in the ER, yet they 
were unable to detect MCO80R/ß2m complexes on the cell surface (Senkevich and 
Moss 1998). The retention of MC080 within the cell argues against it acting as an 
HLA-I mimic, as is the case for HCMV UL18, which is known to reach the surface 
where it can interact with the NK cell inhibitory receptor LIR-1. However, it remains 
possible that MC080 is expressed on the cell surface at levels too low to be readily 
detected but sufficient to interact with immune cells. Moreover, care has to be taken 
in the interpretation data using virus genes expressed ectopically. It is possible that 
MC080 could require co-expression of (an) addition MOCV gene product(s) to reach 
the cell surface. 
6.2 MC080 but not MC033 downregulated MHC I and 
HLA-E in a TAP independent way 
 
MC080 was first shown to downregulate cell surface expression of HLA-I by flow 
cytometry when the MOCV gene was expressed in isolation from an Ad vector 
(Section 4.4). This function of MC080 was further characterised by western blot 
analysis that revealed that expression of MC080 was responsible for HLA-I 
remaining in an Endo-H sensitive form, consistent with HLA-I being retained in the 
ER.  The abundance of HLA-I decreased over time in cells expressing either MC080 
or HCMV US6 (a specific inhibitor of TAP), in both cases retention in the ER 
compartment was associated with a shorter half-life for HLA-I. These results thus 
 151 
identify a novel immune evasion function for MC080 in suppressing MHC-I antigen 
presentation through its retention in ER. 
Experimentally, mc080 acted in a similar fashion to the positive control HCMV US6.  
Both genes exhibited the capacity to retain the heavy chain of MHC-I in the ER and 
downregulate cell surface expression of classical MHC-I and HLA-E. HLA-E 
exhibits limited sequence polymorphism and binds a restricted set of peptides that 
are normally derived in a TAP-dependent manner from the leader sequences of HLA-
I A, B, C and G (see section 1.9).   HLA-E maturation is dependent on peptide 
binding, and results in its expression on the cell surface where HLA-E becomes 
available to bind the NK cell inhibitory receptor CD94/NKG2A. HLA-E thus inhibits 
NK cell-mediated cellular cytotoxicity (Tomasec 2000). HLA-A2 tends to bind 
hydrophobic proteins, and appears to be capable of presenting peptides capable of 
passive diffusion from the cytosol into the lumen of the ER independently of TAP, 
or derived directly from hydrophobic leader sequences (Lorente et al. 2011).  In my 
experiments, US6 did not down regulate HLA-A2 in TAP-deficient cell whereas in 
contrast MC080 did. This result is consistent with US6 inhibiting TAP, and MC080 
working by an alternative mechanism.  HCMV UL40 is able to donate a peptide that 
upregulates HLA-E in a TAP-independent manner, and thereby reverses its 
downregulation by US6 (see section 1.9). MC080 was still able to downregulate 
HLA-E in TAP-deficient when UL40 was being used to rescue HLA-E expression. 
These results indicate that MC080 also targets HLA-E in a TAP-independent way. 
 
Two MOCV MHC I homologues were studied in this thesis, MC033 had no obvious 
impact on the expression of either classical MHC I or HLA-E. It is possible MOCV 
may encode additional genes capable of acting in concert with MC080 to target MHC 
I. HCMV has at least four genes that act in concert to downregulate MHC-I (US2, 
US3, US6, US11) (see section 1.8). The HCMV MHC class I homologue gpUL18 
both binds peptide and is presented on the surface while, in contrast, MC080 did not 
bind peptide and was not detectable on the surface (Senkevich and Moss 1998).  
MC080 and US6 were similar in that both localize to ER and downregulate MHC I 
and HLAE, however MC080 has no apparent effect on TAP. MC080 must 
presumably use another mechanism to downregulate MHC I. HCMV US2 and US11 
also  localise to ER where they direct  retrograde transport of MHC I to the cytosol 
after which it is rapidly degraded  by  proteasomes (Wiertz et al. 1996a; Wiertz et al. 
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1996b; Jones and Sun 1997) whereas US3 retains MHC I in the ER by binding the 
chaperon tapasin and inhibiting peptide loading of MHC I (Hegde et al. 2002; 
Chevalier and Johnson 2003; Noriega and Tortorella 2009). As an MHC-I 
homologue, it is possible MC080 enters the cellular pathway involved in processing 
the MHC-I complexes, only to sequester an essential factor. While MOCV is known 
to downregulate cell surface expression of ß2m from the surface of MOCV lesions, 
it would be interesting now to look directly at cell surface expression of MHC-I in 
vivo.  The downregulation of MHC I is associated with the diminution or abrogation 
of CTL recognition, and this allows viruses to persist and replicate more easily in the 
host. Since endogenous MHC-I and HLA-E are the chief ligands for NK cell 
inhibitory receptors, cells that downregulate these molecules tend to become targets 
for NK cells (Tortorella et al. 2000). Whilst the downregulation of MHC-I by HCMV 
may leave infected cells vulnerable to NK cell attack (see section1.9) the virus 
compensates to some extent by UL40 rescuing HLA-E expression  and gpUL18 
acting as an MHC-I mimic by binding the NK cells inhibitory receptor LIR-1+ 
(Prod'homme et al. 2012).  Since MOCV MC080 also suppresses cells surface 
expression of MHC-I, it is likely that MOCV may need to encode additional 
functions to help evade NK cells. 
 
6.3 MC080 modulates NK cell activation 
 
NK cell function is regulated by a fine balance of signals received by activating and 
inhibitory receptors. Interactions between endogenous HLA-I molecules and NK cell 
inhibitory receptors normally dominate over signals received from activating 
receptors.  NK cell inhibitory receptors that recognise endogenous classical HLA-I 
molecules act to suppress killing by NK cells (Yokoyama et al. 2010). A proportion 
of human NK cells express a surface C-type lectin receptor, CD94/NKG2A, which 
delivers an inhibitory signal to NK cells (Braud et al. 1997).  MC080 downregulates 
MHC I and HLAE, and thus one would expect MC080 to render cells more 
vulnerable to NK cell attack. In this thesis, NK cell function was tested in autologous 
and allogenic assays using a CD107a degranulation assays and PBMCs obtained 
from local volunteer donors and blood transfusion service.  NK lines were also 
established from D007 and the blood donor BD5; assays with the latter being 
restricted to an allogeneic setting. The NK assays unexpectedly gave different results 
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depending on whether they were performed in an autologous and allogenic setting 
for D007, D008 and D009. NK cell activation was variously associated with 
inhibition (in allogenic setting of D007, BD5 and autologous setting of D009), 
activation (in autologous setting of D008 and D007) or no effect (in allogenic setting 
of D008 and D009). The assays performed in an allogeneic setting all used the same 
standard human foetal foreskin fibroblasts (HF-CAR) as targets, whereas the 
autologous assays were performed on skin fibroblasts taken from the donors by 
biopsy. 
The effect of MC080 on MICA was discussed as the possible explanation to its NK 
cell effect. However, when investigated directly by ectopic expression in CHO-CAR 
cells, MC080 had no substantial effect on the expression of either a full-length 
MICA*002 allele or the truncated MICA*008 allele. While the downregulation of 
HLA-I would normally be expected to promote NK cell activation, NK inhibitory 
receptors are commonly paired with an activation receptor that recognises the same 
target, albeit with a different affinity. While HLA-E binds the inhibitory receptor 
CD94/NKG2A with high affinity, it can also bind the paired activating receptor 
CD94/NKG2C with low affinity. Although CD94/NKG2C is normally expressed on 
only a small subset of NK cell, during HCMV infection CD94/NKG2C+ cells expand 
in what can be considered akin to an adaptive response associated with memory. 
Likewise, NK cells are capable of expressing both inhibitory and activating KIRs 
capable of recognising endogenous HLA-I molecules.  KIR genes are highly 
polymorphic, an important variation with respect to the activating KIR genes and 
humans may inherit multiple variants (Maxwell et al. 2004; Ahlenstiel et al. 2008). 
HF-CAR and autologous HSF each have individual HLA repertoires that react 
differently with the various KIRs expressed in NK cells.  The downregulation of 
endogenous HLA molecules by MC080 may potentially either inhibit or activate NK 
cells depending on the KIR and HLA repertoires on the NK cell and HF respectively. 
Thus, it is possible that the downregulation of MHC-I by MC080 could result in NK 
cell inhibition when the NK cell functional assay is dominated by activating KIRs. 
However, it also possible that mc080 may yet have an additional effect on NK cells 
that is independent on MHC-I ligand recognition. 
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6.4 MC080 expression impair CD 8+ T cells activation 
Cytotoxic CD8+ T lymphocytes recognise cells presenting viral peptides bound to 
surface MHC class I molecules. MC080 downregulated MHC-I rendering the 
number of cell surface, peptide loaded MHC class I molecules required for CTL 
recognition is very low. T cell epitopes have not been defined for MOCV. The 
functional effect of MC080 on CTL recognition were therefore investigated by using 
HLA-A2–restricted CD8+ CTL lines generated to HCMV-IE1 VLEETSMVL (VLE) 
and HCMV-pp65 NLVPMVATV (NLV) peptides using a range of peptide 
concentration. MC080 was able to protect against T-cell degranulation at a range of 
peptide concentrations, and with comparable efficacy to HCMV gpUS6 (Ahn et al. 
1997). Interestingly, CD8+ T cells activation was impaired more when the cells were 
coated with lower peptide concentrations of VLE and pp65. The downregulation of 
MHC class I by MC080 provides MOCV with a mechanism for evading T-cells 
degranulation. MC080 interferes with the MHC class I antigen presentation pathway 
to prevent the presentation of processed viral peptides to CD8+ T cells. The MC080 
protein is expressed early in MOCV infection (Senkevich et al. 1997) and it may be 
one of MOCV genes which are responsible for absence T cell at the site of MOCV 
infection (Viac and Chardonnet 1990). MC033 has no effect in MHC-I and HLA-E 
and did not have a significant effect on NK cell and T cell activity in this study. The 
Blast and Phyre of MC033 resulted with MHC-I homology. However, the homology 
was restricted to a very short region of the protein with an Ig-like fold. Phyre did not 
model MC033 on to MHC-I (data presented in the appendix). In view of the restricted 
extremely restricted nature of the homology detected, it may not be helpful to classify 
mc033 as an MHC-I homologue, indeed it may direct experimental enquiries away 
from its true function. 
6.5 Optimizing expression of UL142 
 
The non-codon optimized UL142 ORF with a V5 tag was cloned into the AdZ vector 
(RAd-UL142) as part of a project that generated an expression library of all canonical 
HCMV genes. However, using this construct gpUL142 expression could not be 
detected by immunofluorescence and only weakly by western blot (Seirafian 2012). 
Since UL142 expression was enhanced by substituting a preprotrypsin (PPT) signal 
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peptide for the normal leader peptide (Ashiru et al. 2009), Dr Rebecca Aicheler 
designed three codon-optimized UL142 constructs in AdZ vector with the purpose 
of improving expression (Table 5.1). I found that codon optimisation improved 
gpUL142 expression dramatically and PPT had mild increase on expression of 
gpUL142. The N-terminal signal peptide is a key factor in determining the efficiency 
of ER translocation from ribosome to ER membrane. Several studies have 
demonstrated that recombinant proteins can be produced with a high yield by 
replacing signal peptides (Olczak and Olczak 2006; Celinska et al. 2018). I also found 
that N terminal V5-tagged version of UL142 was much more readily detected than a 
comparable construct with a C terminal V5-tag. This is in agreement with a study 
carried by Park et al who observed that the C-terminal tag was associated with uneven 
expression of recombinant proteins and the N terminal tagged protein associated with 
over-expression of recombinant proteins (Park et al. 2015). To help investigate the 
function of UL142, Dr Sepehr Seirafian also produced a secreted form of UL142 by 
deleting transmembrane and cytoplasmic domains; this secreted version of gpUL142 
was also expressed more efficiently. 
In the AdZ vector system, the expression of UL142 was under the control of the 
constitutive HCMV major IE promoter. Forskolin is known to stimulate expression 
from the CMV IE promoter through its action on the multiple cAMP responsive 
elements in the enhancer in the context of the Ad vector (Jacobs et al. 1992; 
Wilkinson and Akrigg 1992) and was thus used here in an attempt to further enhance 
expression of gpUL142. By using time course to choose the best time point for 
gpUL142 expression (72h), expression was readily detected from all four constructs 
and generally increased over time except where cytotoxicity was observed in cells 
late in infection. Forskolin enhanced the expression of gpUL142 for all four 
constructs. However, in RAd-UL142-soluble supernatant samples the expressions 
were unexpectedly low, and is thought to relate to cytotoxicity induced by 
overexpression with time; in this experiment expression was measured after 96 h, 
120 h and 144 h p.i.  Cytotoxicity was reflected in reduced actin staining that was 
more extreme when forskolin was added to enhance soluble gpUL142 expression. 
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6.6 GpUL142 is expressed on the cell surface and may be 
released/secreted from the cells 
 
Endoglycosidase H is a recombinant glycosidase which cleaves the chitobiose core 
of high mannose and some hybrid oligosaccharides from N-linked glycoproteins, a 
conversion that occurs in the medial Golgi region. When proteins are correctly 
processed through the endoplasmic reticulum (ER) and Golgi apparatus, they become 
resistant to EndoH, and sensitivity to EndoH indicates the presence of proteins that 
have not yet been processed beyond the ER. 
GpUL142 is predicted to contain 17 glycosylation sites and has been shown 
experimentally to be highly glycosylated (Wills et al. 2005). Consistent with this 
observation, the apparent molecular mass of gpUL142 decreased by around 65kDa 
when treated with Endo-H (see section 5.4). The fact that the majority of all three 
forms of gpUL142 expressed by using Ad recombinants was EndoH-sensitive 
implies that most of the protein has not been processed by the Golgi apparatus, and 
thus are likely retained in the ER. This result is in agreement with Ashiru and co-
workers report that gpUL142 is predominantly localised to the ER and Golgi 
apparatus along with MICA, yet a small amount of protein did reach the cell surface 
(Ashiru et al. 2009).  However, the low abundance Endo-H resistance glycoforms 
detected with RAd UL142-1A and RAd UL142-2A could represent the fraction 
expressed on the cell surface. The soluble UL142 glycoprotein was Endo-H sensitive 
when expressed in the cell yet Endo-H resistant when supernatant samples were 
tested, which implies that ‘soluble UL142’ is rapidly secreted once it transits the 
Golgi apparatus. 
Significant amounts of the N-terminally tagged version of gpUL142 were 
unexpectedly detected in the supernatant, and this result was consolidated when the 
samples were tested for glycosylation. The samples were analysed to determine 
whether gpUL142 is released due to spontaneous lysis of cells infected with 
AdUL142 recombinants. The cellular protein actin was only detectable in cells 
exhibiting significant cytotoxicity associated with treatment with certain preparations 
of forskolin. However, actin was not detectable in supernatant in the absence of 
forskolin, thus the low abundance gpUL142 detected in the absence of forskolin was 
therefore not likely to be caused by contamination associated with cell lysis. 
 157 
Crucially, gpUL142 detected in the supernatant with the UL142-1A construct was 
completely Endo-H resistant. Thus, the secreted gpUL142-1A must have trafficked 
through Golgi compartments and is distinct from the predominant form associated 
with AdUL142-1A infected cells, which is EndoH sensitive. Even in the absence of 
any other HCMV gene product, a significant proportion of gpUL142 may be released 
from cells expressing the protein.  Accordingly, gpUL142 may potentially be a 
secreted protein that modulates the immune response by affecting near and distant 
immune cells. 
6.7 UL142 has no effect on MICA 
 
HCMV IE1 upregulates NKG2DL ULBP2, and IE2 which upregulates MICA 
ligands. (Eagle et al. 2006; Venkataraman et al. 2007; Tavalai and Stamminger 2011)  
NKG2Ls are regarded as stress ligands so their expression tends to be extremely low, 
or absent, in cells cultured in vitro. It is thus really only following cell activation 
during productive infection that it is possible to fully evaluate viral evasion function 
that target NKG2DLs.  While the impact of the US12 family on MICA had been 
examined in the context of HCMV lytic infection, the effect of UL142 on MICA has 
only been studied in ectopic expression. 
Ashiru et al found that gpUL142 expressed using adenovirus vector was able to 
downregulate cell surface expression of full-length MICA variants to retain them in 
the ER and the cis-Golgi apparatus, yet UL142 had no effect on the truncated form 
MICA*008. UL142 luminal and transmembrane domains promote the recognition 
and intracellular sequestration of full-length MICA alleles (Chalupny et al. 2006; 
Ashiru et al. 2009).   However, the HCMV laboratory strain AD169 lacks the UL/b’ 
region that contains the UL142 gene. Strain AD169 was reported to downregulate 
cell surface expression of full-length MICA alleles, but not MICA*008 (Zou et al. 
2005). More recently, the US12 gene family was found to be primarily responsible 
for downregulating full-length MICA in productive infection (Fielding et al. 2014). 
The expression level of MICA ligands in normal fibroblast culture is low even though 
Ad vector delivery is able to provide some stimulation of NKG2DLs (Tomasec et al. 
2007). In my results, all forms of gpUL142 expressed in context of adenovirus vector 
downregulates full length MICA, except for the soluble UL142 which had no effect 
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on either truncated or full-length MICA alleles. Thus, ectopic expression of UL142 
was able to downregulate cell surface expression of full-length MICA, but the 
transmembrane/cytosolic domains of gpUL142 were required for this function. 
Unlike the situation in MOCV, with HCMV it is possible to investigate gene function 
in the context of a productive infection. The application of defined HCMV deletion 
mutants has supported the function of individual genes NK evasion functions, UL40 
in the control of HLA-E,  the control of MICB, ULBP1 and ULBP2 by UL16’s, the 
interaction of gpUL18 with LIR1 plus MICA and B7H6 downregulation by the US12 
family members US18 and US20 (Wang et al. 2002; Rolle et al. 2003; Fielding et al. 
2014; Fielding et al. 2017). When I investigated the regulation of MICA in the 
context of productive HCMV infection, deletion of US18 and US20 associated with 
significant increase in MICA cell surface expression relative to HCMV-infected cells 
whilst deletion of UL142 has no overt affect. This indicates that the control of MICA 
expression during productive infection is primarily the responsibility of the US12 
gene family and not UL142. Moreover, gpUL142 was unable to control the 
expression of either MICA*008 or MICA*002 when the genes were expressed in 
CHO-CAR cells; CHO cells lack an endogenous MICA homologue. UL142 is clearly 
capable of modulating the NK cells response. However, the data from the 
experiments preformed in this thesis suggest that the primary mechanism of action 
of UL142 in productive HCMV may not be to target MICA, a result that is consistent 
with the US12 gene family (particularly US18 and US20) playing the predominant 
role in downregulation of full-length MICA (Fielding et al. 2014; Fielding et al. 
2017). 
6.8 UL142 modulate NK cell killing 
 
The results obtained from these preliminary NK cells assays are intriguing. By using 
Ad vectors to deliver UL142, its function is being observed in the absence of any 
other HCMV immune evasion function, the absence of a virus induced stress 
response and also in an environment where gpUL142 over expression can be 
expected to down regulate MICA (see figure 5.5).  HF-CARs express the full-length 
MIC-A*016 MICA*027 alleles (see table 2.3) so the downregulation of NK cell 
activation associated with the UL142-2A construct (see figure 5.8) could in this case 
be due to MICA sequestration within the cell. However, the secreted version of 
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gpUL142 over produced by RAd-soluble UL142 was not capable of suppressing cell 
surface MICA expression (see figure 5.5). Thus, it is likely that in this model that 
cell associated gpUL142 may be acting primarily via its effect on MICA but not the 
secreted form. Nevertheless, the secreted gpUL142 could theoretically possibly bind 
to MICA on the surface of target cells and thereby block its interaction with NKG2D 
(Chalupny et al. 2006; Ashiru et al. 2009). 
 
D007, in contrast, are homozygous for the truncated MICA*008 allele (see table 2.3), 
so the strong NK cell functional effects of UL142 observed in the autologous setting 
are likely to be independent of any potential interaction between gpUL142 and 
MICA. An alternative explanation that is independent of MICA is therefore needed. 
A substantial proportion of NK cell receptors can be considered to be paired, where 
both an activating and an inhibitory receptor are capable of recognising the same 
ligand. As described in the introduction, HLA-E can be recognised by both the NK 
cell inhibitory receptor CD94:NKG2A and the NK cell activating receptor 
CD94:NKG2C. Over time in HCMV infected individuals a change in the NK cell 
repertoire is commonly observed due to an expansion in CD94:NKG2C+ NK cells 
and a compensatory decrease in CD94:NKG2A+ cells (Braud et al. 1997; Wilkinson 
et al. 2008). This effect extends to additional NK cell markers. Thus, there are 
expansion in HCMV carriers of unusual NK cell subsets, possibly to counter or 
circumvent HCMV immune evasion functions. Endogenous HLA-I molecules are 
the chief ligands for NK cell inhibitory receptors yet are downregulated by HCMV 
during productive infection. Many of the NK cell expansions seen in HCMV 
infection express multiple activating receptors balanced by expression of an 
inhibitory KIRs specific for self HLA molecules (see section1.9). Downregulating 
endogenous HLA-I thus potentially comes at a cost. Donor D007 is known to be 
HCMV seropositive and to possess strong cellular immune response to HCMV.  It 
would be interesting to evaluate the NK cell repertoire of D007 for evidence of 
specific NK cell expansions. HCMV UL18 is an HLA-I homologue that is known to 
bind LIR1. Since HCMV UL142 is also an HLA-I homologue expressed on the cell 
surface (see section1.10), it is a strong candidate to bind an NK cell inhibitory 
receptor, possibly one or more KIR. 
Whilst the NK cell functional data presented is too preliminary to define a 
mechanism, it may be useful as a basis for constructing a model to test 
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experimentally. Potentially gpUL142 expressed on the surface of infect cells may 
bind an NK inhibitory receptor at the immunological synapse (IS) to promote a 
negative signal and thereby suppress NK cell recognition. I show in this thesis that a 
significant proportion of gpUL142 appears to be cleaved and released from the cell 
surface. In the case of soluble gpUL142, the protein is only expressed in a secreted 
form. Overexpression of secreted form of gpUL142 could result in it binding an 
inhibitory receptor on NK cells outside the IS without inducing an inhibitory signal, 
i.e gpUL142 blocks its function as an inhibitory receptor and renders NK cells more 
susceptible to activation. In the context of a productive infection the secreted form of 
gpUL142 may serve to impair the capacity of NK cell to discriminate normal cells 
(including self), and this could be manifest by the enhanced killing of uninfected 
target cells, as observed in figure 5.8. The situation becomes more complex if 
gpUL142 is also recognised by a paired NK activating receptor (see section1.8). 
It would clearly aid our understanding of HCMV pathogenesis to characterise the 
mechanism of action of UL142. If gpUL142 is specifically binding to an NK cell 
inhibitory receptor it should be possible to interrogate the mechanism in NK cell 
functional assays using characterised donors (e.g. D007). The KIR genotype of D007 
is currently being determined to facilitate this process. It should be possible to 
determine whether specific NK cell inhibitory receptors correlate with reduced NK 
cell activation, an approach first applied to dissect the mechanism of action of UL18 
(Prod’homme et al, 2007).  Alternatively, the soluble form of gpUL142 was 
constructed with a BirA tag to enable the production of gpUL142 tetramers. I have 
shown that the codon optimised (soluble) form of gpUL142 is secreted in abundance 
and impacts NK cell function when expressed from the Ad recombinant. It should 
therefore now be possible to produce gpUL142 tetramers that can be used to sort NK 
cells expressing the receptor that recognises gpUL142. Immunophenotyping and/or 
proteomic analysis of this cell population may help define the mechanism of action 
of UL142. 
 
6.9 The limitations and future plans of this thesis 
 
As highlighted above, this study outlines several important new observations around 
the immune-evasion functions of HCMV/MOCV which are: For first time, it was 
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observed that MC080 is effective in supressing NK cell activation in certain 
individuals, also, MC080 down regulates surface expression of MHC-I and HLA-E 
in a TAP independent way. Furthermore, MC080 has the ability to protect against 
degranulation by CD8+ T cells. In agreement with previous studies gpUL142 could 
readily be detected on the cell surface when Adenovirus expressing UL142 was used. 
However, for first time, I found the mature Endo-H resistant form is released into the 
tissue culture supernatant, possibly as a result of proteolytic cleavage.  These results 
indicate that gpUL142 has the potential to act either at the cell surface or remotely.  
By contrast with previous studies, Merlin UL142 had no effect on MICA expression 
when expressed by HCMV.  However, it is important to recognise and reflect upon 
some limitations of my thesis which might be addressed in future studies which are 
outlined below: 
1 The MOI 1 that was used to infect HeLa cells with RAd961 and vaccinia virus v293 
expressing MC080 was lower than would have been ideal (section 3.2). This was 
because the observations using a light microscope indicated that significant levels of 
cellular toxicity were associated with high MOI infection. We attempted to 
overcome this by designing coding optimized mc080 in subsequent experiments.  
2 In chapter 3, we performed transfection of HeLa cells with pHAGE plasmids. 
However, these studies were lacking a suitable negative control. Future studies 
will therefore need to repeat these experiments with all appropriate controls. 
3 In this study I generated second-generation lentiviruses expressing codon optimised 
mc033 and mc080. Future studies would optimise the expression of mc033 and 
mc080 from these vectors. Expression from the lentiviral vectors would then be used 
to confirm the results obtained using the adenoviral expression system. 
4 Ideally, we would have performed additional biological replicates of the CD107a 
NK cell degranulation assays (section 4.3 and section 5.6). However, these were only 
performed to a limited n value since the assays require volunteer donors for blood 
which proved difficult to access.  Future studies would therefore focus on increasing 
n values in these important studies to increase confidence in the findings presented. 
5 Future studies may also seek to use NPi cells expressing human Coxsackie 
adenovirus receptor (hCAR) (section 4.5). Npi cells were used to determine whether 
MC080 is able to hinder peptide loading by interfering with TAP, and therefore 
reducing MHC-I and HLA-E surface expression (in section 4.5). In these 
experiments an MOI of 350 was used to infect NPi cells with either two or three 
adenoviruses (meaning for x3 adenoviral vectors, and overall MOI of 1050 was 
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used). This was necessary since the cells do not express the native Ad receptor, CAR, 
and therefore, to efficiently infect these cells, a very high MOI was required. In a 
study was performed by Tomasec et al, the NPi cell line was infected with a Rad 
expressing HLA-A2 using an MOI 50. In this study approximately85% of cells were 
positive for -HLA-A2 after infection with this virus. In my thesis an MOI 350 was 
used, this is seven times higher than that used in the study by Tomasec et al. 
Although not confirmed, in my assays this would suggest that approximately 100% 
of NPi cells were infected in the experiments using these cells in this thesis (section 
4.5) (Tomasec et al. 2000). Also, Dr Rebecca Aicheler (nee Morris) found in her 
PhD thesis that increasing the MOI over 300 does not significantly increase the 
percentage of GFP positive cells when she infected a human skin fibroblast cell line, 
which does not express hCAR, with RAd-GFP (Morris 2005). Future studies may 
require an engineered NPi cell line that expresses the hCAR to facilitate adenovirus 
infection, and reduce the amount of virus required to efficiently transduce these cells, 
and limit potential toxicities associated with these techniques. 
6 Future studies may also focus on the development of an N terminal V5 tagged mc080 
to examine if MC080 is expressed on the surface of infected cells, as well as the C 
terminal V5 tag mc080 described here. I would have examined the possible 
expression of MC080 on the surface of infected cells using N terminal V5 tagged 
mc080. 
7 Future studies may also seek to construct a HCMV Merlin viral genome deleted in 
UL142, US18 and US20. This triple deleted virus would allow a comparison with 
HCMV Merlin deleted UL142 virus and HCMV Merlin deleted US18 and US20 
virus in MICA expression assay (section 5.5). you need to say why you want to do 
this. 
8 Finally, the codon optimised (soluble) form of gpUL142 is secreted in abundance 
from the cells and it impacts NK cell function when expressed from the Ad 
recombinant (section 5.6). Future studies may utilise gpUL142 tetramers to identify 
and isolate NK cells expressing the receptor that recognises gpUL142. 
Immunophenotyping and proteomic analysis of this cell population may help define 
the mechanism of action of UL142. 
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The Optimized mc080R 
 
Not-kozak-atg- optimized gene- mycTAG- stop- bamHI 
 
GCGGCCGCGCCACC ATG ACC GGT ACC CTC ATT CTG CTC CTG GCA 
TGC GTA CTG AAC GCC ATG GCG CAG TTG CTT GCC CGG GTT TGC 
ATG GCT GCC GCT ACA CTC GCA CGC ATG CTC GCC CTT AGC GTG 
GCG TTT CTG CTG GCT CTT GCC AGG ACA CGG ACC GGA CTG AGG 
GCC ATC CTG GTT GCC CTG CTG CTG CGA GCC TTG CTT AGA GCA 
CTG CTG GCC CAC GCA CAT GCG CAC ACA CTG TCC TAC GTA GCT 
GCT GTC GTG TAC ACA CCC GGG AAT GCA CAG CCC TTG CTT CTG 
GCG GAA GGC TCA ATC AAC GAC CTG GTG TTC ATG CGG TAT CAC 
AGA CAA AGC GGC TCA GTG CTG CCA AGT CCC GAA TGG GCT CCA 
AGC GTG TAC TTC CAC GAC GAG CTC TGG ATG CTG AAT GCC CGC 
GTT GAT GCC CTT CGG TCC CTG AGT GTG CCT GGT GCA CGA CTG 
GGG AAT GGC ACC TTG GGT GCT AGA TCT CTC CAA CTC GCA GTG 
GGC TGC GAA AAG GTG GCA GGG GAT GCC AGC TTT TGG GAT CTG 
GTG TAT GAT GGG ACT GAG CAG ATC TGT ATG CAC GCT GAT GCC 
ACC GAG TGT GAG CCT GGA CTC CCC GTT CAT GCC AGG CTG GCC 
AAA GAG CGG TGG ACA AGA CTC GGA GCT CAC AGT CAT GCG CTC 
GAG CAG CGT TGT CTG CAG TGG TTG GAA AGG CAT CTG GGA GCA 
AGG ACC AAC CGA CCG GTG GTG TCT GTT CCG CTG TTG AGC GTC 
GTC GCC TAT GCC GAC GGC TCT GGC ACT CGC CTG CGT TGT ACT 
GCT TCA GGC TTC TCT CCC CGA GAT GTG CGG CTG CTG TGG ACT 
CGC GAT GGA ATT CCA GGA CCA GAC TAC GAC TTC GTG GAA CCT 
CGC CCA TCT GGG GAC GGC AGC TTT CAG CAG TGG GCA GAG CTG 
GTC GTA GCC GCT GGC TTG GAG ACA CAC TAT GTC TGC GTA GCC 
TCC CAT GAC TCC TGG AAG TCA TCC TGG CGG GCT AGA TGG GAA 
GAG GGG AAA CGC AGG GTC GCT ACC AGT GCG AGA GTG GCA CCC 
TTG GCA ACG ATA GCC GAG ATG CTT GTC GCC CTG GAA CTC ATG 
CTG ATT CTG AGG GAA CGT CGC CTT ACT CTG GGT GCC CTG GCA 
ACG ATG CTG GCT TGC AGC ATG CCT AAC CTC CTG CCT CAA GCC 
CTC AGA GAG AGA GCT GGA 
TTTGAACAAAAACTCATCTCAGAAGAGGATCTG TGAGGATCC 
 
MC080 amino acid sequence 
 
GRATMTGTLILLLACVLNAMAQLLARVCMAAATLARMLALSVAFLLALARTRTGLR
AILVALLLRALLRALLAHAHAHTLSYVAAVVYTPGNAQPLLLAEGSINDLVFMRYH
RQSGSVLPSPEWAPSVYFHDELWMLNARVDALRSLSVPGARLGNGTLGARSLQLAV
GCEKVAGDASFWDLVYDGTEQICMHADATECEPGLPVHARLAKERWTRLGAHSHAL
EQRCLQWLERHLGARTNRPVVSVPLLSVVAYADGSGTRLRCTASGFSPRDVRLLWT
RDGIPGPDYDFVEPRPSGDGSFQQWAELVVAAGLETHYVCVASHDSWKSSWRARWE
EGKRRVATSARVAPLATIAEMLVALELMLILRERRLTLGALATMLACSMPNLLPQA
LRERAGFEQKLISEEDL*GSX 
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The Optimized mc033L 
 
Not-kozak-atg- optimized MC033gene- ha TAG- stop- bamHI 
 
 
GCGGCCGCGCCACCATG AGG CCC CAC GTG CTG ATC ACC CTG GCC 
ACT TGT GCC TTG CGG GCT CTT GCC CAG GTG ATA GAC GAA CAC 
GAG CAC TCT GAA CCA CCA GTT TCA ACA TGG CCC GAC ATG TCC 
TAC CTG GTC GCA GAG ATG CGG TCT GAT AGC GTA CTG ATG CGG 
GGC ATG CTG GAT GGC CAT GAG CAC GTG CGC TGT ACT TGC GTG 
CCA AAG TGC GCC TGC TTG GAG CCC ACC CTT CCA CGA GCC GCT 
CTG GAA CAA GCC CGC TCA CGG GTA CTG GAT GCC CAT GCT GGT 
CGT GTG CCC GGA CTG AGA GCC CCT AGC AGG GCA GCA CAT CGC 
AGA GTC GTG CTC ACT GCC GGG TGT CGC TTC ACT CAG GGC TTT 
CCG GAG CCC TTT GAG GGC CTC TGG GTC GCC AGC GCT GAA CCA 
GGT GCT CAC GAC GAG TTC TTT TGT GTC GGT GAG CAC TGT GAC 
GCA CAC CTG TCC TCC ATC TTT TGC CAC GCA GCA TCC ACC ATG 
CCC CTG GCC AGA GCC CCT CAT AGC CCT CCC ATG GTG ACG TTC 
AGT GCC CTG TCA GCC GGC GAA AAC TAC CTC AGG CTG GTT TGC 
CGG GCG TCT GGA GCC TAT CCT CCT GTT GAC ACT CTG ACC CTC 
GTG AGC CAG CCT CAA CAG CCA GAA GAT GCC CCT TGC GAG ACA 
TAC GCC GGA ACA AAC GCT GAC AGC ACC GGC CAC GTC GGA ATG 
GCT TGC GTC CGT TCT GAC GCG CTC GCT GGG GCA GCG TGT GCA 
GTC CAG CAT AGA GGC GTG ACA ACC AGC GCC CGG ATT GTG CTT 
GTG CCG GCA AAT GAT GGG GCC AAA GTC GGA GCC TAT GCT GAT 
GTC GAT GCC GAT TTC TAT GCC GAC GTT CCG CCT CTC CCC GAA 
CCC GAG TCC GAC AGC TTG GCT GTA CAC GCA CTG TTC GTA GCC 
GGG AAC ACT GAG CTG TAT GTT CAC GGG ACA GCG GCT GGC GTA 
CCA TCT GCC TCC TGT AGG TGT GAC ACC AGG AGA TGC ACA TGC 
GTG CTG GCT CCC GCC ACA TGG ACT GCC GGA GTG GTG CGA GAA 
CTG GCG AGA GCG GCT GCT CAT GAC CTT CTG CTT GCT GTG CTG 
GAC GTT CAT GCC TCA GGC CTC GCT CTC AAC CGA TCA TCC ATG 
CAA GTG TAT GCC GAA TGT GGG CCT GCA GGG AGG AGA CTT CGG 
GTT CAC AAT ACC GGT ACC CGG CGA CAG CGC GTG TGC GCA CGC 
GGA GCT TGC GAG CCG GCT TAT CTG GTG GCA TGT GAG CTG TTG 
CGG ACG GAC ACC CCA GCA CCT CGG CGA CCT CGC ATG AGT GTT 
CAG CAC AGA CGG GAT AGT AGC GGG CAT TAC TAC GTG TGC TCT 
GCC TAC GGC TTT TAC CCC AAG GAG ATT GTG CTG GAG ATG AGA 
GCA AAT CGC AGC TGT GAT GAG CGC GCA CGC CTG TCT GGT TTC 
TGG TGC AGA CAC GAT CCA CCC GCA CCT AAT GCC GAT GGC ACC 
TTC TTT GCG AGG GTG TTC TGC AAA GCG CCA GAA AAC GCC CTT 
CTG ATG ACC TGT GTT ACA CGT CAT GCC AGT CGC CCA CGG GCC 
CTG GCC GTA CCA TGT CCC CGA CGA GCT CGT ACT CCT AGG GAA 
AGA TGG GCC GCA CTG CTC ACG GTG TTG GCA CGC GTC CCC TGG 
AGT GCT GTG CTG TTG GCG CTG GCC ATG GGA GCA GCA CCG TTG 
GCT TGC GCT AGG CTC GTC CAT GCT AGG TCC ACA AGG ACG GCC 
CGG AGA GCT AGG CGT GCT AGG AGA GCG TAC CCA TAC GAT GTT 
CCA GAT TAC GCT TGA GGATCC 
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MC033 amino acid sequence 
 
GRATMRPHVLITLATCALRALAQVIDEHEHSEPPVSTWPDMSYLVAEMRSDSVLMR
GMLDGHEHVRCTCVPKCACLEPTLPRAALEQARSRVLDAHAGRVPGLRAPSRAAHR
RVVLTAGCRFTQGFPEPFEGLWVASAEPGAHDEFFCVGEHCDAHLSSIFCHAASTM
PLARAPHSPPMVTFSALSAGENYLRLVCRASGAYPPVDTLTLVSQPQQPEDAPCET
YAGTNADSTGHVGMACVRSDALAGAACAVQHRGVTTSARIVLVPANDGAKVGAYAD
VDADFYADVPPLPEPESDSLAVHALFVAGNTELYVHGTAAGVPSASCRCDTRRCTC
VLAPATWTAGVVRELARAAAHDLLLAVLDVHASGLALNRSSMQVYAECGPAGRRLR
VHNTGTRRQRVCARGACEPAYLVACELLRTDTPAPRRPRMSVQHRRDSSGHYYVCS
AYGFYPKEIVLEMRANRSCDERARLSGFWCRHDPPAPNADGTFFARVFCKAPENAL
LMTCVTRHASRPRALAVPCPRRARTPRERWAALLTVLARVPWSAVLLALAMGAAPL
ACARLVHARSTRTARRARRARRAYPYDVPDYA*GSX 
 
 
 
 
Prediction of transmembrane part and signal peptide  
 
MC080 and MC033 were analyzed using TMHH software to predict 
transmembrane regions and signal peptides 
     A                                               B                            
 
 
 
 
 
 
 
 
 
 
 
 
 
Transmembrane plot (TMHH software) was used to predict transmembrane region and 
signal peptide, (A) MC033; (B) MC080  http://www.cbs.dtu.dk/services/TMHMM  
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MC033 MHC-I homology using BlastT and Phyre 
MC033 [Molluscum contagiosum virus subtype 1]  
 
 
  
Blast Alignment of MC033: MC033 has 26 % homology to   MHC  I and it is 
restricted  to a very short region of the protein with Ig-like fold 
https://blast.ncbi.nlm.nih.gov/Blast.cgi 
RID
Database Name
Description
Program
Query ID
Description
Molecule type
Query Length
AYO88878.1
MC033 [Molluscum contagiosum virus subtype 1]
amino acid
579
BLAST ® » blastp suite » RID-YB6EYUKW015
BLAST Results
Questions/comments   
Job title: gb|AYO88878.1| (579 letters)
YB6EYUKW015 (Expires on 11-10 21:29 pm)
nr
All non-redundant GenBank CDS
translations+PDB+SwissProt+PIR+PRF excluding
environmental samples from WGS projects
BLASTP 2.8.1+
New Analyze your query with SmartBLAST
Putative conserved domains have been detected, click on the image below for detailed results.
Distribution of the top 100 Blast Hits on 100 subject sequences
<40 40-50 50-80 80-200 >=200
1 100 200 300 400 500
Color key for alignment scores
Query
Graphic Summary
Sequences producing significant alignments:
Descriptions
Description Max
score
Total
score
Query
cover
E
value
Ident Accession
MC033 [Molluscum contagiosum virus subtype 1] 1161 1161 100% 0.0 100% AYO87489.1
MC033 [Molluscum contagiosum virus subtype 1] 1159 1159 100% 0.0 99% AQY17137.1
MC033L [Molluscum contagiosum virus subtype 1] 1159 1159 100% 0.0 99% NP_043984.1
MC033 [Molluscum contagiosum virus subtype 1] 1154 1154 100% 0.0 99% AQY16957.1
MC033 [Molluscum contagiosum virus subtype 2] 1041 1041 98% 0.0 94% AQY16606.1
unknown [Molluscum contagiosum virus subtype 1] 271 271 23% 1e-85 100% AAB57948.1
major histocompatibility complex class I-related gene protein-
like isoform X1 [Phascolarctos cinereus] 52.4 52.4 29% 0.002 26% XP_020856818.1
major histocompatibility complex class I-related gene protein-
like isoform X2 [Phascolarctos cinereus]
52.0 52.0 27% 0.002 27% XP_020856819.1
patr class I histocompatibility antigen, A-2 alpha chain-like
[Python bivittatus]
50.8 50.8 17% 0.006 34% XP_025029032.1
PREDICTED: zinc-alpha-2-glycoprotein-like [Monodelphis
domestica] 49.7 49.7 26% 0.012 26% XP_007477530.2
zinc-alpha-2-glycoprotein-like [Monodelphis domestica] 49.7 49.7 26% 0.015 26% NP_001311360.1
LOW QUALITY PROTEIN: uncharacterized protein
LOC105749203 [Sarcophilus harrisii]
49.7 49.7 18% 0.018 33% XP_023351330.1
RLA class I histocompatibility antigen, alpha chain 11/11-like
isoform X2 [Phascolarctos cinereus] 48.5 48.5 24% 0.031 28% XP_020856787.1
zinc-alpha-2-glycoprotein-like isoform X1 [Phascolarctos
cinereus] 48.5 48.5 24% 0.031 28% XP_020856786.1
PREDICTED: zinc-alpha-2-glycoprotein-like isoform X2
[Monodelphis domestica]
48.9 48.9 24% 0.036 25% XP_007477543.1
alpha-2-glycoprotein 1 zinc-binding protein [Phascolarctos
cinereus] 48.1 48.1 24% 0.036 29% ALX81643.1
PREDICTED: uncharacterized protein LOC103096009
isoform X1 [Monodelphis domestica] 48.5 48.5 24% 0.041 25% XP_007477542.1
MHC class I antigen [Monodelphis domestica] 48.1 48.1 24% 0.044 25% AJT46737.1
major histocompatibility complex class I-related gene protein-
like [Notechis scutatus] 46.6 46.6 15% 0.054 27% XP_026546790.1
zinc-alpha-2-glycoprotein-like [Phascolarctos cinereus] 47.8 47.8 19% 0.060 29% XP_020856856.1
hypothetical protein XENTR_v90022327mg [Xenopus
tropicalis]
47.0 47.0 27% 0.078 24% OCA27275.1
PREDICTED: rano class II histocompatibility antigen, A beta
chain-like isoform X2 [Xenopus tropicalis] 47.0 47.0 27% 0.088 24% XP_002940106.1
class I histocompatibility antigen, F10 alpha chain-like
[Sarcophilus harrisii] 46.2 46.2 26% 0.12 26% XP_012396268.1
major histocompatibility complex class I-related gene protein-
like isoform X2 [Phascolarctos cinereus]
46.6 46.6 23% 0.12 27% XP_020856864.1
major histocompatibility complex class I-related gene protein-
like isoform X1 [Phascolarctos cinereus]
46.6 46.6 23% 0.13 27% XP_020856863.1
zinc-alpha-2-glycoprotein-like isoform X1 [Phascolarctos
cinereus] 46.2 46.2 20% 0.15 30% XP_020856861.1
zinc-alpha-2-glycoprotein-like [Sarcophilus harrisii] 46.2 46.2 20% 0.16 31% XP_012396303.1
LOW QUALITY PROTEIN: H-2 class I histocompatibility
antigen, Q10 alpha chain-like [Pogona vitticeps]
46.2 46.2 19% 0.19 32% XP_020633546.1
alpha-2-glycoprotein 1 zinc-binding protein [Phascolarctos
cinereus] 46.2 46.2 23% 0.20 26% ALX81650.1
PREDICTED: major histocompatibility complex class I-related
gene protein-like [Gekko japonicus] 45.8 45.8 26% 0.20 31% XP_015267879.1
major histocompatibility complex class I-related gene protein-
like [Sarcophilus harrisii]
45.8 45.8 20% 0.22 28% XP_023351295.1
class I histocompatibility antigen, F10 alpha chain-like
[Pogona vitticeps] 45.8 45.8 23% 0.23 29% XP_020634628.1
B7 like protein 6 [Myotis brandtii] 45.4 45.4 13% 0.24 28% EPQ18357.1
natural cytotoxicity triggering receptor 3 ligand 1-like [Myotis
lucifugus]
45.8 45.8 20% 0.26 28% XP_014315567.1
PREDICTED: natural cytotoxicity triggering receptor 3 ligand 1
[Myotis brandtii] 45.4 45.4 13% 0.28 28% XP_005883376.1
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The Phyre2 study of MC033: The Phyre does not model it on to MHC-I. No 
evidence that it is MHC-1 functional mimic. Indeed, highly questionable that it is 
an MHC-I homologue 
http://www.sbg.bio.ic.ac.uk/~phyre2/html/page.cgi?id=index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Email wilkinsongw1@cf.ac.uk
Description MC033____
Date Fri Nov 9 14:13:51GMT 2018
Unique Job
ID 08d12977476c9231
Detailed template
information  
# Template Alignment Coverage 3D Model Confidence % i.d. Template Information
1 c3dbxA_ Alignment 98.7 27
PDB header:immune system
Chain: A: PDB Molecule:cd1-2 antigen;
PDBTitle: structure of chicken cd1-2 with bound fatty acid
2 c3p73A_ Alignment 98.7 28
PDB header:immune system
Chain: A: PDB Molecule:mhc rfp-y class i alpha chain;
PDBTitle: crystal structures of the chicken yf1*7.1 molecule
3 c1de4A_ Alignment 98.7 24
PDB header:metal transport inhibitor/receptor
Chain: A: PDB Molecule:hemochromatosis protein;
PDBTitle: hemochromatosis protein hfe complexed with transferrin
receptor
4 c1exuA_ Alignment 98.6 30
PDB header:immune system
Chain: A: PDB Molecule:igg receptor fcrn large subunit p51;
PDBTitle: crystal structure of the human mhc-related fc receptor
5 c2fwoA_ Alignment 98.6 24
PDB header:immune system/viral protein
Chain: A: PDB Molecule:h-2 class i histocompatibility antigen, k-d
alpha chain;
PDBTitle: mhc class i h-2kd heavy chain in complex with beta-
2microglobulin and2 peptide derived from influenza nucleoprotein
6 c2yf6A_ Alignment 98.6 28
PDB header:immune system
Chain: A: PDB Molecule:major histocompatibility complex class i
glycoprotein
PDBTitle: complex of a b21 chicken mhc class i molecule and a
10mer2 chicken peptide
7 c1nezA_ Alignment 98.5 25
PDB header:immune system
Chain: A: PDB Molecule:h-2 class i histocompatibility antigen, tla(c)
alpha chain;
PDBTitle: the crystal structure of a tl/cd8aa complex at 2.1a2
resolution:implications for memory t cell generation, co-receptor3
preference and affinity
8 c4gupA_ Alignment 98.5 26
PDB header:immune system
Chain: A: PDB Molecule:major histocompatibility complex class i-
related gene
PDBTitle: structure of mhc-class i related molecule mr1
9 c1kjmA_ Alignment 98.5 24
PDB header:immune system
Chain: A: PDB Molecule:rt1 class i histocompatibility antigen, aa
alpha chain,
PDBTitle: tap-a-associated rat mhc class i molecule
10 c3bewD_ Alignment 98.5 28
PDB header:immune system
Chain: D: PDB Molecule:major histocompatibility complex class i
PDBTitle: 10mer crystal structure of chicken mhc class i haplotype
b21
11 c1qo3A_ Alignment 98.5 25
PDB header:receptor/immune system
Chain: A: PDB Molecule:mhc class i h-2dd heavy chain;
PDBTitle: complex between nk cell receptor ly49a and its mhc class
i2 ligand h-2dd
Phyre Home Retrieve Phyre Job Id Fetch
Email wilkinsongw1@cf.ac.uk
Description MC033____
Date Fri Nov 9 14:13:51 GMT2018
Unique Job
ID 08d12977476c9231
Sequence MRPHVLITLA ... DownloadFASTA
Job Type normal
Job Expiry 30 days
Summary  
Top model
Image coloured by rainbow N → C terminus
Model dimensions (Å): X:30.599 Y:31.048 Z:46.368
Model (left) based on t pla e
c3dbxA_
Top template information
PDB header:immune system
Chain: A: PDB Molecule:cd1-2
antigen;
PDBTitle: structure of chicken cd1-2
with bound fatty acid
Confidence and coverage
Confidence: 98.7% Coverag : 14%
82 residues ( 14% of your sequence)
have been modelled with 98.7%
confidence by the single highest
scoring template.
You may wish to submit your
sequence to Phyrealarm. This will
automatically scan your sequence
every week for new potential
templates as they appear in the
Phyre2 library.
3D viewing
Interactive 3D view in JSmol
For other options to view your
downloaded structure offline see the
FAQ
Sequence analysis  
View PSI-Blast Pseudo-Multiple Sequence Alignment
Download
FASTA
version
Secondary structure and disorder prediction [Show]  
Domain analysis [Show]  
Detailed template information [Hide]  
 
# Template Alignment Coverage 3D Model Confidence % i.d. Template Information
Phyre Home Retrieve Phyre Job Id Fetch
Email wilkinsongw1@cf.ac.uk
Description MC033____
Date
Fri Nov 9 14:13:51 GMT
2018
Unique Job
ID 08d12977476c9231
Sequence
MRPHVLITLA ... Download
FASTA
Job Type normal
Job Expiry 30 days
Summary  
Top model
Image coloured by rainbow N → C terminus
Model dimensions (Å): X:30.599 Y:31.048 Z:46.368
Model (left) based on template
c3dbxA_
Top template information
PDB header:immune system
Chain: A: PDB Molecule:cd1-2
antigen;
PDBTitle: structure of chicken cd1-2
with bound fatty acid
Confidence and coverage
Confidence: 98.7% Coverage: 14%
82 residues ( 14% of your sequence)
have been modelled with 98.7%
confidence by the single highest
scoring template.
You may wish to submit your
sequence to Phyrealarm. This will
automatically scan your sequence
every week for new potential
templates as they appear in the
Phyre2 library.
3D viewing
Interactive 3D view in JSmol
For other options to view your
downloaded structure offline see the
FAQ
Sequence analysis  
View PSI-Blast Pseudo-Multiple Sequence Alignment
Download
FASTA
version
Secondary structure and disorder prediction [Show]  
Domain analysis [Show]  
Detailed template information [Hide]  
 
# Template Alignment Coverage 3D Model Confidence % i.d. Template Information
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MC080 MHC-I homology using BlastT and Phyre 
 
 
 
 
alignment of MC080 using BlastT: The BlastT reveals that MC080 is MHC-I like 
molecule  
https://blast.ncbi.nlm.nih.gov/Blast.cgi 
 
RID
Database Name
Description
Program
Query ID
Description
Molecule type
Query Length
AYO88929.1
MC080 [Molluscum contagiosum virus subtype 1]
amino acid
395
BLAST ® » blastp suite » RID-YB69MT5H014
BLAST Results
Questions/comments   
Job title: gb|AYO88929.1| (395 letters)
YB69MT5H014 (Expires on 11-10 21:27 pm)
nr
All non-redundant GenBank CDS
translations+PDB+SwissProt+PIR+PRF excluding
environmental samples from WGS projects
BLASTP 2.8.1+
New Analyze your query with SmartBLAST
Putative conserved domains have been detected, click on the image below for detailed results.
Distribution of the top 100 Blast Hits on 100 subject sequences
<40 40-50 50-80 80-200 >=200
1 70 140 210 280 350
Color key for alignment scores
Query
Graphic Summary
Sequences producing significant alignments:
Descriptions
Description Max
score
Total
score
Query
cover
E
value
Ident Accession
MC080R [Molluscum contagiosum virus subtype 1] 789 789 100% 0.0 100% NP_044031.1
MC080R [Molluscum contagiosum virus subtype 2] 660 660 100% 0.0 90% AAC72821.1
hypothetical protein DDJ49_30250 [Klebsiella pneumoniae] 294 294 40% 2e-96 92% RFC01606.1
SLA-11 histocompatibility antigen, class I [Sus scrofa] 124 124 77% 2e-28 29% BAG82704.1
MHC class I antigen [Ovis aries] 122 122 66% 8e-28 30% CAJ57269.1
histocompatibility antigen, class I [Sus scrofa] 122 122 77% 9e-28 29% BBE49437.1
non-MHC class I antigen [Bos taurus] 122 122 66% 1e-27 34% ANG83508.1
non-classical MHC class I antigen [Bos taurus] 122 122 66% 1e-27 34% AAZ74695.1
HLA class I histocompatibility antigen, B-40 alpha chain-like
isoform X1 [Trichechus manatus latirostris]
122 122 72% 1e-27 30% XP_023581056.1
HLA class I histocompatibility antigen, B-40 alpha chain-like
isoform X2 [Trichechus manatus latirostris] 122 122 72% 1e-27 30% XP_023581057.1
BOLA class I histocompatibility antigen, alpha chain BL3-7-like
isoform X1 [Bos taurus] 122 122 66% 1e-27 33% XP_005223758.1
BOLA class I histocompatibility antigen, alpha chain BL3-7-like
isoform X3 [Bos taurus]
121 121 68% 2e-27 33% XP_024839906.1
non-MHC class I antigen [Bos taurus] 121 121 66% 2e-27 33% ANG83507.1
PREDICTED: BOLA class I histocompatibility antigen, alpha
chain BL3-7 [Camelus ferus] 120 120 66% 3e-27 30% XP_014420585.1
PREDICTED: BOLA class I histocompatibility antigen, alpha
chain BL3-7-like isoform X3 [Ovis aries musimon] 120 120 68% 3e-27 31% XP_012019773.1
PREDICTED: BOLA class I histocompatibility antigen, alpha
chain BL3-7-like isoform X3 [Ovis aries]
120 120 68% 3e-27 31% XP_004019325.2
BOLA class I histocompatibility antigen, alpha chain BL3-7-like
isoform X7 [Odocoileus virginianus texanus] 120 120 70% 3e-27 29% XP_020744455.1
PREDICTED: HLA class I histocompatibility antigen, B-7 alpha
chain-like [Chrysochloris asiatica] 120 120 72% 4e-27 28% XP_006875747.1
PREDICTED: BOLA class I histocompatibility antigen, alpha
chain BL3-7-like isoform X1 [Ovis aries musimon]
120 120 66% 5e-27 31% XP_012019769.2
PREDICTED: BOLA class I histocompatibility antigen, alpha
chain BL3-7-like isoform X1 [Ovis aries] 120 120 66% 5e-27 31% XP_011956355.1
major histocompatibility complex, class I precursor [Camelus
ferus] 121 121 66% 6e-27 30% EPY75792.1
PREDICTED: BOLA class I histocompatibility antigen, alpha
chain BL3-7-like isoform X3 [Bos indicus]
120 120 66% 6e-27 33% XP_019841387.1
MHC class I antigen [Bos taurus] 120 120 66% 6e-27 31% AFA35808.1
PREDICTED: HLA class I histocompatibility antigen, alpha
chain G-like [Ochotona princeps] 121 121 80% 7e-27 29% XP_012786138.1
PREDICTED: BOLA class I histocompatibility antigen, alpha
chain BL3-7-like isoform X2 [Ovis aries musimon]
120 120 66% 7e-27 31% XP_012019772.2
PREDICTED: BOLA class I histocompatibility antigen, alpha
chain BL3-7-like isoform X2 [Ovis aries] 120 120 66% 7e-27 31% XP_011956358.1
PREDICTED: BOLA class I histocompatibility antigen, alpha
chain BL3-7-like [Camelus dromedarius] 119 119 66% 7e-27 31% XP_010976497.1
PREDICTED: HLA class I histocompatibility antigen, B-37
alpha chain-like isoform X3 [Ochotona princeps]
119 119 76% 1e-26 28% XP_012786261.1
putative non classical MHC class I antigen [Sus scrofa] 119 119 66% 1e-26 30% CAB63859.1
MHC class I antigen [Sus scrofa] 119 119 66% 1e-26 30% ADD71909.1
MHC class I antigen 8 precursor [Sus scrofa] 119 119 66% 1e-26 30% NP_001107175.1
BOLA class I histocompatibility antigen, alpha chain BL3-6
[Bubalus bubalis]
119 119 73% 1e-26 30% XP_006052358.1
PREDICTED: BOLA class I histocompatibility antigen, alpha
chain BL3-7-like isoform X1 [Bos indicus] 119 119 66% 1e-26 33% XP_019841385.1
PREDICTED: BOLA class I histocompatibility antigen, alpha
chain BL3-7-like [Pantholops hodgsonii] 119 119 69% 1e-26 30% XP_005965545.1
PREDICTED: HLA class I histocompatibility antigen, B-37
alpha chain-like isoform X1 [Ochotona princeps]
119 119 76% 2e-26 28% XP_012786259.1
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The Phyre2 study of MC080: The Phyre provides that MC080 has homology to 
MHC-I  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phyre Home Retrieve Phyre Job Id Fetch
Email wilkinsongw1@cf.ac.uk
Description Mc080____
Date Sat Nov 10 00:20:38 GMT2018
Unique Job
ID 6d71f704c4e18f42
Sequence MTGTLILLLA ... DownloadFASTA
Job Type normal
Job Expiry 30 days
Summary  
Top model
Image coloured by rainbow N → C terminus
Model dimensions (Å): X:54.822 Y:65.785 Z:60.084
Model (left) based on template
c3p73A_
Top template information
PDB header:immune system
Chain: A: PDB Molecule:mhc rfp-y
class i alpha chain;
PDBTitle: crystal structures of the
chicken yf1*7.1 molecule
Confidence and coverage
Confidence: 100.0% Coverage: 66%
261 residues ( 66% of your sequence)
have been modelled with 100.0%
confidence by the single highest
scoring template.
You may wish to submit your sequence
to Phyrealarm. This will automatically
scan your sequence every week for
new potential templates as they
appear in the Phyre2 library.
3D viewing
Interactive 3D view in JSmol
For other options to view your
downloaded structure offline see the
FAQ
Sequence analysis  
View PSI-Blast Pseudo-Multiple Sequence Alignment
Download
FASTA
version
Secondary structure and disorder prediction [Show]  
Domain analysis [Show]  
Detailed template information [Hide]  
 
# Template Alignment Coverage 3D Model Confidence % i.d. Template Information
Phyre Home Retrieve Phyre Job Id Fetch
Email wilkinsongw1@cf.ac.uk
Description Mc080____
Date
Sat Nov 10 00:20:38 GMT
2018
Unique Job
ID 6d71f704c4e18f42
Sequence
MTGTLILLLA ... Download
FASTA
Job Type normal
Job Expiry 30 days
Summary  
Top model
Image coloured by rainbow N → C terminus
Model dimensions (Å): X:54.822 Y:65.785 Z:60.084
Model (left) based on template
c3p73A_
Top template information
PDB header:immune system
Chain: A: PDB Molecule:mhc rfp-y
class i alpha chain;
PDBTitle: crystal structures of the
chicken yf1*7.1 molecule
Confidence and coverage
Confidence: 100.0% Coverage: 66%
261 residues ( 66% of your sequence)
have been modelled with 100.0%
confidence by the single highest
scoring template.
You may wish to submit your sequence
to Phyrealarm. This will automatically
scan your sequence every week for
new potential templates as they
appear in the Phyre2 library.
3D viewing
Interactive 3D view in JSmol
For other options to view your
downloaded structure offline see the
FAQ
Sequence analysis  
View PSI-Blast Pseudo-Multiple Sequence Alignment
Download
FASTA
version
Secondary structure and disorder prediction [Show]  
Domain analysis [Show]  
Detailed template information [Hide]  
 
# Template Alignment Coverage 3D Model Confidence % i.d. Template Information
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Primers to produce RAdmc033 and RAdmc080   
 
were ordered from Eurofins MWG 
 
mc033-Forward primer: 
TGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGA
CACCGGGACCGATCCAGCCTGGATCCGCCACCATGAGGCCCCAC 
mc033-Reverse primer: 
TAGAGTATACAATAGTGACGTGGGATCCTTACGTAGAATCAAGACCTAGGAGCGGG
TTAGGGATTGGCTTACCAGCGCTCGCTCTCCTAGCACGCCTAGC 
 
mc080-Forward primer: 
ACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACAC
CGGGACCGATCCAGCCTGGATCCGCCACCATGACCGGTACCCTC 
mc080-Reverse primer: 
AGTATACAATAGTGACGTGGGATCCTTACGTAGAATCAAGACCTAGGAGCGGGTTA
GGGATTGGCTTACCAGCGCTAAATCCAGCTCTCTCTCTGAGGGC 
 
The green letters are V5, the red letters are the actual primer of gene, the blue 
letters are the link and the black letters are the region of homology. 
 
Primer used to Confirm the sequence of the insert of RAdmc033 and 
RAdmc08:  
Forward primer: 
5-CCA TGG TGA TGC GGT TTT G -3  
Reverse primer:  
5- AAC TAC ATA AGA CC CCA CC-3 
 
 
 
PCR using Phusion® High-Fidelity DNA Polymerase 
(M0530L, New England Biolabs) kit 
 
Sample PCR reaction mixture for 50 µl total volum 
 
5x Buffer: 10 µl 
DNA:  1 µl 
Primers (F+R): 2.5 µl of 100 µM each 
DMSO: 1.5 µl 
Enzyme: 0.5 µl 
dNTPs: 1 µl 
dH2O 33.5 µl 
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PCR program 
Initial denaturation   98°C for 45 seconds then 
Denaturation: 98°C for 12 seconds 
Annealing:     55°C for 40 seconds              36 cycles                                                                                                                
Extension:     72°C for 2 minutes 
Final extension            720C for 12 minutes 
Expand High fidelity (HIFI, 11732 641001, Roche)/Taq 
polymerase 
 
Sample PCR reaction mixture for 50 µl total volum 
 
10x Buffer: 5 µl 
DNA:  1 µl 
Primers (F+R): 2.5 µl of 100 µM each 
DMSO: 1.5 µl 
Enzyme: 0.5 µl 
dNTPs: 1 µl 
dH2O 38.5 µl 
 
PCR program 
Initial denaturation   94°C for 2minutes then 
Denaturation: 94°C for 15seconds 
Annealing:     55°C for 30 seconds                  9 cycles                                                                                                                
Extension:     72°C for 2 minutes 
Denaturation: 98°C for 15 seconds 
Annealing:     55°C for 30 seconds                   24 cycles                                                                                                                
Extension:     72°C for 2 minutes + 5 seconds (increase 5 seconds every cycle) 
 
Final extension            720C for 7 minutes 
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UL142 MHC-I homology using BlastT and Phyre 
 
The alignment of UL142 using BlastT : UL142 is MHC I homologue  
 
The Phyre2 study of UL142: structural prediction (Phyre 2) clearly show UL142 to 
be a Class I like protein with evidence of a peptide binding groove and similarity 
across the molecule. It probably does not bind ß2m 
  
 
Phyre Home Retrieve Phyre Job Id Fetch
Email wilkinsongw1@cf.ac.uk
Description UL142____
Date Fri Nov 9 15:04:30 GMT2018
Unique Job
ID b07652a172cd14b5
Sequence
MRIEWACWLF ...
Download FASTA
Job Type normal
Job Expiry 30 days
Summary  
Top model
Image coloured by rainbow N → C terminus
Model dimensions (Å): X:66.411 Y:56.353 Z:56.842
Model (left) based on template
c4gupA_
Top template information
PDB header:immune system
Chain: A: PDB Molecule:major
histocompatibility complex class i-
related gene
PDBTitle: structure of mhc-class i
related molecule mr1
Confidence and coverage
Confidence: 100.0% Coverage: 78%
238 residues ( 78% of your sequence)
have been modelled with 100.0%
confidence by the single highest
scoring template.
3D viewing
Interactive 3D view in JSmol
For other options to view your
downloaded structure offline see the
FAQ
Sequence analysis  
View PSI-Blast Pseudo-Multiple Sequence Alignment
Download
FASTA
version
Secondary structure and disorder prediction [Show]  
Domain analysis [Show]  
Detailed template information [Hide]  
 
# Template Alignment Coverage 3D Model Confidence % i.d. Template Information
Phyre Home Retrieve Phyre Job Id Fetch
Email wilkinsongw1@cf.ac.uk
Description UL142____
Date Fri Nov 9 15:04:30 GMT2018
Unique Job
ID b07652a172cd14b5
Sequence MRIEWACWLF ...Download FASTA
Job Type normal
Job Expiry 30 days
Summary  
Top model
Image coloured by rainbow N → C terminus
Model dimensions (Å): X:66.411 Y:56.353 Z:56.842
Model (left) based on template
c4gupA_
Top template information
PDB header:immune system
Chain: A: PDB Molecule:major
histocompatibility complex class i-
related gene
PDBTitle: structure of mhc-class i
related molecule mr1
Confidence and coverage
Confidence: 100.0% Coverage: 78%
238 residues ( 78% of your sequence)
have been modelled with 100.0%
confidence by the single highest
scoring template.
3D viewing
Interactive 3D view in JSmol
For other options to view your
downloaded structure offline see the
FAQ
Sequence analysis  
View PSI-Blast Pseudo-Multiple Sequence Alignment
Download
FASTA
version
Secondary structure and disorder prediction [Show]  
Domain analysis [Show]  
Detailed template information [Hide]  
 
# Template Alignment Coverage 3D Model Confidence % i.d. Template Information
1 c4gupA_ Alignment 100.0 13
PDB header:immun  system
Chain: A: PDB Molecule:major histocompatibility complex class i-related
gene
PDBTitle: structure of mhc-class i related molecule mr1
Run Investigatori
2 c3p73A_ Alignment 100.0 15
PDB header:immune system
Chain: A: PDB Molecule:mhc rfp-y class i alpha chain;
PDBTitle: crystal structures of the chicken yf1*7.1 molecule
Run Investigatori
3 c1xz0A_ Alignment 100.0 15
PDB header:immune system
Chain: A: PDB Molecule:t-cell surface glycoprotein cd1a;
PDBTitle: crystal structure of cd1a in complex with a synthetic
mycobactin2 lipopeptide
Run Investigatori
4 c5gjxA_ Alignment 100.0 19
PDB header:immune system
Chain: A: PDB Molecule:mhc class i antigen;
PDBTitle: crystal structure of duck mhc i for 2.06 angstrom
Run Investigatori
5 c1cd1C_ Alignment 100.0 11
PDB header:cd1
Chain: C: PDB Molecule:cd1;
PDBTitle: cd1(mouse) antigen presenting molecule
Run Investigatori
6 c2yf6A_ Alignment 100.0 17
PDB header:immune system
Chain: A: PDB Molecule:major histocompatibility complex class i
glycoprotein
PDBTitle: complex of a b21 chicken mhc class i molecule and a 10mer2
chicken peptide
Run Investigatori
7 c2akrA_ Alignment 100.0 10
PDB header:immune system
Chain: A: PDB Molecule:t-cell surface glycoprotein cd1d1;
PDBTitle: structural basis of sulfatide presentation by mouse cd1d
Run Investigatori
8 c1zhbJ_ Alignment 100.0 16
PDB header:immune system
Chain: J: PDB Molecule:h-2 class i histocompatibility antigen, d-b alpha
chain;
PDBTitle: crystal structure of the murine class i major histocompatibility2
complex of h-2db, b2-microglobulin, and a 9-residue peptide derived3 from
at dopamine beta-monooxigenase
Run Investigatori
9 c1zt4C_ Alignment 100.0 11
PDB header:immune system
Chain: C: PDB Molecule:t-cell surface glycoprotein cd1d;
PDBTitle: the crystal structure of human cd1d with and without alpha-2
galactosylceramide
Run Investigatori
10 c3fonA_ Alignment 100.0 15
PDB header:immune system
Chain: A: PDB Molecule:mhc;
PDBTitle: crystal structure of the class i mhc molecule h-2kwm7 with a
single2 self peptide vndifeai
Run Investigatori
Generate superposition of selected models
Binding site prediction  
The top ranking model of your protein (c4gupA_ 100.0% confidence) has been submitted to the 3DLigandSite server to predict potential binding sites.
Results will appear here when complete
Phyre is now FREE for commercial users!
All images and data generated by Phyre2 are free to use in any publication with acknowledgement
Please cite: The Phyre2 web portal for protein modeling, prediction and analysis.
Kelley LA et al.. Nature Protocols 10, 845-858 (2015)[pdf] [Citation link]
 
If you use the binding site predictions from 3DLigandSite, please also cite:
3DLigandSite: predicting ligand-binding sites using similar structures.
Wass MN, Kelley LA and Sternberg MJ Nucleic Acids Research 38, W469-73 (2010) [PubMed]
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Component software
Template detection: HHpred 1.51
Secondary structure prediction: Psi-pred
2.5
Disorder prediction: Disopred 2.4
Transmembrane prediction: Memsat_SVM
Multi-template modelling and ab initio:
Poing 1.0
RID
Database Name
Description
Program
Query ID
Description
Molecule type
Query Length
YP_081574.1
membrane glycoprotein UL142 [Human
betaherpesvirus 5]
amino acid
305
BLAST ® » blastp suite » RID-YB8HCN2T015
BLAST Results
Questions/comments
Job title: ref|YP_081574.1| (305 letters)
YB8HCN2T015 (Expires on 11-10 22:05 pm)
nr
All non-redundant GenBank CDS
translations+PDB+SwissProt+PIR+PRF
excluding environmental samples from
WGS projects
BLASTP 2.8.1+
New Analyze your query with SmartBLAST
No putative conserved domains have been detected
Distribution of the top 4 Blast Hits on 4 subject sequences
<40 40-50 50-80 80-200 >=200
1 60 120 180 240 300
Color key for alignment scores
Query
Graphic Summary
Sequences producing significant alignments:
membrane glycoprotein UL142 [synthetic human betaherpesvirus 5]
Sequence ID: AVT50373.1 Length: 305 Number of Matches: 1
Range 1: 1 to 305
Score Expect Method Identities Positives Gaps Frame
621 bits(1602) 0.0() Compositional matrix adjust. 305/305(100%) 305/305(100%) 0/305(0%)
Features:
Query  1    MRIEWACWLFGYFVSSVGSERSLSYRYHLESNSSANVVCNGNISVFVNGTLGVRYNITVG  60
            MRIEWACWLFGYFVSSVGSERSLSYRYHLESNSSANVVCNGNISVFVNGTLGVRYNITVG
Sbjct  1    MRIEWACWLFGYFVSSVGSERSLSYRYHLESNSSANVVCNGNISVFVNGTLGVRYNITVG  60
Query  61   ISSSLLIGHLTIQTLESWFTPWVQNKSYSKQPLSTTETLYNIDSENIHRVSQYFHTRWIK  120
            ISSSLLIGHLTIQTLESWFTPWVQNKSYSKQPLSTTETLYNIDSENIHRVSQYFHTRWIK
Sbjct  61   ISSSLLIGHLTIQTLESWFTPWVQNKSYSKQPLSTTETLYNIDSENIHRVSQYFHTRWIK  120
Query  121  SLQENHTCDLTNSTPTYTYQANVNNTNYLTLTSSGWQDRLNYTAINSTHFNLTESNITSI  180
            SLQENHTCDLTNSTPTYTYQANVNNTNYLTLTSSGWQDRLNYTAINSTHFNLTESNITSI
Sbjct  121  SLQENHTCDLTNSTPTYTYQANVNNTNYLTLTSSGWQDRLNYTAINSTHFNLTESNITSI  180
Query  181  HKYLNTTCIERLRNYTLEPVYTTAVPQNVTPEHAITTLYTTPPNAITIKDTTQSHTVQTP  240
            HKYLNTTCIERLRNYTLEPVYTTAVPQNVTPEHAITTLYTTPPNAITIKDTTQSHTVQTP
Sbjct  181  HKYLNTTCIERLRNYTLEPVYTTAVPQNVTPEHAITTLYTTPPNAITIKDTTQSHTVQTP  240
Query  241  SFNDTHNVTEHTLNISYVLSQKTNNTTSPWVYAIPMGATATIGAGLYIGKHFTPVKFVYE  300
            SFNDTHNVTEHTLNISYVLSQKTNNTTSPWVYAIPMGATATIGAGLYIGKHFT VKFVYE
Sbjct  241  SFNDTHNVTEHTLNISYVLSQKTNNTTSPWVYAIPMGATATIGAGLYIGKHFTPVKFVYE  300
Query  301 VWRGQ  305
            VWRGQ
Sbjct  301  VWRGQ  305
membrane glycoprotein UL142 [synthetic human betaherpesvirus 5]
Sequence ID: ATP76408.1 Length: 305 Number of Matches: 1
Range 1: 1 to 305
Score Expect Method Identities Positives Gaps Frame
580 bits(1495) 0.0() Compositional matrix adjust. 289/305(95%) 293/305(96%) 0/305(0%)
Features:
Query  1    MRIEWACWLFGYFVSSVGSERSLSYRYHLESNSSANVVCNGNISVFVNGTLGVRYNITVG  60
            MRIEWACWLFGYFVSSVGSERSLSYRYHLESNSSANVVCNGNISVFVNGTLGVRYNITVG
Sbjct  1    MRIEWACWLFGYFVSSVGSERSLSYRYHLESNSSANVVCNGNISVFVNGTLGVRYNITVG  60
Query  61   ISSSLLIGHLTIQTLESWFTPWVQNKSYSKQPLSTTETLYNIDSENIHRVSQYFHTRWIK  120
            ISSSLLIGHLTIQTLESWFT WVQNKSYSKQPLSTTETLYNIDSENIHRVSQYFHTRWIK
Sbjct  61   ISSSLLIGHLTIQTLESWFTSWVQNKSYSKQPLSTTETLYNIDSENIHRVSQYFHTRWIK  120
Query  121  SLQENHTCDLTNSTPTYTYQANVNNTNYLTLTSSGWQDRLNYTAINSTHFNLTESNITSI  180
            SLQENHTCDLTNSTPTYTYQANVNNTNYLTLTSSGWQDRLNYTAINSTHFNLTESNITSI
Sbjct  121  SLQENHTCDLTNSTPTYTYQANVNNTNYLTLTSSGWQDRLNYTAINSTHFNLTESNITSI  180
Descriptions
Description Max
score
Total
score
Query
cover
E
value
Ident Accession
membrane glycoprotein UL142 [synthetic
human betaherpesvirus 5] 621 621 100% 0.0 100% AVT50373.1
membrane glycoprotein UL142 [synthetic
human betaherpesvirus 5]
580 580 100% 0.0 95% ATP76408.1
membrane glycoprotein UL142 [Panine
betaherpesvirus 2] 82.8 82.8 95% 3e-14 23% NP_612759.2
PREDICTED: LOW QUALITY PROTEIN:
class I histocompatibility antigen, F10
alpha chain-like [Anser cygnoides
domesticus]
40.0 40.0 28% 4.0 31% XP_013026254.1
Alignments
See 1 more title(s)
